2018 Korea Innovative PHARMACEUTICAL Company Potential of in Korea

Aging populations and growing interest in health and welfare continue to drive up the demand for innovative drugs across the world. Globally, R&D spending in the pharmaceutical industry was higher than any other industry (pharmaceutical and bio ranked No. 1 with 150 billion dollars(2015)), indicating that the future industrial structure is shifting from IT to pharmaceutical business.

Pharmaceutical Industry in Korea

In Korean, the value of drugs manufactured in Korea was KRW 18.8 trillion in 2016. The annual average growth rate for the past five years was 4.6 percent. In addition, the size of the pharmaceutical market was KRW 21.7 trillion in 2016.

Size and Market Trends in Pharmaceutical Industry in Korea (Unit: KRW Trillion) Category Production Export Import Balance Market size 2012 157,140 23,409 58,535 △35,126 192,266 2013 163,761 23,306 52,789 △29,483 193,244 2014 164,194 25,442 54,952 △29,510 193,704 2015 169,696 33,348 56,016 △22,668 192,364 2016 188,061 36,209 65,404 △29,195 217,256 YOY 10.8% 8.6% 16.8% - 12.9% CAGR(’12~’16) 4.6% 11.5% 2.8% - 3.1%

Note: 1) Pharmaceutical products include finished products, narcotic drugs, ultra narcotic, psychotropic substance and drug substance 2) Numbers in export and import categories are calculated in Korean won and converted US dollar by using annual average exchange rate at Bank of Korea 3) Market Size= Production-Export+Import Source: Pharmaceutical Industry Statistics, Korea Pharmaceutical and Bio-Pharma Manufacturers Association Facts & Survey Report, Korea Pharmaceutical Traders Association, Korea Health Industry Statistics System

Based on its technological competitiveness and quality drugs, the pharmaceutical industry in Korea has taken a stride in strengthening its ability to develop innovative drugs in a short period of time, including R&D, clinical trials and drug manufacturing. Impressive growth made in the last few years suggests that Korea based pharmaceutical companies are ready to take a leap forward as global players.

[R&D] Development of innovative medicines and strong pipelines across various therapeutic areas

The local pharmaceutical industry began manufacturing both finished products and drug substances in the 1960s, and developed new processes in the 1980s. Following the early phase of drug development in the late 1980s, Korean pharmaceutical industry began to develop innovative drugs in the 2000s. Since then, Korean pharmaceutical industry has been successfully developing one of the most innovative and incrementally modified drugs. Since the introduction of the chemical compound patent system in 1987, the number of innovative drugs introduced in the country has also increased at a very fast pace. Korea has seen development of innovative

2 3 drugs across various therapeutic areas, from “Sunpla ,” a treatment for stomach cancer developed by SK Pharmaceuticals in 1999 to “Invossa” a treatment for osteoarthritis of the knee developed by Kolon Life Science in 2017. So far, Korean pharmaceutical companies have developed therapies in an array of areas including oncology, antibacterial, gastritis, respiratory infections, duodenal ulcer, diabetic foot ulcer, erectile dysfunction, hepatitis B and hypertension. Development of innovative drugs targeting Drug development the global market Early years of drug getting on track 2010’s Development of development Local manufacturing of 2000’s finished products and new processes drug substance 1990’s 1980’s 1960/70’s

Launch of innovative drugs(total of 29) ’99 ’01 ’02 ’03 ’05 ’06 ’07 ’08 ’10 ’12 ’13 ’14 ’15 2017

Sunpla EGF Factive Apitoxin Revanex Levovir Pelubi Noltec Pyramax Supect Duvie Riavax Acelex besivo

Milican Peudovaccin Zydena Mvix Kanab Zemiglo Zabolante Invossa

Sivextro(Tab.) Q-roxin Camtobell Zepeed

Sivextro(Inj.)

Suganon Drug Development in Korea

[Clinical Trials] Clinical trials grew dramatically from both qualitative and quantitative perspectives

Already on a clear growth track with its high level of clinical trial capabilities and reliable data, Korea is emerging as a core clinical trial destination in the pharmaceutical market in . Korea-based 22 major healthcare organizations, including National University Hospital, Seoul Medical Center and Asan Medical Center, have won global certifications for their clinical study environment helping the country to build a clinical infrastructure on a global level. With this advanced infrastructure, Korea ranked 6th in the world for global clinical trial protocol market share in 2017, moving two notches up from the 8th at the previous year. The number of domestic clinical trials came to 658 in 2017, up nearly 4.8% compared to 628 in 2016. Its share in global clinical trials also grew from 3.4% in 2016 to 3.5% in 2017.

The number of multinational regional clinical trials(MRCTs) conducted by multinational pharmaceutical companies in Korea has also increased sharply since the country introduced International Conference on Harmonization Good Clinical Practice(ICH GCP) in 2000. Especially, Pfizer formed a partnership with Korea as part of its global clinical program in 2008, selecting 4 of its 9 global Core Research Sites(CRSs) in Korea.

[Manufacturing] High level of competitiveness and ability to generate rich pipelines of innovative drugs

Pharmaceutical companies in Korea have been working to ensure that their drug manufacturing facilities meet rigorous global standards. To reflect global trends, the guidelines on Good Manufacturing Practices(GMP) changed

2 3 from dosage forms to prior approval of individual items in 2008. As the guidelines shifted from management of dosage forms to that of individual items based on a step-by-step process through 2010, the quality assurance system for domestically manufactured drugs reached a global level.

In addition, Korea has the ability to conduct drug R&D for compounds and commercial technologies, including organic synthesis, agents and global clinical trials. This ability was gained through development of generics and incrementally modified drugs. Korea is also a leader in the pharmaceutical biological technology area. With fruitful results from R&D including development of the world’s first stem cell therapy and xenotransplantation of pancreatic ducts, Korea is in an advantageous position to be a leader in promising future industries. The level of therapeutic technologies in cardiac surgery and management, and cervical cancer in Korea is the best among other OECD countries, according to OECD Health Data 2009.

Korea pharmaceutical industry is shifting its focus from the domestic market to the global market, and the world now pays attention to Korean pharmas as successful partners.

Korean Pharmaceutical Market Clinical Trial Capability KRW 22 Trillion('16) ▶ Seoul,‌ the capital of , ranks 1st for iindustry- ▶ 1.8% of the World Market(13th) sponsored clinical trials among all cities worldwide('17) ▶ Around 3.1% Average Annual Growth('12~'16) ▶ ‌Korea ranked 6th in the world for industry-sponsored ▶ Only‌ 25% MNC dominated clinical trials('17) (reimbursement price based, '12) ▶ 599 manufacturers(353 for finished drugs) World Class GMP & DDS Technology New Drug Release Competency ▶ cGMP & EU GMP standard facilities ▶ Innovative Drug Delivery Systems ▶ 29 New Drugs, 82 IMD products approved • ‌Film-type Viagra and patch-type Alzheimer's and Parkinson’s ▶ 2~3 New drugs coming out to the market every year drugs developed, etc

Top Class Bio-Pharma Competency High Growth in Export

▶ High quality bio products (1st stem cell therapy, 1st ▶ '12~'16,‌ 10.7% CAGR for Drug Export biosimilar approved, 21 biosimilar clinical trials undergoing) • US $3,120M export('16) ▶ Stem cell (Clinical trials 2nd, Patent 4th, # of Researcher 5th, SCI Papers 8th in the world) ▶ Stable supply of • Self supply for essential vaccines Globalization (self-reliance ratio of vaccines 46%, '16) • 5 premium vaccines in Clinical Trials ▶ Joining PIC/S (’14) and ICH ('16) (Phase 1, (PCV, HPV, Rotavirus, Herpes zoster, Cholera)) ▶ 23‌ WHO PQ products() developed (’17) ▶ ‌Joint worldwide marketing of K-pharma developed drugs with MNCs National Pharmaceutical R&D Support ® • Boryung’s Kanarb for hypertension (Fimasartan) • Celltrion’s Remsima Inj. (Inflixmab) ▶ Total government healthcare R&D : $400M • Hanmi’s Amosartan® for hypertension and ▶ Total government pharm. R&D : $250M • Esomezol® for esophageal reflux disease ▶ Total MoHW pharm. R&D : $130M • JW’s 3 chamber IV

4 5 Public-private Partnership for Development of Pharmaceutical Industry Contributing to Global Health

Korea aspiring to transforming itself into one of the top seven pharmaceutical powerhouses Korea has designated the pharmaceutical industry as one of the future growth engines, In order to foster the industry, the Korean government has been placing emphasis on enhancing growth potential through far-reaching policy measures, ranging from technology innovation to promoting market transparency, boosting global competitiveness of companies, and establishing infrastructure for sustainable development, Moreover, with knowledge and capacity mustered, the government, industry, medical society, and academic community are devoting themselves to make a leap forward into global markets.

Under the circumstance where the Korean population has been aging rapidly, the Korean government has keen interest in the pharmaceutical industry, which serves as a foundation for the quality of life of the public, The government introduced “Accreditation of Innovative Pharmaceutical Company” in 2012, and will reinforce its efforts to support the industry every year with a view to reinventing the nation into one of the top seven pharmaceutical titans.

Introduction of Promotion and Support of Innovative Pharmaceutical Company What Company Can Be an Innovative Pharmaceutical Company? Special Act on Pharmaceutical Industry Promotion and Support (enacted in March 2011) serves as the legal foundation to designate innovative pharmaceutical companies verified to possess high R&D capacity for new drug development and to be globally competitive, Those companies are expected to play a leading role in developing the domestic pharmaceutical industry into a future growth engine.

Accreditation Process The Accreditation Screening Committee conducted written and verbal evaluations on candidate pharmaceutical firms which met the requirements (Article 2 of the Enforcement Decree of the Special Act: investment volume over a certain level), In the evaluations, the committee assessed candidate companies based on specific requirements, such as R&D performance in the past, company’s capacity, vision and investment plan, ethical business practice, etc, The results of the evaluations delivered by the screening committee were finalized after the review carried out by the Committee for Pharmaceutical Industry Promotion and Support, which is chaired by the Minister of Health and Welfare.

Composition of Designated Innovative Pharmaceutical Companies • General‌ pharma firms [34]: 34 leading firms that have marked high scores in terms of R&D investment as well as researchers, manufacturing facilities, patent and license-out, and overseas market advancing plus ten SMEs that have built on expertise in specialized areas such as development of incrementally modified drugs • Bio‌ venture companies [8]: firms with relatively low sales but highly competitive technology and creative business models • Multinational‌ pharma firms [2]: one local company of an MNC considered outstanding in terms of R&D investment (in early clinical trials), local production performance, overseas market advancing, etc.

List of Companies Certified as Innovative Pharmaceutical Companies [44] (April, 2018) Category Name of Company Boryung Pharm, Bukwang Pharm, Celltrion, Chong Kun Dang Pharm, CJ HealthCare, Dae Hwa Pharm, Daewon Pharm, Daewoong Pharm, Dong-A ST, Dong Wha Pharm, GC Pharm, HanAll BioPharm, Handok, General pharma firms [34] Hanlim Pharm, Hanmi Pharm, Huons, Hyundai Pharm, IL-Yang Pharm, Isu Abxis, JW Pharm, Kolma Korea, Korea United Pharm, Kuhnil Pharm, LG Chem, Pharma Research Products, Pharmicell, Samjin Pharm, Samyang BioPharm, Shin Poong Pharm, SK Chemicals, ST Pharm, Taejoon Pharm, , Yungjin Pharm Bio venture companies [8] BC World Pharm, Bioneer, Corestem, CrystalGenomics, Genexine, Medytox, ViroMed, Tego Science Multinational pharma firms [2] Korea Otsuka Pharm, Sanofi-Aventis Korea

4 5 7 Products Pamiron Inj., Risidro Tab. Mepem Inj.,Cilacin Inj. etc. Mucopid BC Tab., Ranitidine Inj. etc. Merogel Gel, BC Itraconazol etc. Tab., Starova BC Tab., Atorvastatin etc. Tab. Ibertan Ibertan Tab., Duo Duomax Tab., etc. Tab. Tibare Inj., BC Morphine Sulfate Inj., BC Fentanyl Inj. etc Narcotics GI AgentsGI Category Anti-Infectives Hyperlipidemia Anti-Hypertensives Therapeutic categories such as pain, anesthesiology, neurology, and musculoskeletal diseases Antibiotics (Carbapenem) Anti-Osteoporosis Agents BCWORLD PHARM. CO., LTD. Steve H. Hong · DDS-oriented Pharmaceutical Company · ‌ 78 Gaepo-ro 22gil Gangnam-gu, Seoul, Korea www.bcwp.co.kr · Company · CEO Specialty · · Location Homepage· Main Products Therapeutic Class Products R&D Pipeline Stage Indications Item Category GRS BCWP_C003 Hyperlipidemia Phase I Microsphere BCWP_D001 Anti-cancer Preclinical Microsphere BCWP_D003 Anti-cancer Phase I Microsphere BCWP_D009 Schizophrenia Phase I Nano- BCWP_D010 Schizophrenia Formulation Anti-cancer Formulation BCWP_Y001 Liposome Liposome BCWP_Y002 Anti-fungal Preclinical BCWORLD PHARM strives to establish its position as a pioneer in developing value-added pharmaceuticals as a pioneer in developing value-added BCWORLD PHARM strives to establish its position immediate/controlled release as well as fast-dissolving through cutting-edge formulation technology including of proactive investments and depot formulation by way DDS, combined formulation, gastro-retentive system in R&D and strategic alliances. Company (KIPC) as Korea Innovative Pharmaceutical Recently BCWORLD PHARM not only has been certified by Korea Center (ATC) but also designated as Advanced Technology by Korea Ministry of Health & Welfare Ministry of Knowledge Economy. BCWORLD PHARM is a technology-driven pharmaceutical company in is a technology-driven pharmaceutical BCWORLD PHARM development enables in formulation and process Korea whose expertise novel formulation generics as well as value-added it to provide quality products.

Head Office : 78 Gaepo-ro 22gil Seoul,Gangnam-gu, Korea Head Office : 78 Gaepo-ro 22gil Seoul,Gangnam-gu, Korea CONTACT US CONTACT David Kim,David Director Overseas Business Department • Phone : +82-2-2182-0466 • E-Mail : [email protected] •  Jinseok Jeon, Head of BD Business Development & Licensing Team • Phone : +82-2-2182-0420 • E-Mail : [email protected] •  BCWORLD PHARM. CO., LTD. BCWORLD Towards Global Standard R&D for Healthcare Products R&D for Healthcare Global Standard Towards 6

Pharmaceutical Pharmaceutical 7 Phase III Phase II Clinical Trials Phase I Preclinical Supported by Korea Drug Development Fend BIONEER CORPORATION Han-Oh Park, Ph.D. Molecular Diagnostic, Genomic New Drug, Genomic Science 306-220, Korea Daejeon 49-3, Daedeok-gu, Munpyeong-dong, www.bioneer.com L/O to Yuhan Corp. L/O to Yuhan BIONEER PROGRAMS Supported by Ministry of Health and Welfare Fund grant Development · Company · CEO Specialty · · Location Homepage· R&D COLLABORATION PROGRAM R&D COLLABORATION Discovery , a genome-wide drug target identification technology TM is an is innovative drug target identification technology using world’s unique S. pombe genome–wide Programs TM IPF (SAMiRNA) Solid Cancer (SAMiRNA) Lung Cancer(miRNAs) Skin whitening Alopecia Immuno-Oncology Yuhan Corp. Immuno-Oncology Yuhan Keloids (SAMiRNA) Solid Cancer (SAMiRNA) Bioneer, an innovative biotech company since 1992 1992 since company biotech an innovative Bioneer, R&D Pipeline Bioneer currently is developing SAMiRNA-based drugs various in fields of indications, which include Keloids, IPF, immuno-oncology, cancers, skin whitening and alopecia. Some pipelines have been licensed out to the biggest pharmaceutical company in Korea, and the progresses of the early stage research are being made resources. in the research other our with internally area, Bioneer’s siRNABioneer’s SAMiRNATM Program using Development Drug Technology SAMiRNA (Self-Assembled-Micelle-inhibitory-RNA) a nontoxic is RNAi nanomedicine, which allows efficient deliveryof siRNA/miRNAto target tissues. SAMiRNA SCE a is (Single Chemical Entity)manufactured using the solid phase synthesizer, which greatly simplifies the manufacturing and QC processes compared to other RNAi drug candidates. SAMiRNA overcomes major challenges that current oligonucleotide-based therapeutics face, such as insufficient delivery and adverseeffects. The advantages of SAMiRNA include its flexibility toincorporate siRNA/miRNA sequences against any disease targets. Pre-clinical research data suggest that SAMiRNA would be the most unique and singularly effective RNAi prodrug system developed to date. The company now is moving forward with the human proof-of-concept. total a provide Program Development Drug siRNA/miRNA Bioneer’s within processes integrated Vertically solution for SAMiRNA therapeutics discovery and development, fromhigh-throughput SAMiRNA™ synthesis, HT RT-qPCR screening and preclinical tests to IND filing. With its world’s-best RNAi core technologies and infrastructure, Bioneer the is ideal partnerfor pharmaceutical and biotechnology companies currently developingRNAi therapeutics, or seeking to enter the RNAi therapeutics space. Bioneer’s research and technical support teams ensure top-quality products and services to meet unique needs of partners. RNAi Therapeutics Innovator: Established1992in based on proprietaryoligonucleotide synthesis and PCR technology,Bioneer the is first biotechnology company of Korea.The company has developedsingle-molecular RNAinanoparticle, SAMiRNA™, which transforms miRNA/siRNA into novel therapeutics. In line with its root in molecular technologies, the company has also developed instruments enabling high-throughput oligo syntheses, fully-automated real time qPCR assays, and automatic protein syntheses. Leveraging these unique capabilities, Bioneer well is positioned to develop the next generation therapeutics and molecular diagnostics that can serve as uniquely- and fully- integrated drug discovery anddevelopment platform. By capitalizing on these foundational technologies developed over the past years, 10 Bioneer leading is the innovative RNAi drugsand molecular diagnostics development. GPScreen GPScreen knockout library. This technology provides the drug targets in the genome levels and can be applicable to almost theall areas of drug discovery such as drug target identification, drug toxicity evaluation for drug prioritization, drug repositioning & repurposing and natural drug target discovery. TM Innovation · Value · Discovery · Value Innovation BIONEER CORPORATION Taewoo Lee, Ph.D., Director, RNAi Therapeutics Center Research • Phone : +82-42-930-8675 • E-Mail : [email protected] CONTACT US CONTACT SAMiRNA 6 9 ○ ○ Launch RG ○ ○ ○ ○ PIII PII PI ○ ○ ○ Boryung Pharmaceuticals co., Ltd. Hong,Tae Choi Full ingredient Pharmaceutical product and substance 136, Changgyeonggung-ro, Chongro-ku, Seoul www.boryung.co.kr ○ PC (Fimasartan + Rosuvastatin) ® ○ RS · Company · CEO · Specialty · Head Office Homepage· (Fimasartan + HCTZ) ® Tuvero Dukarb BR3001 BR2002 BR1006 BR1008 BR1009 BR1010 BR4002 BR8002 BR8003 Product by our proprietary technology. After its launch in March 2011, Kanarb recorded After its launch technology. by our proprietary ® Vaccine Vaccine Lymphoma Indication Hypertension Hypertension Type 2 Diabetes Type Alzheimer's disease Hypertension Diabetes Hypertension Dyslipidemia Hypertension Dyslipidemia Hypertension Dyslipidemia (Fimasartan + Amlodipine) • Tuvero (Fimasartan) • Kanarb Plus ® ® NCE IMD Biologics Category • Dukarb Boryung has developed Kanarb Boryung has developed 10 million USD sales in the same year, and 42.4 million USD in 2016, making it the No. 1 ARB in Korea . USD in 2016, making it the and 42.4 million 10 million USD sales in the same year, drug) in 2013, the Kanarb lineup has extended to other After launching Kanarb Plus (HCTZ combination drug, Dukarb launched in August 2016 and a hyperlipidemia drugs starting from the Amlodipine combination licensed- successfully has Boryung now, Until 2016. December in launched is also (Tuvero) drug combination China, 13 Southeast Asian countries and 10 African out Kanarb Family with 13 Latin countries, Russia, countries. Kanarb combination drugs patients who are suffering from hypertension, Kanarb combination drugs for more severe Boryung is developing hyperlipidemia, heart failure and diabetic mellitus. is now on progress and it will be launched in 2020. And for For BR1006 and BR1008, Phase III clinical trial in 2021 and 2022. BR1009 and BR1010, Phase I clinical trial is on progress and it will be launched Boryung has invested continually on research and development and made continuous efforts to produce high- produce to efforts continuous made and development and research on continually invested has Boryung antineoplastic and antibiotics drugs. As a result, quality products in the specialty areas such as cardiovascular, Megace have become the best selling products and Astrix and our products such as Gelfos M, Yongkaksan, brand in Korea. Boryung has emerged as the most familiar and trusted Products Kanarb Family • Kanarb Boryung Pharmaceutical company (here after Boryung), since founded since Boryung), after (here company Pharmaceutical Boryung health and well-being trying its best to contribute to the in 1963, has been mutual health and co- corporate mission to 'realize of humanity with on human centered values'. prosperity based R&D Pipeline

[email protected] : 120mg fimasartan 60mg fimasartan Molecular Structure Ji Hyun Min R&D stratergic planning • Phone : +82-2-740-4019 •  Contact Information Boryung Pharmaceutical co., Ltd. Boryung Pharmaceutical Lifetime care company Lifetime 8

Pharmaceutical Pharmaceutical 9

Bukwang Pharmaceutical Co., Ltd. Hee Won Yoo Pharmaceuticals and sanitary aids Sangdo-ro,7, Dongjak-gu, Seoul, Korea http://www.bukwang.co.kr · Company · CEO Specialty · · Location Homepage· cap.(clevudine) : an innovative new drug for chronic hepatitis B virus ® A small-molecule targeted anti-cancer therapy which selectively inhibits VEGFR-2, known to be involved in A small-molecule targeted anti-cancer therapy which selectively inhibits VEGFR-2, angiogenesis of tumor cells Technology Targeting A special formulation applying Lymphatic Levovir was developed by Bukwang and it is the 4th drug developed for HBV infection worldwide, and the 11thLevovir was developed by Bukwang and it is the L B virus and it has excellent safety and tolerability profiles.. newdrug in Korea. It is potent in suppression of hepatitis Dexid® tab.(R-thioctic acid tromethamine) : a new drug for diabetic neuropathy It only contains R-thioctic acid which drug for diabetic neuropathy. Dexid was developed by Bukwang and it is a new exerts better antioxidant effect than S-thioctic acid. R&D Pipeline MLR-1023: insulin sensitizer in type 2 diabetes kinase - Lowering blood glucose level by activating Lyn FDA IND - Phase 2b clinical trial currently ongoing in US and Korea, under US FDA and Korea JM-010: candidate for levodopa-induced dyskinesia in Parkinson’s disease patients - Controlling neurotransmitter release from the presynaptic neurons - Completed phase 2a proof-of-concept clinical trial in South - Phase 2b global study is under preparation Apatinib mesylate: targeted anti-cancer agent - ‌ ongoing - Phase 3 clinical trial to validate efficacy as 3rd line gastric cancer treatment is SOL-804 : new formulation anti-cancer drug agent - ‌ - Phase 1 study is planned JM-012: candidatefor morning akinesia in Parkinson’s disease patients - A special formulation under development to control absorption of L-dopa Products Levovir Bukwang Pharmaceutical Co., Ltd. is one of the innovative pharmaceutical Co., Ltd. is one of the Bukwang Pharmaceutical dedication to development and was founded in 1960 with companies in Korea of novel, outstanding medicines. and commercialization growth for over fifty years. Bukwang achieved US$141 million as Bukwang has successfully achieved remarkable of financial year 2017. to out licensed and world the B in hepatitis for drug new 4th the as Levovir®cap.(clevudine) developed Bukwang countries in Asia. with pharmaceutical and bio-venture in partnership candidates new drug innovative is developing Bukwang out multinational clinical trial for an anti-diabetes compound companies in Korea and abroad. Bukwang is carrying a targeted anti-cancer drug with LSK US, and co-developing together with Melior Pharmaceuticals in the disease Parkinson’s disorder in movement for candidate a novel in licensed Also, Bukwang US. the in BioPartners Bukwang acquired in 2014. patients from Contera Pharma in Denmark, which R&D in order to sustain new drug development with the aim of Bukwang is planning to continue investment in improving global health. To Contribute to Society through Supplying Value-added New Products to New Products Value-added through Supplying to Society Contribute To from disease Suffering Help Patients Ltd. Pharmaceutical Co., Bukwang Phone : +82-2-8288-114 E-mail : [email protected] Levovir CONTACT US CONTACT •  •  8 11 Current Status Colorectal Cancer Rheumatoid Arthritis Rheumatoid Arthritis Rheumatoid Arthritis Respiratory Diseases Major Indication Large Intestine Cancer Rabies Influenza Hepatitis B Virus Approved in more than 80 countries around the globe. Major Indication Breast Cancer (ADC) - Approved by MFDS in 2014 - Approved by EMA in 2018 - Filed in FDA (2017) - Approved by MFDS in 2012 - Approved by EMA in 2013 - Approved by FDA in 2016 -  - Approved by MFDS in 2016 - Approved by EMA in 2017 - Filed in FDA (2017) Influenza virus infection Celltrion, Inc. Celltrion, Kee Woosung Biopharmaceutical development and manufacture 23, Academy-ro, Yeonsu-gu, Incheon, 22014, Korea www.celltrion.com INN Cetuximab Etanercept Palivizumab Adalimumab Bevacizumab · Company · CEO Specialty · · Head Office Homepage· Antibody Biologics Indication CT-P17 CT-P16 CT-P15 CT-P14 CT-P05 CT-P27 CT-P26 CT-P25 CT-P24 CT-P19 Remsima SC Early breast cancer, Metastatic breast cancer, Metastatic breast cancer, Early breast cancer, Metastatic gastric cancer Rheumatoid arthritis, Adult Crohn’s disease, Rheumatoid arthritis, Adult Crohn’s disease, Ulcerative colitis, Paediatric Crohn’s Paediatric ulcerative colitis, Ankylosing spon- dylitis, Psoriatic arthritis, Psoriasis Non-hodgkin’s Lymphoma, Chronic lymphocytic Lymphoma, Non-hodgkin’s leukaemia, Rheumatoid arthritis, Granulo- matosis with polyangiitis and microscopic polyangiitis (INN) Target Target Project Project Infliximab Rituximab Trastuzumab Antibody Biologics Antibody Biosimilars Truxima Herzuma Remsima Product Celltrion focuses on promoting the health and welfare of patients in need of innovative biopharmaceutical Celltrion focuses on promoting the health and research facilities, developing state-of-the-art technologies, products through world-class manufacturing and and establishing quality systems. Products & Pipeline is a biosimilar monoclonal antibody Remsima and Inflectra (CT-P13), Biosimilar infliximab, also known as its brand name medicine (also known as the reference product). The referencedeveloped to be comparable to an already approved biological which is an anti-inflammatory medicine for the treatment ofproduct for biosimilar infliximab is Remsima (infliximab), Crohn's Disease, ulcerative colitis, pediatric ulcerative colitis,inflammatory conditions including Crohn's Disease, pediatric and plaque psoriasis. rheumatoid arthritis, ankylosing spondylitis, psoriatic psoriasis Herzuma, Celltrion is actively developing other and Remsima, Truxima Following successful development of mAb biosimilars both of which are global blockbuster biologics. and Avastin, biosimilars in various fields such as biosimilars for Humira which based on Antibody-Drug Conjugate (ADC) technology, Celltrion is developing new biologics such as biobetters Moreover, overcomes limitations of existing antibody therapeutics. Based in Incheon, Republic of Korea, Celltrion, Inc. is a global biopharmaceutical leader of Korea, Celltrion, Inc. is a global Based in Incheon, Republic in biosimilar monoclonal and development (R&D) capabilities with strong research areas, including oncologyand novel drugs for various therapeutic antibodies (mAbs) approval for and EMA FDA Celltrion previously received and autoimmune diseases. regulatory a from approval receive to mAb biosimilar first world’s the is which Remsima R&D expertise, coupled with a passion for Celltrion’s agency in a developed country. that allowed the Company to enter intopatient well-being, is a unique set of capabilities this highly challenging space.

Herzuma Truxima Remsima Celltrion Headquarters : +82-32-850-5000• Phone : +82-32-850-5057• Fax • E-mail [email protected] CONTACT US CONTACT Celltrion, Inc. A Global Technology Leader in the Field of Leader Technology A Global Drug Development and Biologic Biosimilar 10

Pharmaceutical Pharmaceutical 11 A ○ ○ ○ PhIII ○ ○ ○ ○ ○ PhII ○ ○ ○ ○ PhI ○ ○ ○ ○ ○ NC Chong Kun Dang Pharmaceutical Corp. Young-Joo KimYoung-Joo R&D of new medicine and incrementally modified drug (IMD) Korea Seoul, Seodaemun-gu, Chungjeong-ro, 8, www.ckdpharm.com Cancer Anemia Glaucoma Expectorant Solid cancerSolid Neutropenia Colon cancer Indication Auto-immune President & CEO & President Gastric disorder Multiple myeloma Multiple myeloma · Company · · Specialty · · Location Homepage· Pain, Uremic, Pruritus SLE, Dermatomyositis SLE, Dyslipidemia Oncology Hypertension/Dyslipidemia Neurodegenerative disease Neurodegenerative Age-related Macular DegenerationAge-related Macular CKD-581 CKD-702 CKD-12101 CKD-841 CKD-11101 CKD-943* CKD-351 CKD-333 CKD-701 CKD-495 CKD-497 CKD-509 CKD-506 CKD-508 CKD-516 CKD-504 CKD-971* Project CNS Others Oncology Immunology CV & Metabolic Therapeutic area * CKD-943 is an in-licensed product from Cara Therapeutics Inc. Global R&D USA, Europe and Korea to accelerate the development of novel CKD has launched several clinical programs in clinical trial of CKD-506, has been completed in Europe and a NCE drug candidates. A phase 1, first-in human available start in 2018. CKD-506 is an orally will patients arthritis rheumatoid in adult 2 study phase multinational, disease including inflammatory various for treatment targeting is which inhibitor HDAC 6 selective highly and autoimmune diseases. HDAC 6 inhibitor targeting treatment for neurodegenerative CKD-504, a blood-brain barrier (BBB) penetrating neuronal function is in the phase 1 trials in disease) by improving disease and Alzheimer’s diseases (Huntington’s USA and Korea. R&D Pipeline In 1968, CKD received US FDA approval for Chloramphenicol, Chloramphenicol palmitate and sterile ChloramphenicolIn 1968, CKD received US FDA approval for Chloramphenicol, US FDA approval for raw materials in the history of Koreansodium succinate. It was the first commemorative addition, CKD has received US FDA approvals for other raw materials such as In pharmaceutical industry. CKD is one of the first Rifampicin, Demeclocycline and etc. Remarkably, Oxytetracycline hydrochloride, Tetracycline, Center in early 1970's to accelerate the development ofKorean pharmaceutical companies to establish Research novel technologies and therapeutics. as Lipilou (anti- drugs such successfully launched pharmaceutical of its own R&D, CKD has Through a long history (immunosuppressant), in different therapeutic areas. Tacrobell hyperlipidemic agent), Dilatrend (hypertension), and products since 2008. The first biological product, darbepoetin- In addition, CKD has been developing biological Investing over 11.2% of its revenue (as of 2017) in research andalfa biosimilar is currently in NDA review stage. novel therapeutics, Camtobell for anti-cancer and Duvie for type 2development, CKD has successfully launched two Cantabel and Dilatrend SR. Especially, such as Telminuvo, diabetes, and various IMDs and fixed dose combinations through potential business partnership.CKD is currently exploring global market opportunities Chong Kun Dang Pharmaceutical Corp. (CKD) was established in 1941 with Pharmaceutical Corp. (CKD) was Chong Kun Dang to is dedicating its efforts the best quality medicines and a goal of supplying health and quality of life. for improving human develop novel therapeutics Products BINT Medicine R&D Corporation for Terminal Illnesses for Terminal R&D Corporation BINT Medicine Technology) Bio-Info-Nano (BINT: Pharmaceutical Corp.Chong Kun Dang [email protected] Tab. anti-diabetic agent Tab. ® • Phone : +82-2-6373-0633 • E-Mail : Joo-Hyun Lee Business Development Team CONTACT US CONTACT Duvie Camtobell inj., anti-cancer agent Lipilou tab., anti-hyperlipidemic agent Celltrion, Inc. Celltrion, Kee Woosung Biopharmaceutical development and manufacture 23, Academy-ro, Yeonsu-gu, Incheon, 22014, Korea www.celltrion.com · Company · CEO Specialty · · Head Office Homepage· 10 13 Asia can help to Southeast Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Partnering availability ® ® ® MKT NDA PIII I.V. solution bag is convenient to use for I.V. ® I.V. solution bag is convenient to use for I.V. PII ® Clinical Trial PI , HONGSAMJIN GOLD is safe and effective in treating anemia of hemodialysis ® ® PC Details DS (Cefpodoxime) tab. & dry , CONDITION ® Target Indication Target is an outstanding energy drink produced with 6-yeared red ginseng. ® Renal Anemia IBS-C, NASH ArthritisRheumatoid Type 2 Diabetes / Hyperlipidemia Hypertension Hypertension/ Hyperlipidemia Hypertension / Hyperlipidemia Prevention of Hand, Foot & Mouth Disease DegenerationMacular Cancer Gastric Acid-Related Disorders has been launched in 1992 creating a new market of hangover relief drink in Korea. contains the goodness of Hovenia dulcis with its function of liver protection. ® ® Lipid is parenteral nutrition IV solution bag for supplying energy, essential fatty acids and omega-3 fatty acids to patients. Lipid is parenteral nutrition IV solution bag for supplying energy, Amino acid and Glucose to patients. Peripheral is total parenteral nutrition (TPN) IV solution 3 chamber bag for supplying Lipid, is the best choice for MRSA & MRSE. ® Inj. is an injectable drug used for the treatment of colorectal cancer. ® ® was developed 1st in Korea and 3rd in the world. Epokine has excellent antibacterial effects on MRSA, MRSE and Enterococcus. ® Description ® Inj. is a chemotherapy RTU(ready-to-use) injectable drug for the treatment of pleural esothelioma and non-small cell lung cancer. Inj. is a chemotherapy RTU(ready-to-use) injectable drug for the treatment of pleural esothelioma ® ® ® CJ HealthCare corporation CJ HealthCare Seok Hee Kang, Sang Hyun Yoon ETC (CVs, Antibiotics, IV Solution, Oncology, Endocrinology, Nephrology&Urology, GastroIntestinal, Musculo skeletal,Respiratory, Others) & Health functionalproducts CJ CheilJedang Center, 330, Dongho-ro, Jung-gu, Seoul 100-400, Korea www.cjp.co.kr doctors and nurses in hospitals. Calmtop CONDITION doctors and nurses in hospitals. As the treatment of vancomycin-resistant Enterococcus faecium infections, Cinezolid Tapocin PEMTA HongSamJin Gold As a fourth-generation synthetic fluoroquinolone antibacterial agent, Moveloxin Epokine HutGaeSoo OmapOne OmapOne support their natural defenses during strong chemotherapy Vancorin patients with end-stage renal disease cause the Neutropenia. Leukokine Chemotherapy in advanced cancer patients and in acute Leukemia patients can Molecule , HONGSAMJIN, · Company · CEO · Specialty Business · Head Office Homepage· Darbepoetin alfa alfa Darbepoetin biosimilar Ranibizumab biosimilar Small moleculeSmall moleculeSmall Atorvastatin, Metformin Candesartan, Amlodipine Valsartan, Amlodipine, Rosuvastatin Valsartan, Amlodipine, Atorvastatin Vaccine Tegoprazan Pemetrexed solution Pemetrexed ® Product Pipeline CJ-40001 CJ-14199 CJ-15314 CJ-30056 CJ-30059 CJ-30060 CJ-30061 CJ-40010 CJ-40012 CJ-12420 CJ-30045 IMD NCE ‌ SoutheastAsia EPO, - G-CSF, VancomycinInj., Inj., Teicoplanin Ciprofloxacin Inj., Moxifloxacin Inj.,Irinotecan, Linezolid Inj., Entecavir tab., Ceftriaxone Inj., Ceftazidime Inj. CONDITION Biologicals Calmtop Inj. (Irinotecan) CONDITION (Hangover relief drink) Cinezolid I.V. solution bag (Linezolid) Cinezolid I.V. Tapocin Inj. (Teicoplanin) Tapocin Pemta Inj. (Pemetrexed) HongSamJin Gold (Red Ginseng drink) Moveloxin I.V. solution bag (Moxifloxacin) Moveloxin I.V. Epokine Inj.(rh-EPO) OmapOne Lipid Inj. bag (Fish/MCT/Soybean/Olive oil) OmapOne Peripheral Inj. bag (Lipid, Amino acid, Glucose) HutGaeSoo (Thirst –quenching tea drink) Vancorin Inj. (Vancomycin) Vancorin Leukokine Inj. (rh- G-CSF) DS: Discovery, PC: Preclinical Studies, MKT: Market, IMD: Incrementally Modified Drug Global Business China - CONDITION1. 2. Japan - Cefozopran, Cefotiam, Cefmenoxime, Banan 3. 4. The , Africa and CIS - EPO, G-CSF, Vancomycin Inj., Levofloxacin Inj., Ciprofloxacin Inj., Ceftriaxone Inj., Cefotaxime Inj. 5. - EPO, G-CSF, Vancomycin Inj., Inj Teicoplanin R&D Pipeline Products Heal the World, Better Life the World, Heal HealthCare CJ CJ Healthcare more than 30 years of experience pharmaceutical company, aims to the global company throughactive R&D investment and open innovation. CJ HealthCare developing is new drugs indicated for treatment of digestive or inflammatory diseasesbased and cancers, on its own distinguished R&D capabilities. At the same time, it also is sparing no effort to conduct constant R&D activities for the 2nd-generationvaccines, EPOs and developing is and cutting edge incrementally modified drugs (IMDs) and combinations with a focus on chronic diseases including circulatory and endocrine disorders.

-

[email protected] (Mr. Donghee Lee) (Dr. Sun Park) [email protected]

Floor 6 Le Thanh St., Ton District th 1, HCMC1, • TEL: +84 - 8 - 3911 – 5114 • E-MAIL: [email protected] (Mr. Minki Ku) CJ Europe GmbH Ober der Roeth 4 65824 Schwal bach, Germany bach, • TEL: +49 - 6196 - 590128 • FAX: +49 - 6196 - 45418 • E-MAIL: [email protected] (Dr. Young Sun Lee) CJ Japan Corp. 8F, CJ Bldg, 2-7-4, Nishishinbashi, Minato-ku, Tokyo, 105-0003,Japan • TEL: +81-80-1249-0427 • FAX: +81-3-3580-1055 • E-MAIL: [email protected] (Mr. Sungbin Cho) China branch office 12ceng, yidigang yizuo, 20hao, Beijing, Chaoyangqu, Jiushanqiaolu, China, 100016 P.C • TEL: +86 - 10 - 5639 - 6090 • E-MAIL: ‌ Contact Information CJ HealthCare, Korea(Headquarters) CJ CheilJedang Center, 330, Dongho-ro, Jung-gu, Seoul 100-400, Korea • Tel: +82-2-6740-2186 • FAX: +82-2-6740-2492 • E-mail: 

Vietnam branch office 15 CJ HealthCare Corp. CJ HealthCare Big leap to global pharmaceutical company to global pharmaceutical Big leap 12

Pharmaceutical Pharmaceutical 13

(2016.06)

Remarks Phase I Phase I : NCT03265444 : NCT03174587 : Partnership Market (2015.01) NCT01363401 : NCT02210624 approval IND : NCT01758510 NCT03214146 (2015.5) approval IND IIT (ongoing) IIT (ongoing) • • • • • • • • NDA inj has an effect on alleviating ® Clinical IND

® ® Preclinical

® CORESTEM Inc. Kyung Suk Kim Korea Gyeonggi-do, Seongnam-si, Bundang-gu, Pangyo-ro 255beon-gil, 24, http://CORESTEM.com/en/ , received the permission of medicines by Korea’s Ministry of Food and of medicines by Korea’s , received the permission Basic ® Reseach NEURONATA-R HYNRCS-Allo-ALS-02 CS20AT04 CS30MS02 NEURONATA-R CS10BR05 President & CEO & President · Company · · Location Homepage· ALS ALS MSA (Allo) (Allo) Lupus (Auto) (Auto) (Auto) defect Indication OA/cartilage Anoxic brain injury is a bio-pharmaceutical company specializing in research and development of personalized stem specializing in research and development is a bio-pharmaceutical company inj is an autologous bone marrow-derived mesenchymal stem cell therapeutic product for amyotrophic inj is an autologous bone marrow-derived mesenchymal ® Diseases Diseases Disorders Autoimmune Neurological Musculoskeletal Therapeutic area Drug Safety in July 2014 and began commercialized medication to patients in February 2015. CORESTEM leads thein patients to commercialized medication began and 2014 July in Safety Drug limitations through ongoing research expectations beyond national, ethical and economic market in meeting patient into incurable diseases. advancing preferred stem cell treatments for intractable diseases, research and development is focused on Corestem’s care offerings. Corestem is an integrated innovation engine,driving scientific advancement, and expanding patient in a new era ushering and mastery of state-of the art technology, combining unparalleled scientific expertise, creativity, generation curative stem cell therapies and treatments of tailored medical products with a suite of new 2nd Products NEURONATA-R CORESTEM R&D Pipeline cell therapies for incurable disease. We developed the world’s first stem cell therapeutic product for ALS (Amyotrophic first stem cell therapeutic developed the world’s disease. We cell therapies for incurable of NEURONATA-R Lateral Sclerosis), name lateral sclerosis. MSCs are capable of differentiating into various types of cells that constitute the human body. They body. human the constitute that cells of types various into differentiating of capable are MSCs sclerosis. lateral . NEURONATA-R also secrete neuro-trophic factors and anti-inflammatory deteriorating physical through anti-inflammatory and immune modulatory effects, inhibition of motor neuron death,deteriorating physical through anti-inflammatory and prolongation of motor neuron in ALS patients.

®

Leading Stem CEll Therapy Products, CORESTEM. CEll Therapy Leading Stem CORESTEM Inc. NEURONATA-R WooNa Cho Strategic Business Dept. Product Manager • Phone : +82-70-4706-9713 • E-Mail : [email protected] Strategic Business Dept. Executive Director • Phone : +82-70-4706-9745 • E-Mail : [email protected] CONTACT US CONTACT Huh JungIm 12 15

Ph III Preclinical Ph II Osteoarthritis DEVELOPMENT STATUS: Ph I INDICATION: Staph aureus Preclinical AML, MCL & CLL CrystalGenomics, Inc. Joong Myung Cho, Ph.D. Discovery and Development of Novel Therapeutics Novel of Development and Discovery Korea A Tower, 5th Bio F., Park, 700 Daewangpangyo-ro, Bundang-gu, 463-400 Gyeonggi-do, Seongnam-si Korea www.crystalgenomics.com Discovery INDICATION: Specialty Business · Company · CEO · · Head Office Homepage· IBD AML MDS MDS MRSA Indication AML, MCL, CLL Pancreatic cancer Anti-inflammatory Pain Anti-inflammatory ‌ Out-licensed to Aptose Biosciences (NASDAQ: APTO) in a licensing deal worth potentially up to $303 million (June 2016); CrystalGenomics retained Korea and China rights

CG400549 (First-in-Class Fab I Inhibitor for MRSA) HDAC inhibitor inhibitor  Dual BTK-FLT3

Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibitor Dual Cyclooxygenase-2 and Carbonic Anhydrase Pain Area ABSSSI and other serious infections associated with ABSSSI and other serious infections associated MDS, AML, etc.) and Hematologic Cancers (Pancreatic Cancer, Solid Tumors Various Cancer Cancer Cancer Cancer Inflammation : Phase 2 clinical trial ongoing for pancreatic cancer and Phase 1b clinical trial ongoing for MDS Phase 2a completed (USA) Approved in Korea (2015) Infectious Disease Disease Infectious Acelex (polmacoxib) is a novel NSAID with a unique mode of action, approved for the relief of signs and symptoms ofsymptoms and signs of for the relief approved unique mode of action, a with NSAID a novel is Acelex (polmacoxib) being sold by Dong-A ST and Daewoong Pharmaceutical Co.,Ltd,osteoarthritis. Acelex was launched in 2015 and is 2016, CrystalGenomics had signed a supply agreement with TR- CrystalGenomics’ commercial partner for Korea. In coveringcountries 19 Acelex in of marketing and sales for responsible be would TR-Pharm where Pharm of Turkey Acelex is the second biggest selling COX-2 inhibitor in Korea and the MENA region. Currently, Turkey CG400549 is a novel antibacterial its walls, cell bacterial of ingredient an are acids fatty Since synthesis. acid fatty in enzyme essential an (fabI), drug candidate that inhibits enoyl-[acyl-carrier-protein] synthesis is critical for the survival of bacteria (ACP) reductase CG ‘806 is a once daily, oral, first-in-class FLT3/BTK inhibitor. This small molecule demonstrates potent inhibition inhibitor. oral, first-in-class FLT3/BTK CG ‘806 is a once daily, tyrosine mutations of the receptor and or ITD, duplication, tandem internal (including FLT3 forms of mutant of and represents kinase domain), eliminates AML tumors in the absence of toxicity in murine xenograft models, AML. Likewise, CG’806 demonstrates potent, a potential first-in-class therapeutic for patients with FLT3-driven developed for non-covalent inhibition of the Cys481Ser mutant of the BTK enzyme, suggesting the agent may be CLL and MCL patients that are resistant/refractory/intolerant to covalent BTK inhibitors CG200745 is an epigenetic agent that deactivates HDAC, an enzyme that catalyzes the histone deacetylation. Based onCG200745 is an epigenetic agent that deactivates HDAC, an enzyme that catalyzes the histone deacetylation. showeda series of anti-cancer efficacy tests using various cancer cell lines and xenograft animal models, CG200745 superior profile when compared to other compounds in the same class of drugs. 2 1 4 5 6 7 3 DRUG TARGET: DRUG DRUG TARGET: DRUG STATUS: INDICATION: STATUS: TARGET: DRUG INDICATION: STATUS: TARGET: DRUG PARTNERING STATUS: No. - - -  · CG200745 (Best-in-Class HDAC Inhibitor for Solid and Liquid Tumors) -

· CG400549 (First-in-Class Fab I Inhibitor for MRSA) CrystalGenomics is developing several drug candidates for various therapeutic areas and has an approved product. CrystalGenomics is developing several drug candidates approved by the MFDS of for osteoarthritis which has been Acelex (polmacoxib) is a next generation NSAID antibiotic for MRSA and other a first-in-class is CG400549, Korea in 2015. The second therapeutic program third therapeutic The U.S. in the study 2a phase a completed successfully had which infections staph serious therapeutic with two ongoing clinical studies: phase 2 pancreatic program is CG200745, an epigenetic anti-cancer In addition to the aforementioned programs, (MDS) study. cancer study and phase 1b Myelodysplastic syndromes in its R&D pipeline. CrystalGenomics has several other therapeutic programs Product · Acelex (Polmacoxib, Next Generation NSAID for Osteoarthritis) R&D Pipeline CrystalGenomics, Inc. is a commercial stage biopharmaceutical company dedicated to the dedicated company biopharmaceutical stage a commercial is Inc. CrystalGenomics, R&D and commercialization pharmaceuticals of novel to address significant unmetmedical needs in the therapeutic area infectious and of disease, inflammatoryoncology diseases. The of headquartered the is management Company for and has in a subsidiary in Korea the U.S. exchange. traded the KOSDAQ on publicly studies, is clinical and it multi-national · CG026806 (First-in-Class dual BTK-FLT3 inhibitor for AML, MCL & CLL) 

Steven Kim, R.Ph., MBA, Executive Business Director, Development : +82-31-628-2720• Phone • E-mail : [email protected] CONTACT US CONTACT

Acelex CrystalGenomics, Inc. CrystalGenomics, Commercial Stage Biopharma Company with a Robust Pipeline and Proven with a Robust Pipeline Company Stage Biopharma Commercial of Novel Drugs Commercialization in R&D and Record Track 14

Pharmaceutical Pharmaceutical 15 Dae Hwa Pharmaceutical Co. Ltd. Eun-Seok Kim / Byung-Tae Noh Cosmetics products, Medicinal (Seoul Office) 2145 DaeHwa Bldg., Nambusunhwan-ro, Seocho-gu, Korea Gangwon- Hoengseong-gu, Hoengseong-eup, 495, Hanu-ro, site) (Manufacturing do, Korea www.dhpharm.co.kr · Company · CEO Specialty · · Location Homepage· DAE HWA has developed all kinds of medicines ranging all kinds medicines from ulcer peptic of has developed HWA DAE adult treatments and cancer, a assistant including to preventive medicines disease, etc.related society through pharmaceutical Pharmaceutical Co., Ltd. was established in the spirit of “serving DAEHWA have thriving ever since to improve national life”. We business and contributing to build more human-centered for its business development with has been seeking new paths health. Since its foundation in 1984, DAEHWA unique and creative to is constantly seeking a consistent progress-oriented core-target. DAEHWA the Korean pharmaceutical industry thanks to its global improve the patients’ quality of life and to develop effort. produces APIs and finished products. With its own platform technologies, DAEHWA antibiotic market. Flospan is ranked 1st in the antispasmodic Cephametyl is ranked 3rd in the oral cephalosporin for transdermal drug delivery system (TDDS) product in market. As the biggest and unique CMO Company possesses the system. DAEHWA is equipped with a highly qualified, sterile and flawless Korea, DAEHWA minimized its side effects. a new TDDS Platform that has world's best TDDS technology and has developed most of its company resources into is investing more than 10% of its sales into R&D and focuses DAEHWA the development of QoL products. runs a the world. DAEHWA around countries to 20 more than 60 products exports currently DAEHWA and took over a German company for the manufacture and distribution representative office in Vietnam, from a middle-sized Korean company into a global has grown DAEHWA of medical device. Consequently, company specialized in pharmaceuticals. created the first oral Paclitaxel anticancer formulation platform technology, DAEHWA’s DH-LASED technology, and achieved astonishing results 17 year-study, of DAEHWA’s drug in the world. Liporaxel Solution is the result convenience. Liporaxel Solution will launch domestically in 2018; application safety and proving its efficacy, result for US FDA (IND type) is in process. administration. to Oral has changed the market paradigm from Injection With Liporaxel Solution, DAEHWA new natural product DHP1401 Daehwa’s technology for elderly people. is a specialized DH-HERBAL Technology thanks to its for dementia, has high efficiency for memory improvement and the protection of brain cells. Also, we are gradually approaching the results we have dreamed. safety, food and to Besides, efforts are put into the development of blood-pressure improving health functional oral disintegration film (ODF) is easily DAEHWA's products for elderly people. prepare the best optimized who suffer from which facilitates the drug administration to children and elders administered without water, dysphagia. clinical secures various meaningful DAEHWA platform technology, through its DH-BIO Technology Moreover, expansion for new drugs. data for Lou Gehrig disease among others, and strengthens the basis of overseas company, manufacturing/distribution device medical & cosmetics German a and Inc. Redoxbio over taking By expect that these new area has stepped into the new area of the cosmetic surgery market. We DAEHWA specialized in would contribute to sales growth by expanding our business into the cosmetics manufacturing, antioxidants and in developing biomedicines and compounds. Healthful WORLD, Dynamic DAEHWA! WORLD, Dynamic Healthful CO., LTD PHARMACEUTICAL DAE HWA Tel: 82-2-6716-1073 e-mail:[email protected] Tel: 82-2-6716-1074 e-mail:[email protected] Tel: 82-2-6716-1071 e-mail:[email protected] Tel: 82-2-6716-1072 e-mail:[email protected] Regulatory Affair • Claire Kim • Rachel, Cha Overseas Business • Hanwoong, Seo • Paul Cho CONTACT US CONTACT Resnalin patch Kebanon plaster Liporaxel Solution Amalian Filler Top-Roll soft cap. Top-Roll Baratis ODF Rivamensa Patch Loxona Cataplasma 14 17 RG ○ ○ ○ P3 P2 ○ ○ P1 Daewon Pharmaceutical Co., Ltd. Baek, Seung Ho / Baek, Seung Ryel Drug manufacture and sales 386 Chunhodaero, Seongdong-gu, Seoul, Korea www.daewonpharm.com PC · Company · CEO · Specialty · Location Homepage· CR Tab, have CR excellent Tab, anti-Inflammatory effects while ® ○ ○ RS Tab and Pelubi Tab Type ® Arthritis Gastric ulcer Hypertension Hypertension Hyperlipidemia Acute bronchitis Neuropathic pain Neuropathic CR Tab are CR NSAID-class Tab anti-inflammatory analgesics that were created by Daewon. ® CR Tab. ® Code DW-1710 DW-1501 DW-1601 DW-1702 DW-1502 DW-1503 DW-4301 Forte Syrup ® Tab. / Pelubi Tab. Tab and Pelubi Tab ® ® IMD IMD IMD IMD IMD IMD NCE Category Codaewon® Forte Syrup, the main product of Daewon Pharm, an is antitussive/expectorant combined with four different main ingredients including Dihydrocodeine. It has greatly improved convenience by applying the disposable stick pouch package for the first time in Korea, which greatly improves dosage convenience. Pelubi Pelubi R&D Pipeline Products Daewon Pharm is one of the representative pharmaceutical in companies therepresentative Pharm of one is Daewon capability and R&D manufacturing on based Korea excellency Daewon Pharm a specialized is company that has been producing therapeutic agents from its foundation with its founding idea, “based on our customer’s belief and trust, be a companion that protects the healthy human Daewonlife.” possesses numbers of new chemical and incrementally modified drug pipelines to improve human life quality further. Basedon one of the highest level of R&Dcapability on formulation research, modification technology, and clinical trial capability in Korea, Daewon has built the Core Platform technology and applying it to many new modification of development the in edge competitive strong possesses also Daewon developments. product drugs that reduces frequency of drug use and side effects Daewon Pharm specialized is in manufacturing technology of syrup liquid and suspensions, using state-of-the- art manufacturing facilities. R&D platforms and liquefied manufacturing facility operation are Daewon’s core competencies. By utilizing it to other various medicines, Daewon taking is big step toward becoming one of the global syrup market leaders. The 12th new drug in Korea, Pelubi minimized gastrointestinal side-effects. It has been recognized for its excellence with the Korea New Drug Development Award in 2009 and 2016. Codaewon

[email protected] [email protected]

Oramin Soft Cap. Eswonamp Tab. Bongsu KimBongsu • Phone : +82-2-2204-6979 • E-mail : CONTACT US CONTACT Dongwoo Kang • Phone : +82-2-2204-6971 • E-mail : Renamezin Cap. Codaewon Forte Syrup

Pelubi / Pelubi CR Tab. Daewon Pharmaceutical Co., Ltd. Daewon Pharmaceutical Reliable Partner for Human Health Partner for Human Reliable 16

Pharmaceutical Pharmaceutical 17 M M M* PIII PIII ANDA PII PII BE PI PI Pre Pre Pre Development Status Development Status Development Status R R R

indication Diabetes / BIC / Diabetes Anti-ulcer / BIC Anti-fibrotic disease / FIC Osteoarthitis Description Crohn's disease Crohn's Neuropathic pain, Cancer pain Cancer pain, Neuropathic Atopic dermatitisAtopic Autoimmune disease (RA) / FIC (RA) / disease Autoimmune FIC (RA) / disease Autoimmune Immuno-oncology Dry eye syndrome Dry eye Rheumatoid arthritis Rheumatoid Type 1 and 2 Diabetes Epidermolysis Bullosa Glabellar Lines (US/EU) injection 505(b)(2) Daewoong Pharmaceutical Co., Ltd. Sengho Jeon, Jaechun Yoon small-molecule new drugs, biological drugs, value-added chemical drugs Bongeunsa-ro12, 114-gil, Gangnam-gu, Seoul, Korea www.daewoong.com Description Dementia/Alzheimer's disease Biomedical device for spinal fusion Weekly patch, 505(b)(2) 1M IM injection, 505(b)(2) injection, IM 1M Ointment for regeneration of doral soft tissue Chronic Obstructive Pulmonary Disease(COPD) Sustained released formulation released Sustained Olmesartan + Rosuvastatin FDC Rosuvastatin + Olmesartan Generic of Emend, New nano technology Ursodeoxycholic acid 250, 500mg tablets Carbepem dedicated faclity, Patented process Patented faclity, dedicated Carbepem · Company · CEO Specialty · · Head Office Homepage· Suspension (nanoparticles), 1M IM injection, 505(b)(2) injection, IM 1M (nanoparticles), Suspension Leuprolide depot(suspension method, Gelatin included) method, depot(suspension Gelatin Leuprolide type Powder for suspension (lyophilised aripipazole monohydrate powders), EGF EGF EGF Powder for suspension (polymeric microspheres), SC injection, 1M PRS inhibitor Supersaturated solution contaning lanreotide acetate nanootubes, SC 1M MOA Insulin BMP-2 SGLT2 inhibitor APA(Reversibles) Stem Cell Dual taget inhibitor Dual taget inhibitor Dual Ion channel blocker channel Ion Undisclosed Anti TNF Alpha Botulinum Toxin + + , HL187 + Olostar Brand Ursodiol Leuprolide Aprepitant HL036 Brand Aripiprazole Meropenem Novosis Propafenone Nabota* monohydrate Medicine Bio-better Code Donepezil Patch Regenerative Goserelin acetate Goserelin HL186 &D Pipeline Growth factors DWJ212 DWJ213 DWJ208 Lanreotide acetate Lanreotide DWP14012 DWP16001 DWN12088 Paliperidone Palmitate Daewoong Pharmaceutical is the Pharmaceutical Company with No. 2 with No. Pharmaceutical the Pharmaceutical is Company Daewoong drugs prescription of market. insales the Korean Value-added Generics & Generics Generics & Value-added Biologics The reinforcement of focused on developing new chemical entities, biologics,Daewoong Lifescience Research Institute has been the R&D capacities APIs. Daewoong has also been studying to find solutionsincrementally modified drugs and high-value added through disease as well as other innovative thepain disease, Alzheimer’s for the unmet therapeutic needs of neuropathic establishment Daewoong is operating several overseas offices in China, Vietnam, programs like anticancer gene therapy. of R&D centers India has R&D centers in China, India and Indonesia.Indonesia, Thailand, , USA, Japan and in China, India and Indonesia.R New Chemical Entities Established in 1945 in South Korea, Daewoong Pharmaceutical offers high-quality and innovative pharmaceutical Korea, Daewoong Pharmaceutical offers high-quality Established in 1945 in South top market leaders in Korea. products and is one of the for people through its total dedication to Pharmaceutical has been providing better health For over 60 years, Daewoong for new drug development to meet diverse medical needs andhealthcare. Daewoong has built strong core competency enhance human life. has involved in becoming a global healthcare group byBuilding on our core strength, Daewoong Pharmaceutical to have an inspiring mission with global partners. We operating our foreign branches in SE Asia and by collaborating to improving the quality of life for people worldwide. become a top 50 global healthcare company which contributes Pharmaceutical Company with the No.1 Company Pharmaceutical Drugs in Korea Prescription Sales of Pharmaceutical Co., Ltd. Daewoong Mr. Doyoung(Brian) Kim, Team Leader, Global Strategy Dept. • Phone : +82-2-550-8112 • [email protected] : CONTACT US CONTACT 16 19

, and ® Japan Available Available Available Available Available Available Available Available territories territories territories Licensing Not available Not Available Not Available Availability LATAM, Japan EU,CIS/Russia, Available except Available except , Zydena Available for some Available for some ® Ph II (USA) (Korea) Preclinical Ph III (Global) completed (USA) completed Launched (Korea) Launched (Korea) Launched (Korea) Ph I completed (EU) Ph 1 completed (EU) Preclinical completed Preclinical Ph II completed (USA) Ph I completed (Korea) Ph completed 1a (USA) Launched (Korea), Ph II Ph 1 completed (Japan) Launched (USA, EU, etc.) Development Stage Preclinical completed (Korea) completed Preclinical

Hormone) PEG-G-CSF Dong-A ST Dae Sik, Eom Prescription drug specialized company 64, Cheonho-daero, Dongdaemun-gu, Korea Seoul, http://www.donga-st.com(Korean) http://en.donga-st.com (English) Description GPR119 agonistGPR119 Recombinant FSH Recombinant Stimulating Factor) Stimulating New anti-VEGF mAb Trastuzumab Biosimilar Ustekinumab Biosimilar M3 receptorM3 antagonist Darbepoetin α Biosimilar Botanical (Herbal extract) Botanical (Herbal extract) Botanical (Herbal extract) Botanical (Herbal extract) Oxazolidinone class antibiotic class Oxazolidinone (Pegylated Granulocyte-Colony- (Recombinant Follicle Stimulating 5-HT(Hydroxytryptamine) agonist 4 DPP(Dipeptidyl Peptidase)-4 inhibitor · Company · CEO Specialty · · Head Office Homepage· women women Anemia Psoriasis constipation Neutropenia Indication Breast Cancer Type 2 diabetes Type 2 diabetes Parkinson disease Alzheimer disease Overactive bladder stimulation) in ART Diabetic neuropathy Diabetic Functional dyspepsia Functional Pneumonia (HABP/VABP)Pneumonia Irritable bowel syndrome- bowel Irritable COH (Controlled Ovarian Hyper- Ovulation induction in anovulatory Age-related macular degenerationAge-related macular Skin and Skin Structure Infections) Infection (ABSSSI, Acute Bacterial

, medical devices, diagnosis and overseas business. ®

DA-1241 DA-7218 DA-7218 DA-1229 DA-3131 DA-8010 DA-9701 DA-3031 DA-9801 DA-3801 DA-9805 DA-3880 DA-9803 DA-6886 DMB-3111 DMB-3115 (Dulastin®) (Sivextro®) (Suganon®/ Code Name (Motilitone®) (Gonadopin®) Sugamet® XR)Sugamet® (Brand name) Botanical Drug Botanical Biopharmaceutical ProductsBiopharmaceutical New Chemical Entity Major R&DMajor Pipeline Dong-A ST envisions a future where it will be a respectable world-class a future world-class willrespectable be a it envisions where ST Dong-A pharmaceutical company through drugs. its innovative Dong-A ST focuses on Prescription drug, such as domestically developed new drugs Stillen like Motilitone Withits optimized research infrastructures such as its world-class, sophisticated research center completed in as well as its excellent2011, researchers, Dong-A ST furthering is its efforts to develop global new drugs. Also, with the backing of these infrastructures, Dong-A ST vows to positively explore overseas markets, to expand its overseas exports, and to establish itself as a global pharmaceutical company, operating beyond the domestic market.

Hyung-Shik Kang Pricing & Deputy manager, general Public Affairs Team • Phone : +82-2-920-8341 • E-mail : [email protected] CONTACT US CONTACT Sugamet XR Suganon Zydena Sivextro Motilitone

Stillen Dong-A ST An R&D-driven company that has been leading the that has been company An R&D-driven years. for over 80 industry in Korea healthcare 18

Pharmaceutical Pharmaceutical 19 China Remark Signed Agreement in MENA and DONG WHA PHARM. CO., LTD. Koang Ryale Yoo Antibiotic1) 2) Cancer 3) New Herbal Drug 98, Huam-ro,19F, Seoul, Korea www.dong-wha.co.kr compared to existing quinolone antibacterial asthma pneumonia Indication breast cancer ulcerative colitis · Company · CEO · Specialty · Location Homepage· Community acquired irritable bladder syndrome Obstructive Pulmonary Disease Acute Exacerbations of Chronic Clinical Status PhaseⅡ Phase Ⅰ Phase Ⅰ Phase Ⅰ preparation preparation preparation Launched in Korea S. pneumoniae and H. influenza , including one basement level and four stories high. In addition, it has in place an array 2 Project DW1018 DW2007 DW2008 DW2005 (New Quinolone Antibiotic: Zabofloxacin D-aspartate Hydrate) ® Zabofloxacin(DW224) Zabofloxacin(DW224) Quinolones Antibiotics Quinolones Antibiotics agents. Best-in-class activity against - Rapid symptom relief compared to Moxifloxacin - Good safety profile: No serious adverse events, no QT prolongation, no phototoxicity, no rash, no dysglycemia - Launched in Korea 2016 in - Signed ‘Distribution and License Agreement’ with Novosci Healthcare MENA (12 regions) in Jan. 17th, 2017. - Signed ‘Distribution and License Agreement’ with SJ IBPharm (China region) in March. 31th, 2017. Zabolante R&D Pipeline Products Established Established as the firstKorean pharmaceuticalDong Whacompany 1897, in remained committedhas tobringing always to and customers hapiness people. of happiness on focusing management with its employees Whal Myung Su the is first western medicine in Korea invented by Min Byung-ho, a bureaucracy of Chosun dynasty, in order to popularize the secret of herb medicine available only in the palace in 1897 when Chosun transferred to the Korean Empire. Founded in 1973, Dong Wha Pharmaceuticals Research Institute has developed a number of original drugs includingGas Whal Myung Su, Fucidin ointment and Pancold. It nowis a transition in period towards more advancedR&D, focusing on developing new drugs at state-of-the-art research facility which was newly built in 2010 The new plant(built in 2009) located in the Chungju Industrial Complex has a total area of 82,500m² and total floor space of 52,800m - Indication : Acute Exacerbation of Chronic Obstructive Pulmonary Disease - ‌ of equipment and systems to satisfy Current Good Manufacturing Practice (cGMP) Regulations A. D. of US F. Withthe state-of-the-art automated production system at the plan, Dong Wha can now compete shoulder to shoulder with major global pharmaceutical companies. Human & Happiness Human & PHARM. CO., LTD. DONG WHA

® [email protected] CONTACT US CONTACT Yoon Kyung Kim Director Global Business Team • Phone : +82-2-2021-9341 • E-mail : Zabolante 18 21 Ⅲ & Other Recombinant GC1102 MG1111 GC1111F GC5107B GC5101B GC3110D GC1101D QIV(child) Hunterase(P3) Phase Hepabig-gene(LT) IVIG-10%(US/CA) GreenGene F(China) Varicella(Thailand...) IVIG-5%(US/CA)*child Vaccine Ⅱ Plasma GC1109 Anthrax GC1111B GC1102B GC5112A Phase Hunterase(US) * Hepabig-rene(CHB) Hunterase(ICV,JPN) GC Pharma Huh, Eun Chul Plasma Derivatives & Recombinant Proteins, Vaccines, ETC& Korea Gyeonggi-do, OTC Products Yongin-si, Giheung-gu, 30beon-gil, Ihyeon-ro 107, www.greencross.com Ⅰ BCG Tdap EGFR QIV-HD Phase GC1118A GC3114A GC3107A GC3111A · Company · CEO Specialty · · Location Homepage· PCC TFPI DTaP IG-CAP LAFATE GC5121A GC3104A GC1124A GC5113A GC5112A GC5111A GC5112A MG1120A MG1113A MG1121A Fibrinogen CEACAM1 MG11124A GreenVIII-U VZA (subunit) Hunterase(SC) Pre-Clinical Albumin 25%(CA) Products Plasma Fractions & Recombinants 1971, Green Cross currently manufactures more than 12 first Albumin production in Starting from the nation’s Recent innovations factors, and anti-thrombin factor. plasma fractions including immunoglobulin, anti-hemophilic recombinant Factor VIII for hemophilia A treatment.include ‘rhFVIII (GreenGene F)’, a 3rd Generation of Vaccines first epidemic hemorrhagic third Hepatitis B vaccine in 1983, the world’s to develop the world’s succeeded We useQuadrivalent was approved for GCFLU in 1988. The quadrivalent inactivated influenza vaccine, fever vaccine vial was approved in December 2016, and receivedin Korea in 2015, WHO PQ(pre-qualification) for single-dose approval for multi-dose vial in April 2017. ETC& OTC Medicines medicines in the field of cardiovascular disease, metabolicGreen Cross has provided a broad range of ethical alsoproducts), we OTC core of our (one with patches hypertensive disease. Along including diabetes, disease dermatology and immunology. have provided OTC products in respiratory, A leading global R&D institute conducting research of plasma- institute R&D of research conducting A leading global antibodies. and therapeutic proteins recombinant vaccines, derivatives, such as vaccines, plasma-derivatives, pioneered in the field of biopharmaceuticals, Green Cross Corp.(GCC) has been well known for the R&D and proteins and therapeutic antibodies. GCC has diagnostics, recombinant first epidemic hepatitis B vaccine, ‘Hantavax’, a world’s biggest selling commercialization of ‘Hepavax B’, a world’s chicken pox vaccine. A complete flu pipeline includes second hemorrhagic fever vaccine, and ‘Suduvax’, a world’s and etc. GCC is also pursuing opportunities in rare diseasesseasonal flu vaccine, H1N1 vaccine, avian flu vaccine asit recording revenue in million $1,041 earned GCC 2016, In (Hunterase). syndrome Hunter for therapies developing 2nd largest Korean pharmaceutical company. R&D Pipeline

[email protected]

CONTACT US CONTACT Park/General Young-Seoub Manager Business Development • Phone : +82-31-260-1817 • Fax : +82-31-260-9417 • E-Mail : [email protected] Byung Lim Lee/General Manager Overseas Business • Phone : +82-31-260-9493 • Fax : +82-31-260-9491 • E-Mail :  GC Pharma Devotion to healthy lives of people to healthy lives Devotion 20

Pharmaceutical Pharmaceutical 21 Phase 2 Phase 2 Phase 2 Phase 2 Phase 1 Phase 1b/2 Non-Clinical Phase 1b/2a Phase 1b/2a Phase 3 IND Approval Stage Development of hyFc is derived from hybridization of non-cytosolic hybridization from derived is : hyFc Anemia Diabetes Diabetes Solid Tumor Solid Neutropenia Glioblastoma Therapeutic vaccine is prepared by introducing antigen Therapeutic vaccine is prepared by introducing Primary Indication Adult Growth Hormone Deficiency High-Grade Intraepithelial Squamous Pediatric Growth Hormone Deficiency Growth Hormone Pediatric Cervical Cancer with Checkpoint Inhibitor Triple Negative Breast Cancer with Checkpoint Inhibitor IL-7-hyFc Papitrol-188 Compound Long-Acting EPO Long-Acting hGH Long-Acting GLP-1 Long-Acting G-CSFLong-Acting : Genexine, Inc. Genexine, SukYou Suh, Ph.D. Orphan Cancer diseases, immunotherapy Korea of 13488, Republic Gyeonggi-do Bundang-gu,Seongnam-si, B, Bldg. Park Bio Korea 700 Daewangpangyo-ro, www.genexine.com HyLeukin Papitrol-188 Category HyTropin (GX-H9)HyTropin HyPoietin (GX-E2) HyGlutide (GX-G6) HyGrastim (GX-G3) · Company · CEO Specialty · · Location Homepage· Long-acting -7 as not only the first-in-class lymphopenia treatment, but also a breakthrough cancer Long-acting Interleukin-7 as not only the first-in-class immunotherapeutics and (HPV) induced pre-cancer and cancers (cervical Virus HPV DNA immunotherapy targeting Human Papilloma therapeutic vaccine head & neck cancer) via CD8+ T cells based DNA (weekly and twice-monthly) treatment in Adult and Long-acting human growth hormone as Best-in-Class (GHD). Pediatric patients with Growth Hormone Deficiency R&D Pipelines 1) hyFc Technology – Long-acting Fc-based Technology Long-actingFc-based – hyFcTechnology 1) therapeutic areas with our proprietary drugs for multi- Focused Areas: Two billion dollar market 1) Bio New Drug -  -  2) Bio Better Drug: -  and Diabetes. - Three more ongoing pipelines on Anemia, Neutropenia Genexine Inc. (KOSDAQ, 095700) is a clinical stage biotechnology company focused on the development and 095700) is a clinical stage biotechnology company Genexine Inc. (KOSDAQ, novel long-acting biologics. Our goal is immunotherapeutics and next generation commercialization of innovative lives. transform patient’s to bring medicines that will Platform Technology site-directed mutagenesis. This hybridization combination gives immunoglobulin Fc portions of IgD and IgG4 without of drug candidate and prevents adverse immunogenicity and flexible hinge that minimizes the loss of bioactivity and superior long-acting characteristics less side-effects applicability, by enzymes. hyFc thus has broad cleavage to the drug candidates. Technology: 2) DNA-based Immunotherapy Vaccine & gene and dendritic cell targeting gene into high-efficiency expression vector. When administered, it induces expression vector. gene and dendritic cell targeting gene into high-efficiency The killer CD8+ T cells then eliminates HPV- HPV specific T-cells. antigen-specific immune response and activates infected expressing cells. To Improve Patients’ Quality of Life Patients’ Quality Improve To Inc.Genexine, Ga-Young Lee Business Development Team Phone • : +82-31-628-3215 [email protected] : E-Mail • CONTACT US CONTACT 20 23 Information HanAll BioPharma Co. Ltd. JaechoonDr. Seungkook Yoon, Dr. Park Oncology1) & Fibrotic Disease 2) Infectious Diseases 3) Immunology 4) Endocrinology 3th floor Bongeunsa-ro 12, 114-gil, Gangnam-gu, Seoul, Republic of Korea www.hanallbiopharma.com · Company · CEO Specialty · · Location Homepage· HL009, adenosylcobalamin liposomal gel, has three different potential mechanisms of actions for the HL009, adenosylcobalamin liposomal gel, has three different also it dermatitis; (NO) which causes HL009 can bind to nitric oxide dermatitis. treatment of atopic From an immunology synthase (iNOS) to further reduce NO levels. nitric oxide can inhibit inducible which excrete IL-10 and TGF-beta suppressing perspective, HL009 can activate T regulatory cells immune response. due to its large molecular size and relatively Adenosylcobalamin has low permeability through skin topical product utilizing liposomal Thus, HanAll has formulated adenosylcobalamin high hydrophilicity. Benefits of liposomal formulation technology include improved stability, formulation technology. and reduced skin irritation by using lipids with enhanced skin penetration due to increased lipophilicity, proven safety. 2017) *KR Phase II (complete) / US Phase II (complete) (Nov. HanAll is currently developing fully human monoclonal antibodies targeting the Fc Neonatal Receptor HanAll is currently developing fully human monoclonal by IgG autoantibodies. (FcRn) for the treatment of autoimmune diseases caused a salvage pathway that prevents lysosomal FcRn plays an essential role in IgG homeostasis by regulating in the circulation. While FcRn-mediated half-life degradation of IgG, thus contributing to a long half-life pathogens, it also prolongs the serum half-life extension is beneficial for IgG antibody responses against in autoimmune diseases. of IgG autoantibodies and thus promotes tissue damage by blocking FcRn, leading to reduced levels of Hence, HL161 will reduce overall concentration of IgG pathogenic IgG 2017) *AU Phase I Stage (Nov. HL036 is TNF-alpha receptor fragment for the treatment of local inflammatory diseases caused by TNF- HL036 is TNF-alpha receptor fragment for the treatment smallinclude limitations drugs’ anti-TNF systemic Current AMD. and eyes, dry uveitis, as such alpha to high dosage. Therefore, by utilizing fragment,volume of distribution and adverse drug events due TNF receptor fragment will have greater volume of distribution when administered topically HanAll’s having larger molecular size. Furthermore, viacompared to currently marketed anti-TNF-alpha products It is allow smaller doses and increase the efficacy. protein engineering, HL036 will have greater affinity to administeredwhen areas ocular targeted in found be will HL036 of concentrations higher that anticipated first indication and undergone the preventing systemic ADEs. HanAll has selected dry eye as the topically, POC clinical trial study with HL036 ophthalmic solution. 2017) *US Phase II Stage (Nov. HL040, a fixed dose combination product, is composed of atorvastatin and losartan for the treatment of and currently conducting phase III hyperlipidemia and hypertension. HanAll finished the phase I study, trial in Korea and phase I study in US. 2017) *KR Phase III (complete) / US Phase I (complete) (Nov. HL009 HL040 HL036 HL161 Product HanAll BioPharma is a R&D-oriented pharmaceutical company, currently HanAllR&D-orienteda is pharmaceutical company, BioPharma (KOSPI) Exchange Stock the Korean listed on R&D Pipeline

US BRANCH HPI. Inc 9605 Medical Center Drive, Suite #290 Rockville, MD, 20850 M. J. Shin, Director : +1-301-738-3982• Phone • E-mail: [email protected] Gibum Kim,Gibum Director • Phone : +82-2-2204-1753 • E-mail: [email protected] CONTACT US CONTACT HanAll BioPharma Co. Ltd. HanAll BioPharma Innovative Medicines to Improve the Quality of Improve the Quality Medicines to Innovative Human Life 22

Pharmaceutical Pharmaceutical 23 Remarks Genexine partnered CMG Pharm. Partnered Medical device Medical Phase III Small molecules Phase II Phase I Biologics Preclinical Discovery IMD* device Medical Biologics Chemical Chemical Category Cancer Resistant Glaucoma Diabetes+ Diabetes+ Deficiency Indication Hypertension HANDOK Inc. Kim YoungJin Pharmaceutical product(ETC, OTC), Medical device & diagnostics, Healthcare products132 Teheran Street & service Gangnam-gu Seoul 06235 Korea www.handok.co.kr hyperlipidemia Growth Hormone DENEX HL1550 HL5101 HL3501 HL2356 Project · CEO Specialty · · Location Homepage· · Company CV TA Orphan Oncology Diabetes / Diabetes Ophthalmic Innovative and best way to consume Theracurmin, Curcumin made as small particles to be soluble and Innovative and best way to consume Theracurmin, Curcumin made as small particles to be absorbed 28times better into body Metabolism *IMD : Incrementally Modified Drug Modified Incrementally : *IMD R&D Pipeline Main Products Tenelia M(Teneligliptin + Metformin HCl) rate target HbA1c achievement - provides powerful blood glucose control with high Release Micro-coating Technology) (Dual - minimized the pill size by applying DRM Technology use - improves medication adherence rate with once-daily Amaryl M(Glimepiride + Metformin HCl) and metformin HCl in Korea - The first fixed dose combination of glimepiride profile - provides glycemic control with favorable safety - registered 57countries and exported to 9countries Amaryl Mex(Glimepiride + Metformin HCl) metformin HCl in the world combination of glimepiride and - The first patented sustained-release fixed dose 2009) (Winner of Korea New Drug Award, Technology) - applied by DRM technology (Dual Release Micro-coating - registered by 19countries and exported to 5 countries Ketotop Plaster (Ketoprofen) pain in Korea - No. 1 sales* plaster for osteoarthritis and muscular - Patent in 10 countries and Launched in 4 countries *Data on file : Based on IMS data, 1996-2017 Ulgeum Theracurmin - HANDOK (CEO & Chairman Young-Jin Kim), a leading innovation-driven Kim), & ChairmanHANDOK Young-Jin (CEO pharmaceutical/health-care manufactures in company develops, Korea, and human and quality life. the health of to improve distributes solutions healthcare skeletal, psychoneurotic disease, muscular focus in diabetes, cardiovascular, Handok has a core business founded in 1954, grew as a joint health. Handok, and consumer diagnostics devices, medical human vaccines, from 1964 to 2012. Handok has also established strategic collaborations venture with Hoechst/Aventis/Sanofi companies. For more information, please visit in several areas with multiple multinational pharmaceutical www.handok.co.kr. The Health Innovator The Health HANDOK Inc. [email protected] CONTACT US CONTACT SoHyun Kwon Head of Corporate & Business Development • E-mail :  Ulgeum Theracurmin Ketotop Plaster Amaryl Mex Amaryl M Tenelia M Tenelia 22 25 NDA Phase I Phase I Phase II Phase III Phase III Development stageDevelopment

AMD HANLIM PHARM. CO., LTD. JAE YOON KIM and JUNG JIN KIM R&D and manufacturing of API/BPIs, pharmaceutical product 42, 52 Seochodaero, Gil, Seocho-Gu, Seoul, Korea http://www.hanlim.com Indication Acute bronchitis Rheumatoid arthritis Surgery area marker Mixed hyperlipidemia - Allergic rhinitis, pruritus Specialty Business · Company · CEO · · Location Homepage· Anti-allergic rhinitis agent (Mometasonefuroate 0.5mg, Azelastine HCl 1.4 mg) HL151 HL237 HL-PIF HL217 HL301 HL-LMN Products Anti-osteoporosis agent including VitaminD (Sodium Risedronate 35mg, Cholecalciferol 5,600IU) Digestives (Pepsin 25mg, Papain 50mg, Diastase 15mg, Cellulase 15mg, Pancreatin 50mg,Pancrelipase 13mg, UDCA 25mg) drugs New drugs Category Incrementally modified modified Incrementally Increase tear production R&D Pipeline In 1993, the future-oriented GMP factory was completed together with the founding of the central research together with the founding In 1993, the future-oriented GMP factory was completed we continue to make a great investment scheme of the company, As a part of the long-term investment center. lately to enhance the health of manufacturing facilities in accumulating advanced technologies and reorganizing mankind as a leading pharmaceutical company. Products [1] T-SPORIN EYE DROPS : Agent for dry eye (Cyclosporin 0.5mg) -  - Minimize droplet size by Nano-emulation - Reduced eye irritation [2] NASAFLEX NASAL SPRAY :  - Perennial allergic rhinitis [3] RISENEX PLUS TAB :  osteoporosis and prevention of postmenopausal - Treatment of osteoporosis in men - Treatment [4] DAGES CAP. :  secretion - Insufficiency of gastric, enteric and pancreatic irregularity - Anorexia, meteorism, flatulence, steatorrhea, fermentative, dyspepsia with intestinal - Dyspepsia in cholecystectomized patient - Superalimentation during convalescence and fattening diets - Insufficiency of biliary secretion - Cholelithiasis, cholecystitis, cholangitis, jaundice With the corporate mission of protecting the precious human from various life protecting the precious of the corporateWith mission the to improve diseases, HANLIMforms endeavored of has consistently the leading of grown one to become have andwe standards people, health of incompanies Korea. DAGES CAP NASAFLEX NASAL SPRAY RISENEXPLUS TAB T-SPORIN EYE T-SPORIN DROPS

E-Mail : [email protected] Jeonghwa Jenny Yang (Ms.) Manager Genearal Global business Dept. • Phone : (822) 3489-6214 • Contact Information HANLIM PHARM. CO., LTD. HANLIM PHARM. Thinking of the Human Health and the Future of the Human Health Thinking 24

Pharmaceutical Pharmaceutical 25 Hanmi Pharmaceutical.co.,Ltd Hanmi JongSoo Woo, SeChang Kwon products pharmaceutical based R&D Wiryeseong-daero,14, Songpa-gu, Seoul, 05545, Korea www.hanmipharm.com · Company · CEO Specialty · · Location Homepage· R&D Pipeline Established in 1973, Hanmi Pharmaceutical is the No.1 pharmaceutical new drug development in terms of R&D spending and company in Korea achievements. Hanmi Pharm. Co., Ltd. is based in Korea, and has a strong focus in new drug R&D, specifically in 3 majorHanmi Pharm. Co., Ltd. is based in Korea, and long-acting peptides. Key therapeutic areas are diabetesfields: 1) Biologics: LAPSCOVERY platform applied platform applied bispecific antibody pipelines. Key targeting areas are targeted and obesity; 2) PENTAMBODY 3) NCE: Mainly oncology and auto-immune disease targetedimmuno-oncology and autoimmune disease; and combination programs for approved drugs. In addition, thepipelines. Hanmi Pharm also has strong fixed-dose in various co-development and collaboration projects. Hanmicompany also works closely with global partners efforts through its "Open Innovation Strategy" ofcontinues to expand its drug discovery and development teaming with potential partners for innovative solutions.

Duted R&D Driven Pioneer for Innovation in Life Sciences Innovation in Life Pioneer for R&D Driven Co., Ltd. Hanmi Pharmaceutical. Phone : +82-2-410-9087 [email protected] : Phone : +82-2-410-9291 E-mail : [email protected] Phone : +82-2-410-0462 E-mail : [email protected] Development •  •  Licensing In / Information Management Kyoung Woo Lee Leader,Team eR&D/Licensing •  •  Export (FinishedProducts/APIs/CMO Business) Steven Cho Part Leader •  •  CONTACT US CONTACT Licensing out Yang Joshua Global Leader, Businesseam Rosuzet Amosartan Tab Esomezol Cap. 24 27 Phase I Phase III Remark Discovery Discovery Discovery Discovery Pre-Clinical Remark US FDA approved Eye drop for dry eye Dental Anesthesia (PMDA approved) Indication Anticoagulant Antithrombotic Atopic dermatitis Vial Dry eye syndrome Dry eye syndrome Ampoule BFS (0.8mL) Sensorineural hearing loss Inflammatory bowel disease Dosage Form Prefilled Cartridge Ampoule Cyclosporine Lidocaine HCl Composition Hyaluronic Acid Botulinum Toxin HU017 HU035 HU039 HU024 HU047 HU007 HUG182 100, Biovalley-ro, Jecheon-si, Chungcheong-buk-do, Republic of Korea www.huons.com HUONS CO., LTD. Um, Key An 902, Pangyo innovalley C, 253, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea of Republic Gyeonggi-do, Seongnam-si, 253, Bundang-gu, Pangyo-ro, C, 902, innovalley Pangyo Composition Lidocaine HCl, Epinephrine Bitartrate · Factory · Homepage· · Company · CEO · Head Office Humia Inj. Medicaine Inj. NCE IMD Clacier Eye Drop Product name Lidocaine Inj. 1% Hutox Inj. 100 Units Biologics Category R&D Pipeline Global business · Exclusive Distribution Agreement with Novartis (former Alcon) for Kynex and Clacier eye drop · Exclusive Distribution Agreement with Spectra, USA for Lidocaine Injection & Sodium Chloride Injection · Exclusive Distribution Agreement with Nipro, Japan for Lidocaine Ctg. · Co-promotion with Kabi, Germany (Korean Branch) for Fresofol MCT Injection · Exclusive Distribution Agreement with Biosyn, Germany for Selenase Huons one is of the fastestgrowing company manufacturing qualityfinished pharmaceutical product since 1965 and possess cGMP standard of manufacturing site. Products are fully under control by strict quality system from global authorities including JAPAN and USA. For the last 60 years, we have continuously improved the business performances and it keep is ongoing. For more information, please visit our website www.huons.com or you can directly reach us by “CONTACT US” information Main Products Huons, started as Kwang Myung Pharmaceutical Company in 1965, has in Myung started 1965, Pharmaceutical Company Huons, as Kwang original and effective producing grown company, to an outstanding global through improvement products, and continuous medical medicines essential years. 50 over and innovation

MEDICAINE Inj. Han Seok, Ko • Phone: +82-2-854-4700 • Fax: +82-2-6455-0740 • E-mail : [email protected] CONTACT US CONTACT Clacier Eye Drop

Hutox Inj. HUONS CO., LTD. HUONS CO., HEALTHCARE INNOVATOR HEALTHCARE 26

Pharmaceutical Pharmaceutical 27 Launched Launched Launched Launched Launched Launched Launched Launched Launched Launched Launched Launched Launched Launched Remarks MA ApprovalMA Under phase I Under Phase 3 Under non-clinical study non-clinical Under Under non-clinical study non-clinical Under study non-clinical Under Under FIH study (Europe) Stage of Development Under preparation of phase I Exporting Countries Hong Vietnam, Kong Hong Japan Vietnam, , JapanMyanmar, Kong, USA, Hong Mongolia USA Use Use Antitussive Senile disease Senile disease Type 2 Diabetes 2 Type Anticonvulsants Nocturnal Enuresis Alzheimer's disease Treatment of episodes of major depression Parkinson's disease Alzheimer's disease Hypertension, coronary artery disease schizophrenia, of Treatment bipolar disorder Male pattern hair loss Alzheimer's disease Acute & chronic Bronchitis Cough: Acute & chronic bronchitis Main pattern baldness Antiinflammatory analgesic Eczema, dermatitis, erosion, miliaria, rhus dermatitis, pruritus, pernio, insect bite, hives Antitussive/Expectorant Hyundai Pharm Co.,Ltd Young Hak, Kim, Sang Joon, Lee Research and Development of new medicine and incrementally modified drug(IMD) Hyundai Pharm Bldg, Bongeunsa Street 135, Gangnam-Gu, Seoul, Korea http://www.hyundaipharm.co.kr Diabetes & Hypertension Hypertension & Diabetes Postmenopausal Osteoporosis · Company · CEO Specialty · · Location Homepage· Code BPDO-1602 BPDO-1603 HDDO-1614 HDDO-1601 HDDO-1602 HDDO-1609 HDDO-1604 HDNO-1605 Product (Ingredient/Formulation) Surfolase Levotuss Syrup, Tablet - 3%, 5% solution - 3% Gel (Minoxidil) 5. Tamirin SR Tablet (Galantamine HCl) (Mirtazapine) Mirtapin6. Tablet Mirap ER7. tablet (Pramipexole HCl) 13. 14. 2. Hyundai Moolpas-F Solution etc) (Methyl salicylate, dl-camphor, 3. Bumooly-S Solution (Diphenhydramine HCl, Dibucaine HCl, etc) (Desmopressin Acetate) 4. Uremin Tablet 10. Olapin Tablet (Olanzapine) Tablet Olapin 10. (Finasteride) Minopecia Tablet 11. 12. Dimantin Tablet (Memantine HCl) 1. Minoxyl 8. Hypezil Tablet (Donepezil HCl) 9. Varosc Tablet (Amlodipine besylate) R&D Pipeline We, Hyundai Pharm. with corporate philosophy in "Contribute to public health promotion" which embodies philosophy in "Contribute to public health promotion" Hyundai Pharm. with corporate We, focused in transparent health and quality of life and CEO's philosophy public improving humanistic philosophy in fast changing business are in order organization's vision and value and actively handle enterprise spirit, implements in 21st century. to have a new leap forward Main Products The Company Which Has Dream of Healthy Society Dream of Healthy Which Has The Company Co.,Ltd Hyundai Pharm [email protected] Byung-Girl, Rhee Licensing Manager / Team Team • Phone : +82-2-2600-3951 • E-Mail : CONTACT US CONTACT 26 29 Marketed NDA Ph III Ongoing Ongoing Ph II Ph I Ongoing IL-YANG PHARMACEUTICALIL-YANG CO., LTD. DONG YEON, KIM Urology, GI, Dermatology, Oncology, Vaccine, Biopharmaceutical Hagal-ro,110, Giheung-gu, Yongin-si, Gyeonggi-do, Korea www.ilyang.co.kr Pre Ongoing Ongoing USA China · Company · CEO Specialty · · Location Homepage· Korea Korea Korea Korea Korea Korea Korea Korea Korea Korea Korea Country Korea, China in the world, in Asia) 1st th eradication NERD GU / DU GERD / EE and NERD Application 1st line CML-CP 1st line CML-CP 2nd line CML-CP H.pylor Seasonal Flu vaccine Flu Seasonal Antiviral agent IY7640 Flu Quadrivalent Vaccine Quadrivalent Flu Avian Flu Vaccine (H7N9) Flu Quadrivalent Vaccine(Child) Quadrivalent Flu H. Pylori Respiratory Syncytial Virus agent IY1001 s generation BCR-ABL1 tyrosine kinase inhibitor(TKI) for the treatment of Philadelphia chromosome New Drug developed in Korea (4 New Drug developed in Korea th th line therapy for newly diagnosed CML-CP has been approved Korea in byMFDS and has beenlaunched on FEB, 2016. nd st st - Low frequency serious adverse events adverse serious frequency Low - - High, fast and deep response - High overall survival rate - Superior effect on Severe GERD/EE patients - Low reoccurrence - Reduces symptoms of night time heartburn - Low DDI 1 ‌2 positive(Ph(+))CML ‌1 ‌ 1Noltec a Proton is Pump Inhibitor (PPI) that controls the secretion of gastric acid for the treatment of DU, GU, GERD/EE, Virology Radotinib Ilaprazole Compound 5) Key features Key 5) 2. Noltec (API: Ilaprazole) 1) 14 2) 3) Indication: Ph(+) chronic myeloid leukemia (CML) in chronic phase (CP) 4) 2) 3) Expert Opinion: “Ilaprazole, developed to overcome the limitations of currently available PPI’s” features Key 4) 3. Anti-Viral agent IY7640 has been announced at American Society for Virology on 22 2012 that July, it 20~30 is times potent than Tamiflu R&D Pipeline Product Supect1. (API: Radotinib) 1) 18 Respect humanity, promote human’s health, and improve welfare through welfare and improve health, human’s promote humanity, Respect pharmaceutical advanced products. of and development research continuous PHARM. IL-YANG CO., has LTD., been exerting its intended efforts in manufacturing superior pharmaceutical products for the past 70 years. Since its first supply of pharmaceutical products Korea in has 1946, in IL-YANG been own advancing its established into a top-ranking pharmaceutical IL-YANG Biopharmaceutical. company and the in world Virology, with developments Vaccine, Oncology, in the areas Gastroenterology, of Urology, vaccine plant in April with 2011 theproduction capacity of 60mil has doses been per exporting IL-YANG year. a variety of pharmaceuticals to approximately 30 countries including USA and established Europe. IL-YANG two joint ventures in China, PHARM. YANGZHOU IL-YANG CO., and LTD., HEALTH TONGHUA IL-YANG PRODUCTS CO., for LTD., manufacturing and distribution of finished pharmaceuticals in China. Since their establishment, the sales and business are expanding exponentially. In Sept. 2014, had YANGZHOU completion IL-YANG ceremony for newly built GMP plant which compliance is to EU-GMP standard.

E-Mail : [email protected] Noltec Supect Young Hwi KO General Manager / Global BD • Phone : +82-2-570-3804 • Fax : +82-2-570-3708~9 • CONTACT US CONTACT IL-YANG PHARMACEUTICAL CO., LTD. PHARMACEUTICAL IL-YANG Respect Humanity, Promote Human’s Health, Human’s Promote Humanity, Respect Welfare Improve 28

Pharmaceutical Pharmaceutical 29 Marketed Phase III Phase II Phase I Development Status Non-clinical Discovery Indication Cancer (Solid Tumor) Hemoglobinuria Cancer Immunotherapy B Hemophilia Gaucher Disease Fabry Disease Anti-thrombotic Paroxysmal Nocturnal ® ® ® ISU305 ISU106 ISU104 ISU304 ISU Abxis Co., Ltd. Sang Beom Kim, Seok Joo Lee Biological pharmaceutics development based on the technology Gyeonggi- platform Seongnam-si, Bundang-gu, for Daewangpangyo-ro 22, 712beon-gil, biologics Fl., 5th C and animal Bldg. cell culture Center, R&D Global do, 13488, Korea www.abxis.com Fabagal Clotinab Product Abcertin (Imiglucerase) (Abciximab) (Abciximab) (Agalsidase beta) ® ® ® Drug Drug Novel Novel Orphan Orphan Biosimilar Category R&D Pipeline Products Abcertin Since 2001, ISU Abxis has established its own biotherapeutics development platform and technologies and Since 2001, ISU Abxis has established its own of all therapeutic antibody industry as its name stands for product pipeline with a desire of being an axis first development and market launch of ISU Abxis’s (ABXIS = AntiBody + aXIS). Beginning with the successful biopharmaceutical industry as specialized in biosimilars therapeutic antibody in 2006, ISU Abxis has led Korean launched two rare disease treatments for Gaucher disease and novel drugs. In 2012 and 2014, ISU Abxis has the world-class manufacturing and QC/QA management and Fabry disease. ISU Abxis has accumulated compliance. experiences in the globally harmonized through the full development and manufacturing and Iran Mexico, Turkey, including countries 30 around to supplied products, three marketed Abxis’s ISU Furthermore, world. the in products original the against alternatives only the as available are Kazakhstan, cGMP facility as obtained the GMP certificates from ISU Abxis operates the mammalian production dedicated America and Middle East. Colombia and a number of major countries in Latin Mexico, Kazakhstan, Turkey, with partner potential local and global providing of capable is biotechnology in expertise excellent Abxis’s ISU (2) development management system enabling the first-in- (1) the higher productivity at CMO level (2-5g/L), 24 months, and (3) higher biosimilarity to its original product. human IND from the cell line development within and non-clinical and clinical development of novel ISU Abxis also has excellence in screening, optimization, Besides the internal development activities, ISU Abxis monoclonal antibody and recombinant protein drugs. lack of treatment options. patients suffering from the strives to import and provide orphan drugs for Korean based business for difficult-to-treat and rare diseases both ISU Abxis will expand its advanced technology domestically and worldwide. ISU Abxis is a Korean leading biopharmaceutical company which biopharmaceutical company Abxis is a Korean leading ISU succeeded in development on the first therapeutic antibody in Korea. ISU America and and Latin world-class products to MENA Abxis provides the with the US and its business portfolio by collaboration continues to expand EU based pharmaceutical companies. · Indication: Enzyme Replacement Therapy (ERT) for Gaucher Disease (GD) · Indication: Enzyme Replacement Therapy (ERT) Imiglucerase second the world’s · The first treatment for GD developed in Korea and Iran, and etc. · Launched in 2012 in Korea and exported to Mexico, · Preparing to enter the Europe and US markets Fabagal · Indication: Adjunct to Percutaneous Coronary Intervention (PCI) second Abciximab · The first therapeutic antibody developed in Korea and the world’s etc Colombia, and · Launched in Korea in 2006 and exported to twelve countries including Turkey, · Indication: Enzyme Replacement Therapy (ERT) for Fabry Disease (FD) · Indication: Enzyme Replacement Therapy (ERT) Agalsidase beta second the world’s · The first treatment for FD developed in Korea and · Launched in 2014 in Korea and global phase III clinical trial will be initiated · Preparing to enter the Europe and US markets Clotinab · Company · CEO Specialty · · Location Homepage· @isu.co.kr Research Based Biotechnology Company Developing Treatments Developing Treatments Company Based Biotechnology Research Diseases of Rare Chronic ISU ABXIS [email protected] ® ® ® E-Mail : E-Mail :choijm Clotinab Fabagal Abcertin Esther Park Staff Administration & Planning • Phone : +82-31-696-4616 • Fax : +82-31-696-4691 • CONTACT US CONTACT Jung-Min Choi Deputy Manager General BusinessGlobal • Phone : +82-31-696-4665 • Fax : +82-31-696-4690 • 28 31 MKT NDA P3 P2 Clinical Trials Product Group P1 Pre- Clinical 1. Carbapenem Antibiotics 2. Amino Acid Solutions & Other Sterile Solutions Solutions 3. General I.V. 4. Antimicrobial & Antifungal Agents 5. Gastrointestinal Agents 6. Topical 7. Multivitamins 8. Agents for Antibiotics 9. Miscellaneous 1. Carbapenem Antibiotics: Imipenem/Cilastatin, Meropenem 2. Anti-fungals: Ketoconazole, Itraconazole, Fluconazole Acid 3. Chiral Products for Custom Synthesis & Specialty Amino 4. Miscellaneous HBV Gout Diabetes Histography Indication Brain Cancer Dyslipidemia Stomach cancer Stomach Atopic DermatitisAtopic Multiple Myeloma Acute Myeloid Leukemia HepatoCellular Carcinoma HepatoCellular Dyslipidemia/Hypertension ® ® ® JW Pharmaceutical Corp. Shin Jae-Kwang Young-Sub Chun, anticancer and nephrology gastrointestinal, urology, endocrinology, cardiovascular, antibiotic, solutions, I.V- Nambusunhwan-ro,2477 Seocho-gu, Korea Seoul, www.jw-pharma.co.kr Type Livalo-E URC102 JW1601 CWP291 Product Livalo-V™ GuardMet CWL080061 CreaVax BC tenofovir IMD tenofovir CreaVax HCC CreaVax · Company President· Specialty · · Location Homepage· Small Finished Product API (Active Pharmaceutical Ingredient) Biologics Molecule Category R&D Pipeline JW is focusing on developing Small Molecules as well as Biologics in the area of oncology andplatforms. endocrinology by employing its novel Major ExportMajor Products JW Group provides pharmaceuticals vital for maintaining the lives of patients maintaining pharmaceuticals of vitalJW for the lives provides Group into a leading and as has drugs anticancer developed such and antibiotics, Solutions. manufacturer I.V. and global pharmaceutical of company For 70 years ever sinceits foundation 1945, in JW Pharmaceutical focuses on healthcare, ETC, OTC, diagnostics and medical equipment. Based on new technologies and services forhealthy lives of human beings, JW Pharmaceutical has built up strong sales network across the country and superior solutions, pipelines in I.V. antibiotics, oncology, cardiology, endocrinology, rheumatology, and gout

[email protected]

Research Planning Research DaeKyung Koh R&D Strategic Planning • Tel: +82-2-840-6089 • E-mail: [email protected] Global Sales Team, Global Business Division • Tel: +82-2-840-6829 • E-mail:

Contact Information BD & Licensing Zi-Ho Yeom Business Development • Tel: +82-2-840-6885 • E-mail: [email protected] Export (APIs/FinishedProducts/CMO Business) Youngkyoung Pak, Senior Manager JW Pharmaceutical Corp. JW Pharmaceutical 30

Pharmaceutical Pharmaceutical 31 Phase I Phase I Phase I Non-clinical Non-clinical Non-clinical Non-clinical Non-clinical Non-clinical Development stage http://www.kolmarpharm.co.kr Kolmar Korea Co., Ltd. Lee Kyoung Ho Pharmaceuticals/Cosmetics/Health Foods Functional CNI BD 1596-3 Seocho-Dong Seocho-Gu Seoul Korea Asthma Antidots Indication Antiallergics Osteoporosis Antithrombotics Antithrombotics Antithrombotics Ulcerative Colitis Diabetes mellitus · Company · CEO · Specialty · Location Homepage· KKM 162 KKM-163 KKM-152 KKM-153 KKM-154 KKM-164 KKM-165 KKM-171 KKM-174 Candidate Category Incrementally Modified Drug New Herbal Drug Ointment and external liquid dosage forms : Strengthening of specialization through the researchesOintment cream and external liquid dosage forms : Strengthening of specialization through the for commercialization following the customer demand with the Internal liquid dosage forms : Available agents Internal solid dosage forms : Development of agents for tablets and capsules including the powder Steril product : Eye drops, Infusion and Injection wash,in toothpaste, mouth product in various types for production of no-pharmaceutical : Agency Quasi-drug R&D Pipeline Products system forspecialized production and is equipped with the development outsourcing service , Korea Kolmar Total the first time in Korea to implement total outsourcing service. pharmaceutical product, quasi-drug and others for • for improvement • facilities for and others • • • cleansing agent and others Kolmar’s CMO Service on Pharmaceutical Business CMO Service on Kolmar’s service do development to analytical service and clinical Trial All integrated services from the pharmaceutical Kolmar as it provides fast formulation development, scale updistribution channel could be collaborated with delivery. manufacturing, strict quality control and just-in-time R&D into its research and development, grafting 100 years’ Kolmar Korea reinvests more than 6% of net sales and leading the latest trend by developing worldclass worth of R&D know-how into research and development, not only in domestic Kolmar Korea has been approved foods and cosmetics. health functional pharmaceuticals, predominant technology. market but in international market for its great and Global Kolmar Americas Inc., Kolmar on based Group Kolmar The Group. Kolmar world-wide the in roots its has Korea Kolmar has 1921, in Wisconsin, Milwaukee, in established was and Group Kolmar of organization parent the is which Korea, and China, showing off the vast scale in the world. the world-wide network including Kolmar Japan, information continuous the know-how, R&D 100-year-old with equipped Kolmar of network global the In and academic activities by affiliated research group exchanges are carried out through the regular symposium may be shared as well as technologies. Also Kolmar Korea members, so that latest data concerning marketing cosmetic history. world-wide pharmaceutical and takes the initiative in the development history of Leading Korean Pharmaceuticals CMO company including Cosmetics and Pharmaceuticals CMO company Leading Korean Foods. Functional Health grown to the biggest Kolmar has a joint venture company with Nihon(Japan) Kolmar, Since founded in 1990 as manufacturer. Korean Pharmaceutical contract customers who want to outsource their customized contract manufacturing service with Kolmar Korea has provided foods to be more competitive and to develop new formulations pharmaceutical products, cosmetics and healthcare feasible in the market. Creating the Value of Health and Beauty of Health the Value Creating Co., Ltd. Kolmar Korea Fax : +82-2-515-1532 E-mail : [email protected] Fax : +82-2-515-1532 E-mail : [email protected] Ms. Elena Ryu Regional Manager / Global Business Dept. • Phone : +82-2-3485-0397 •  •  Contact Information Moon-Su Pyo Director / Global Business Dept. • Phone : +82-2-3485-0497 •  •  30 33 , ® : Tourette’s : Tourette’s ® , Busulfex ® and Samsca ® , Mucosta ® Korea Otsuka Pharmaceutical Co.,Ltd. Sung-hoMoon, The manufacture, sale, import and export of pharmaceutical products 770-9 Yeoksam-dong, Gangnam-gu, Seoul, Korea www.otsuka.co.kr ) through independent clinical trials in Korea and released them ) through independent ® , Pletaal . The company has faithfully performed itsThe company . ® ® · Company · CEO Specialty · · Location Homepage· , AbilifyMaintena ® Deltyba mission of becoming ‘A company contributing to the healthy life of Korean’ to the healthy life of Korean’ company contributing mission of becoming ‘A products, but also engaging in R&D,by not only selling pharmaceutical manufacturing and export Korea Otsuka Pharmaceutical has engaged in Korea-China-Japan collaborative clinical R&D activities, leading Korea Otsuka Pharmaceutical has engaged in Korea-China-Japan collaborative clinical R&D introduction of the improvement of clinical research and expansion of the market of Korea, and expediting the excellent new drugs to Korea. (Phase 1: Welfare Through such efforts, the company signed an investment MOU with the Ministry of Health and domestic R&D to 2009 - 2013, about $900 million / Phase 2: 2014 - 2018, about $800 million) and has invested in by expanding support research of disease treatment while contributing to revitalizing the pharmaceutical industry its production facilities. As a result, the company succeeded in developing new indications (Abilify Japan, Taiwan, Malaysia, Vietnam, Indonesia, China, Cambodia, Thailand, Philippines, Hong Kong, Macao, Indonesia, China, Cambodia, Malaysia, Vietnam, Japan, Taiwan, [21 European countries] Sweden, Switzerland, Spain, Slovakia, Slovenia, Iceland, Romania, Bulgaria, Denmark, Germany, Greece, Norway, Ireland, U.K., Austria, Czech, Portugal, France, Finland R&D Hyangnam Plant of Korea Otsuka Pharmaceutical commenced construction in 1989, acquired KGMP (Korea Good Hyangnam Plant of Korea Otsuka Pharmaceutical Good Manufacturing Practice) in 1999, and in 2000 received FDA's Manufacturing Practice) in 1990 and BGMP (Bulk and acquired cGMP certification. The plant has continued to bulk drug substance manufacturing facility inspection operated world-class quality control and has and processes, equipment advanced introducing equipment, invest in as role its expanding finished product, the to synthesis ingredient from process, end-to-end the handle to systems a production base of Otsuka Pharmaceutical. Export Korea Otsuka as a multi-national pharmaceutical company, Operating large-scale production facilities in Korea but also secured global quality competitiveness and Pharmaceutical has not only supplied products domestically, and expanded 1991 in company parent its Japanese to re-export starting with economy, national the to contributed through acquiring the EU and Indonesia. Additionally, Vietnam Malaysia, to Asian countries, including Taiwan, Korea Otsuka Pharmaceutical has for its achievements, GMP in 2014, it has even expanded to EU. Recognized in 1998, the 20 Export Tower to win the 10 Million Dollar company pharmaceutical become the first multi-national in 2015. Million Dollar Export Tower in 2009 and the 30 Million Dollar Export Tower Export to 33 countries [12 Asian countries] Established in 1982, Korea innovative pharmaceuticalhas supplied various excellent and corporation that Otsuka Pharmaceutical is products, including Abilify a Japanese joint domestically for the first time in the world. The Korean approval and clinical data has been utilized by many foreign domestically for the first time in the world. The Korean approval and clinical data has been utilized promoted the authorities, including the US FDA and other countries as authorization data, which has consequently company's exports. indications) and a new formulation (Pletaal SR cap eam t ® ® ® ® Abilify Maintena Abilify Mucosta • Phone : +82-2-3287-9203 Others Kim Taejin Planning Team • Phone : +82-3287-9124 R&D/Export/Product Taegyu Han Development CONTACT US CONTACT Pletaal Otsuka-people Creating New Products for BetterNew Products for Creating Otsuka-people Health Worldwide Pharmaceutical Co.,Ltd. Korea Otsuka 32

Pharmaceutical Pharmaceutical 33 CR Tab., CR Tab., ® Tab5/50, Tab5/50, ® CR Tab. In addition, CR Tab. ® CR Tab. Tab, Losasc Tab, Stage of Developmen ® ® Duo Cap., Cilostan ® CR, UNIGRIL ® Remark CR, UNIGRIL CR, Kalomin ® ® Use CR Tab in 2015. CR Tab ® Asthma, COPD CR Tab., Calvixin CR Tab., ® Pulmonary Disease) (Chronic Obstructive CR Tab, Levotics CR Tab, Pain caused by rheumatism (Antiinflammatory Analgesic drug) Gastrointestinal symptoms associated with functional dyspepsia(brash, nausea, vomiting) Ischemic symptoms, Thrombosis (Antithrombotic drugs) Acute coronary syndrome (Antithrombotic drugs) CR, Levotics ® ® · Growth Rate from 2016 to 2017 : 11.4% · Growth Rate from 2016 : 833 (Dec. 31, 2017) · Number of employees · Sales : $179M (2017) Duo Cap, Cilostan KUP was nominated as Forbes’ ‘Asia’s 200 Best Under A 200 Best Under KUP was nominated as Forbes’ ‘Asia’s ® · Indication : ‌ · Improved dosing regimen from b.i.d. to q.d. · Less side effects of gastrointestinal · Indication : ‌ · Improved dosing regimen from t.i.d. to q.d. · Indication : Cough suppressant · Improved dosing regimen from t.i.d. to b.i.d. · Indication : Antithrombotic drugs · Improved dosing regimen from t.i.d. to b.i.d. · Indication : Hypertension (Anti-hypertensive drugs) · CCB+ARB in ONE tablet · Patent protected unique formulation · Indication : ‌ · Improved dosing regimen from b.i.d to q.d. · Reduced side effects of headache & tachycardia · Indication : Upper respiratory tract infection (Antitussive) · Improved patient compliance for adults · Indication : ‌ · Improved patient compliance KUP invested about 10.26% of net sales and 10.7% of total about 10.26% of net sales and 10.7% of KUP invested UI009 UI010 Code Tab5/100, Gastiin Tab5/100, Tab5/100, Gastiin Tab5/100, CR, Clavixin ® ® ® UP is aiming to be not only a local leader but also global leading company UP is aiming to be not only a local leader but also Clanza Losasc Drug delivery system - Novel Controlled Release Formulation - Novel Fixed Dose Korea Combination Sejong, Jeondong-Myeon, 25-23, Nojanggongdan-Gil, http://www.kup.co.kr Korea United Pharm. Inc. Kang Duk-Young Tab5/50, Losasc Tab5/50, 250, 500 ® ® Research Focus Research · Location Homepage· · Company · CEO · ACTIVAIR ® CR Tab. Tab. Duo Cap. CR Tab ® ® Tab5/50, 5/100 Tab5/50, Tab., Losasc Tab., CR Tab. ® ® ® ® ® Product (Ingredient/Formulation) Compound Name &D Pipeline(IMD Pipeline) xinafoate 250/72.5, 500/72.5ug (Aceclofenac 200mg/ Controlled Release Formulation) 2. Cilostan (Mosapride 15mg/ Controlled Release Formulation) 7. Levotics®CR Tab. ( Levodropropizine 90mg/ Controlled Release Formulation) 8. UNIGRIL®CR Tab. ( Sarpogrelate HCl 300mg/ Controlled Release Formulation) 6. Gastiin (Amlodipine 5mg and Losartan 50mg/Amlodipine 5mg and Losartan 100mg Dual Layer Anti-Oxidant) 3. Clavixin 5. Losasc (Cilostazol 200mg / Controlled Release Formulation) (Pelargonium Sidoides(as dry extract) 20mg / New Dosage Formulation) (Clopidogrel 75mg and Aspirin 100mg / Fixed Dose Combination) 4. Kalomin 1. Clanza SERETEROL Fluticasone propionate Salmeterol employees in R&D continuously. KUP is successful developing innovative drugs and commercializing them. employees in R&D continuously. Clanza As a result, KUP has launched several IMDs including Billion’ over two consecutive years. KUP is one and only pharmaceutical company in Korea nominated by the by nominated Korea in company pharmaceutical only and one is KUP years. consecutive two over Billion’ A Billion’ over two consecutive years (2009~2010). KUP 200 Best Under Forbes magazine as one of the ‘Asia’s in Korea for Cilostan was awarded the Best Drug Research Award Kalomin by offering wide range of generics as well as differentiated products, incrementally modified drugs. KUP has by offering wide range of generics as well as differentiated and exports 416 different items to 32 countries through broad and well balanced portfolio of 302 products business alliances with has and Vietnam, in USA, facilities manufacturing overseas and marketing, global KUP established manufacturing facility in Alabama, US for manufacturing and oversea companies. Especially, in markets expand to KUP allowed have facility This 2003. in foods functional health and drugs distrubuting regulatory processes. US, Japan, and Europe with know-hows of FDA Company Profile 3, 1987 · Establishment Date : Dec. · Business Activities : Manufacture, Marketing & Sales of Pharmaceuticals and Other Healthcare Products Other Healthcare and Marketing & Sales of Pharmaceuticals · Business Activities : Manufacture, : about 302 items · Number of registered products of net sales (2017) · Investment in R&D : 10.26% · Incrementally Modified Drug : ‌ Main Products (IMD Products) KUP export-oriented is company. KUP invested in Research&Development. KUP acknowledged been abroad. at has home and R KUP has well balanced R&D portfolio including differentiated products of anti-neoplastic, Anti-hypertensive, Anti-hypertensive, anti-neoplastic, of products differentiated including portfolio R&D balanced well has KUP and Antithrombotic Drugs. KUP is a Glabal Pharmaceutical Company All Company Glabal Pharmaceutical KUP is a World around the Pharm. Inc. Korea United Tab. Tab. Tab. CR Tab. Duo Cap. ® CR Tab. ® ® ® Contact Information Sangmin Lee • Phone : +82-2-558-8612 • E-mail :[email protected] Cilostan Clanza Kalomin GastiinCR Tab. Clavixin 32 35 - - - - - Under Launch Launch Launch registration Phase III Major Export Country Phase II Phase I/PK Content Melatonin Deferasirox Eodolac Micronized Calcium polycarbophil Budesonide micronized Saccharomyces boulardii Omega-3-acid ethyl esters Preclinical Thiocolchicoside Amorphous aescin Formerol Dry syr. Formoterol fumarate Formerol Dry syr. Omega-3-acid ethyl esters Rosuvastatin QOL Others Cardiovascular Gastrointestinal Research Product Omacor Cap Circadin Tab Experid Pow Wellcon Tab. Wellcon Diarrhea Rosumega Cap Thiosina Tablet Indication Bioflor 250 Pow Iron Chelator Pulmican Respule Kuhnil Pharmaceutical Co., Ltd Joong Young Kim Development, Manufacturing, and Distribution of Various Pharmaceutical ProductsDosage including Forms, Oral Injectables, Inhalers, etc. 100-120 Korea, Seoul, Jung-gu, Jeongdong-gil, 14, B/D, OhSong www.kuhnil.com Hyperlipidemia Hyperlipidemia Hyperlipidemia Hyperlipidemia Hyperlipidemia Hyperlipidemia Female Hypoactive Sexual Desire Disorder Lodine kuhnil Cap/Tab/SR Tab Lodine kuhnil Cap/Tab/SR Formerol Dry syr. Formoterol fumarate Formerol Dry syr. Specialty Business · CEO · · Head Office Homepage· · Company KI 3110 KI 1115 KI 1120 KI 1101 KI 1102 KI 1107 KI 1114 KI 3101 KI 3106 Product Hypnotics Respiratory Cardio Vascular Gastrointestinal Muscle relaxants Products in a wide selection of therapeutic areas including antibiotics, circula Kuhnil Pharm possesses pharmaceutical products and endocrinology. CNS, respiratory, gastrointestinal, anti-inflammatory, tory, ity against Rosuvastatin monotherapy in South Korea in control of combined dyslipidemia patient. The merit of ROSUMEGAof combined dyslipidemia against Rosuvastatin monotherapy in South Korea in control ity medication convenience.is that in not only provides clinical benefit but also improves Drug) of Exjade, dispersible tablet developed by Novatis. ComparingKuhnil has developed an IMD (Incrementally Modified provides economical efficiency by developing higher dosage than deferasirox generic to the original Novartis Exjade, Kuhnil’s type with improvement to dissolving rate compared to dispersiblethe original drug and better patient compliance as powder tablet. only insomnia treatment with the ingredient of which is the world’s In 2014, Kuhnil received sales approval of ‘Circadin’ and continue to expand sales. melatonin to the Ministry of Food and Drug Safety, pharmaceutical company that engages in the research and develop Kuhnil Pharm is a medium-sized, fully-integrated Korean muscu with strengths for the therapeutic areas of cardiovascular, ment, manufacture, and sale of pharmaceuticals products infection and neurology. loskeletal, gastrointestinal, respiratory, combi and formulation drug and DDS advanced of areas the in development and research in specialized also is company The The competitiveness of kuhnil is multi-layer capsule coating technology. nation drug development. Especially, injectable,general and products penicillin in specialized CMO a is which Ltd., Penmix subsidiaries; two has Kuhnil addition, In trade and business consulting of finished drug products and APIs. and Ohsong Pharm, which is specialized in international Kuhnil Pharm continues to strive to become an unique research-focused global to strive to become an unique Kuhnil Pharm continues global biopharmaceuticals, development of innovative company through to improve in an effort and combination drug products DDS pharmaceuticals, patients. quality of life in and Rosuvastatin which was launched in South Korea on 1st ofKuhnil has developed a fixed dose combination of Omega-3 2017 with the brand name ROSUMEGA. November, and Rosuvastatin have successfully demonstrating its superior ROSUMEGA, as the new fixed dose combination of Omega-3 R&D Pipeline

Pentacillin Inj. Pulmican Respule Thiosina Tablet Piperacillin Inj. Tabaxin inj. Tabaxin Amocla/Amocla Duo Tab/Syr/inj

CONTACT US CONTACT Yun Sook Kim R&D Center Manager / Team • E-mail : [email protected] Kuhnil Pharm., Co., Ltd. Kuhnil Pharm., Global pharmaceutical company committed in committed company Global pharmaceutical of life for people. better quality providing 34

Pharmaceutical Pharmaceutical 35

• • • NDA •

P III P • • • P II Clinical Trial • • P I PC • • • • • • • • DS LG Chem, Ltd Jin-Soo Park Diagnostics Biosimilar, Vaccine, New chemical entity, LG Gwanghwamun Bldg.92, Sinmunno-2ga, Jongno-gu, Seoul, Korea www.lgchem.com Indication · Company · CEO · Specialty · Location · Homepage DTP/HepB/Hib/IPV prevention prevention Poliomyelitis Autoimmune disease deficiency growth hormone Pediatric Osteoarthritis Diabetes/Dyslipidemia Myocardial infarction colitis Ulcerative Diabetes 2 Type Diabetes 2 Type Pneumonia prevention Pneumonia Type 2 Diabetes 2 Type Autoimmune disease

Product LBAL PentypeEutropin combo. Synovian Immune Cell therapy Stem Cell therapy ZemiStatin LC280126 LC510255 LC541239 LC65AOD5 New targets LBVD LBVC pipelines vaccine New LBVE Zemimet LBEC0101 High molecular weight hyaluronic acid viscosupplement made by microbial fermentation for low side-effect,High molecular weight hyaluronic acid viscosupplement quality proven by EMEA and CE marking -  Recombinant FSH, used in the treatment of female infertility in controlled ovarian hyperstimulation to induceRecombinant FSH, used in the treatment of female infertility reproduction program as well as anovulation the development of multiple follicles in a medically assisted Combined Diphheria, Tetanus, whole cell Pertussis, Hepatitis B and Haemophilus influenza typeB. whole cell Pertussis, Combined Diphheria, Tetanus, injection Eupenta can prevent five different childhood with a single ® The right choice for managing short stature recombinant human growth hormone with proven efficacy andThe right choice for managing short stature recombinant safety since 1993 A novel dipeptidyl peptidase IV (DPP IV) inhibitor for T2DM with good efficacy and safety profiles. A novel dipeptidyl peptidase IV (DPP IV) inhibitor for T2DM Approved by the MFDS in June, 2012 Fixed dose combination drug of gemigliptin and rosuvastatin for patients with T2DM and dyslipidemia. Fixed dose combination drug of gemigliptin and rosuvastatin Approved by the MFDS in July, 2017 Approved by the MFDS in July,  -  Fast Active, the most potent quinolone antibiotic in the world, commercialized in over 30 countries worldwide Fast Active, the most potent quinolone antibiotic in the - Human recombinant erythropoietin, safe and effective treatment for anemia of chronic renal failure - Human recombinant erythropoietin, safe and effective -  - ® -  ® - ® ® ® ® Class Vaccine Biologics Chemicals R&D Pipeline *NME: New Molecular Entity IMD: Incrementally Modified Drug CRF: Chronic Renal Failure NASH: Nonalcoholic Steatohepatitis Espogen Hyruan Plus Eupenta® -  Products Factive Zemiglo Zemilro The First Pioneer in Korean Pharmaceutical R&D Products in Korean Pharmaceutical R&D The First Pioneer contributing chemical company, LG Chem has served as Korea's representative Since its foundation in 1947, quality of life through continuous national economy and the enhancement of the to the development of the growth. on its stable based new product introduction, and quality innovation technological development, our business abroad, expanding and home at networks R&D and sales, production, the established have We provides innovative materials and aiming to become a world-class company that into the global market, in high-value added core businesses while expanding new solutions by sharpening our competitive edge and Energy Solutions. business opportunities in IT & Electronic Materials a former subsidiary of LG Chem in order to strengthen In addition, we have recently merged LG Life Sciences, and expand its business in Life Science area. on nurturing as a new growth engine of the future, LG In the business area which LG Chem has focused by applying genetic engineering technologies Chem became the first in Korea to develop gamma drug from U.S. Food and Drug Administration (FDA) with in 1989 and the first to receive approval for a new competitiveness secure to continue will Chem LG 2003. in antibiotic) "Factive"(quinolone of development its of its R&D capabilities based on its investment and enhancement in the global market through aggressive the drugs. technological prowess that has succeeded in commercializing Follitrope Eutropin ® Leading Global Life Science Company Global Life Science Leading Ltd. LG Chemical, ® ® ® ® ® Zemiro Synovian Eupenta Zemiglo Eutropin Pen Factive Jong-heon Won, Manager Won, Jong-heon Business Development Team • Phone : +82-2-6924-3233 • E-Mail : [email protected] CONTACT US CONTACT 34 37

® is an is is the is ® ® ® Deep, ® ranks No.1 Clinical Clinical Clinical Clinical Clinical Stage Clinical Clinical Clinical ® Discovery Discovery Discovery Discovery Discovery Discovery Discovery Non-Clinical Non-Clinical Non-Clinical Non-Clinical Non-Clinical is a representative representative a is ® Lidocaine, Neuramis ® Melanoma Indication Osteoarthritis Facial wrinkles Hangover relief Hangover Midfacial Volume Type 1 diabetes 1 Type Nose, Lip wrinkles Lip Nose, Penis enlargement Penis Various solid tumor Decreasing body fat Anti-adhrssive agent Fat reduction injection reduction Fat Immunological disease Immunological disease Diabetic retinopathy Diabetic ), all developed),all by in-house R&D. Since the successful Macular degenerationMacular Light Lidocaine, Neuramis ® Inflammatory bowel disease bowel Inflammatory ® Post-stroke upper limb spasticity Aesthetic and treatment (USA & EU) , Coretox , Volume Lidocaine which can be used to add volume and fullness to ® ® Idiopathic overactive bladder, Lateral canthal wrinkles, Migraine wrinkles, canthal Lateral bladder, overactive Idiopathic Essential blepharospasm, Neck dystonia, Benign masseteric hypertrophy, Medytox Inc. HyunJung Ho Botulinum toxin products, Medical aesthetics, Bio-pharmaceuticals Korea 28126, Chungcheongbuk-do Cheongju-si, Cheongwon-gu, Ochang-eup, 1-gil, Gangni 78, www.medytox.com , INNOTOX , ® Meso(Export Only), Neuramis ® MT941 MT971 MT921 MT981 MT961 MT942 MT927 MT932 MT933 MT963 MT943 MT912 MT914 MT925 Potenfill Innotox Coretox Lidocane Lidocane Neuronox · Company · CEO Specialty · · Location Homepage· Description Neuramis Deep Neuramis Volume is the is hyaluronic acid dermal filler product developed and launched The Neuramis in 2011. Deep Lidocaine, Neuramis ® ® Drugs Health Device Code Medical Biodrug Synthetic Synthetic in market share in Korea and has gained significant market share in many other countries.INNOTOX Neuramis botulinum toxintype product of Medytoxthat being is exportedto over 60countries. Neuronox the skin to correct moderate to severe nasolabial folds, the lines from your nose to the corners of your mouth. advanced new botulinum toxin type product that excludes animal derivatives, HSA and non-toxin proteins fromits ingredients. It also prevents the immune system from developing antibodies that would eventually wear down the effects of botulinum toxin type A. Neuramis Medytox the is only biopharmaceutical company in the world to have three different types of botulinum (Neuronox products toxin series, Neuramis world’s first formulation liquid of botulinum toxin type product which has been developed by totally excluding animal derived ingredients and human serum albuminin order to enhance product safety. Coretox developmentof the fourth botulinum toxin type productA thein world, Neuronox Botulinum product Toxin  Supplements 2. Hyaluronic Acid Dermal Filler  Main ProductsMain  1. Medytox is at the forefront of Korean biopharmaceutical industry, with our industry, biopharmaceutical Korean of the forefront at is Medytox and to our our on based top-tier biotechnologists, capabilities R&D excellent facilities. state-of-the-art and production operations As the first botulinum toxin developer and the market leader in Korea, we feela sense of pride and responsibility for this industry, which why is we are leading the efforts to improve the transparency and the competitiveness of the Korean biopharmaceutical businesses by pushing for implementation of more objective and scientific guidelines for industry practice. Medytox, as a company striving to change the future, has set a new goal of entering 20 the list Top of biopharma companies by 2022. R&D Pipeline

[email protected]

® ®

Neuramis Nueronox Junghwan Kim, Manager Business Development Team • Phone : +82-2-6901-5839 • E-Mail :  CONTACT US CONTACT Medytox Inc. Studying the Time of Humankind the Time Studying 36

Pharmaceutical Pharmaceutical 37 Activity test Activity test Approval Process Approval Process Approval Formulation studyFormulation Clinical study(Pivotal) Development StageDevelopment Clinical Study(Phase 3) Indication Anti-adhesion cosmeticsAnti-aging Beauty Anti-aging Joint Health Ulcer Beauty PharmaResearch Products Co., Ltd. Ahn Sang-Soo, Jung / Won-Joon, Anti-aging and QOL (quality of life) products based on Regenerative medicine (Office) 74, Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea / (Factory) 77-19, Gwahakdanji-ro, Gangneung-si, Gangwon-do, Korea www.pr-products.co.kr Project Name Functional peptide Functional cosmeticsAnti-aging PRM-0011 SupplementNucleic acid Joint Health Therapeutic peptide PRM-003L · Company · CEO · Specialty · Location · Homepage

Drugs devices Medical Cosmetics ® Classification ® Health Supplement Health R&D Pipeline New Regenerative Filler (Healer) for Satisfying both skin regeneration and filler effect 1) Skin elasticity improvement 2) Dermis density and thickness improvement Conjuran Intra-articular injection for Cartilage regenerative osteoarthritis treatment 1) Knee pain relieft Major Products Over the Counter Drugs (OTC) Re-an® eye drop (Sodium Polydeoxyribonucleotide) Cornea and conjunctiva regenerative eye drop diseases due to the lack of nutrition 1) Nutrition supply to cornea and conjunctiva with ulcerative caused by external stress such as contact lenses tec. 2) Applicable to micro injuries of cornea and conjunctiva Ethical Drugs (ETC) Rejuvenex® injection (Sodium Polydeoxyribonucleotide) and tissue regenerative injection healing Wound and tissue restoration for skin graft healing 1) Wound Medical device Rejuran PharamResearch Products is a R&D focused biopharmaceutical company Products is a R&D focused biopharmaceutical PharamResearch for a better and longer life.creating a value anti-aging and for products healthcare developing and researching been has Products PharmaResearch in regenerative medicine going to become a leading healthcare company are We improving Quality of Life. through DNA fragment optimizing technology(DOT). as the first pharmaceutical consulting firm for introducing PharmaResearch Products was established in 1993 in Korea. Through the consulting business, PharmaResearch and registering new drugs and medical devices experience about new technology and products. In 2007, Products get to have enough information and regenerative medicine company by developing endogenous PharmaResearch Products stood up as a leading Optimizing technology. repair stimulator PDRN® utilizing DNA fragment the product pipelines for regenerative medicine on license-in, PharmaResearch Products diversified Moreover, competitiveness of techniques and continuous R&D, co-developments and strategic investments. Through extension in both domestic and global. Also, starting from PharmaResearch Products is promoting market overseas business. China and Japan, PharmaResearch Product is practicing Total healthcare company Practicing Regeneration medicine for medicine Practicing Regeneration company healthcare Total and Longer Life a Better Ltd. Products Co., PharmaResearch injection ® ® ® Eye drops ® Conjuran Re-an Rejuvenex Rejuran CONTACT US CONTACT Sungoh LEE • Phone : +82-31-8039-1570 • E-Mail : [email protected] 36 39

Approved PhaseIII Phase II Phase I Investigator Initiated Trial Pre- Clinical SCI GvHD IPF CLI Respitory Failure , Cellgram- , AMI Kidney transplant - Liver Cirrhosis(US) Liver Cirrhosis (KR) IS ® Parkinson’s Disease Hemorrhagic StrokeHemorrhagic Erectile DysfunctionErectile Critical Leg Ischemia LC Acute Ischemic StrokeAcute Ischemic Chronic Cardiac Disease Ovarian/Prostate Cancer Chronic Spical Cord Injury , Cellgram- , Acute Myocardial Infarction Myocardial Acute is active is pharmaceutical ingredients to enhance stability of therapeutics such as growth DC ED Breast/Kidney/Ovarian Cancer Pharmicell Co., Ltd. Hyunsoo Kim, Seonglae Kim stemcell therapy products,cell therapy products, PEGs,API, flame retardantsstem 7th cell cosmetics, floor, Ssangbong etc B/L, Unju-ro, Gangnam-gu, Seoul, Republic of Korea www.pharmicell.com Glio-blastoma/Malignant Melanoma

Commercialization StepsCommercialization Pulmonary Disease Cellgram- Liver Disease Cellgram- Disease Liver Etc. Cellgram- Etc. Cardiac Disease Cellgram Neuro Disease Cellgram- Disease Neuro Cancer Cellgram- -AMI · Company · CEO Specialty · · Location Homepage· ® (DC) (MSC) Class Stem Cell t was approved from Ministry of Food and Drug Safety and in July became 2011 the world’s first commercialized stem Polyethylene glycol(PEG) Polyethylene hormone, and insulin. PEG supplied is to internationally well know pharmaceutical companies as Merck and Roche. DNA diagnostic kits and therapeutics’ core material of Nucleoside are supplied to Thermo Fisher and Sigma-Aldrich. Cellgram Also, various clinical trials are being conducted for such diseases of stroke, spinal cordinjury, liver cirrhosis, erectile dysfunction, and critical ischemia. limb The efficacy of Pharmicell’s stem cell therapy product was introduced via local and international mass communication which giveshigh reliability of the product. Especially, to precede clinical trials in US for liver cirrhosis, the Pre-IND meeting with US FDA was completed in 2014. The clinical trials begin will during second half of 2017. celltherapy product. As can be seen from the attached file, the product was approved forimproving rapidly decreased cardiac function(Ejection Fraction) and MACE(Major Adverse Cardiac Events) from acute myocardial infarction patient. I Dendritic Cell ‌  Mesenchymal Mesenchymal R&D Pipeline 2. API(Active Pharmaceutical Ingredients)  Main ProductsMain 1.   The world The best thefirst beyond world world stem cell therapyproduct withparadigm technology. bio-chemical shiftof Pharmicell a bio-pharmaceutical is and bio-chemical research and development company that specializes producing in stem cell therapy products and active pharmaceutical ingredients, innovating stem cell banking technology. Pharmicell further is committed to technological innovations that involve the commercialization of stem cells through bio-based businessand cosmetics. Since the company’s founding in 2002, Pharmicell has been driven by passiona for innovative research and technology, coupled with its commitment to improving the quality of life by pioneering safe, deliverable, new, revolutionary treatment products. At the forefront of Pharmicell operational strategy its is unrelenting focus on ensuring the quality of life on a globalscale by offering holistic and sustainable solutions to unmet medical needs through stem cell research and product distribution. Most importantly, Pharmicell sets itself apart in the bio technology industry by practicing generosity. Over the past fifteen years, Pharmicell has become an asset to the stem cell treatment industry onredefining a global scale bythe boundaries of science orderin to create more innovative solutions for medical issues, thus cultivating global dependency and demand for Pharmicell’s products. 

[email protected]

Jinyoung Jo executive director / Sales Department • Phone : +82-2-3496-0190 • E-Mail :  CONTACT US CONTACT Cellgram product

Cellgram Box Pharmicell Co., Ltd. Pharmicell Pioneer of stem cell industry and Bio-company with cutting and Bio-company of stem cell industry Pioneer edge technology 38

Pharmaceutical Pharmaceutical 39 Oral Oral Oral Oral Oral Oral Oral Oral Oral Oral Topical Injection Injection Oral / Topical Route of Administration NSAIDs Indication Antithrombotic Appetite stimulant Antihyperlipidemia Antiatherosclerotic Treatment of dementia of Treatment Surgical chemotherapeutic Surgical Clinical Preclinical Preclinical Preclinical Clinical Phase I Clinical Phase II Clinical Phase II Biological testing Biological testing Biological testing Biological testing Biological testing Biological testing Preclinical / Clinical Development Stage Treatment of dementia, age related memory loss and head injury HIV Cancer Cancer Cancer Cancer Cancer HIV, HBV HIV, Diabetes Hormones Indication Dry eye syndrome Dry eye syndrome Sjogren syndrome Platelet aggregation Alzheimer's disease Taurolidine Category Oxiracetam Rosuvastatin calcium Acetaminophen, etc Clopidogrel bisulfate DL-Carnitine hydrochloride, etc Atorvastatin calcium trihydrate calcium Atorvastatin Donepezil hydrochloride monohydrate hydrochloride Donepezil Samjin Pharmaceutical Co., Ltd. Sung Woo, Lee Manufacture, Marketing and Distribution of Pharmaceutical Products (Finished Products 121,Wausam-ro,Mapo-Gu,Seoul,Korea and APIs) www.samjinpharm.co.kr Code SA001 SJP003 SJP005 SJP004 SJP002 SJ-3366 SJ-3902 SJP1602 SJP1610 SJP1801 SJP1601 SJP1701/SJP1702 SJP1604 (APTA-16) · Company · CEO · Specialty · Location Homepage· Trestan Products Neutoin Tablet Geworin Tablet Geworin Plateless Tablet Taurolin Injection Taurolin Neustatin-R Tablet Neustatin-A Tablet Neuracetam Tablet NCE IMD R&D Pipeline Main products Samjin Pharm Co.,LTD. development of novel complement our expertise in the partnerships that seeks to business capabilities. important scientific, clinical and therapeutics with establish strategic alliances and companies striving to produce novel therapeutics with Samjin is one of the Korean leading pharmaceutical Samjin has grown massively and achieved fruitful outcomes relentless effort. Since its establishment in 1968, (antiarteriosclerotic agent), Neuracetam® (Nootropics), through its representative products such as Platless® of Samjin covers several crucial therapeutic areas including Geworin® (NSAIDs) and etc. The R&D portfolio Samjin is actively engaged in joint research with and neurology. diabetes/obesity dry eye syndrome, oncology, leading therapeutic candidates acting on dry The Samjin’s more than 20 cooperative research institutions. (AML)/myelodysplastic syndrome (MDS), immune checkpoint eye syndrome and acute myelogenous leukemia Samjin has a track record in creating stage, respectively. inhibition have entered clinical and pre-clinical institutions and commercial enterprises to accelerate the innovative strategic partnerships with academic are waiting for an innovative and collaborative global partnership with development of novel therapeutics. We variety of business models. For the Health Life and Fruitful Future Life and Fruitful For the Health Co., Ltd. Samjin Pharmaceutical [email protected] ® ® PLATLESS Ferbon Tab Tiroxin Neutoin NEUSTATIN-A CONTACT US CONTACT Bum Kyu, Shin Manager, General Overseas Business Department • Phone : +82-2-3140-0673 • Fax : +82-2-392-5315 • E-Mail :  38 41 Market Market Clinical Research Research Preclinical Preclinical Preclinical Registration Development Status Comment Japan (PMDA) Japan (PMDA) Germany (BGV) Germany (BGV) Australia (TGA) Inspection Authorty · CEP completed · KDMF completed · KDMF completed · Launched in Korea & Georgia · CEP completed · Cremophor-free, Ethanol-free formulation · Cremophor-free, as CMO) · Launched in EU & Japan(Working · All dossiers are ready for approval procedure as CMO) · Launched in EU (Working · Launched in Korea · Launched in Korea (Size reduction) · Dosage form : Tablet · Reduced API (50%) with same PK as original · Tween-80 free formulation (No diluent vial) · Tween-80 · Reduced API (66%) with same PK as original · Launched in EU (Registered in DE, BG, RO, UK) BG, RO, EU (Registered in DE, in Launched · & Japan · MRP running for other EU members · Launched in Korea · Approval process ongoing in Iran · Launched in Korea pDNA siRNA mRNA Sirolimus Paclitaxel Products SYO-1644 Docetaxel Docetaxel Ramosetron Prednisolone Temsirolimus 100mg 500mg 3.5 mg EP, USP EP, EP, USP EP, in-house in-house 4mg / 5mL 20mg, 80mg 200mg/40mL 30mg, 100mg 1000mg / 40mL Strength / Grade 4.6mg/day, 9.5mg/day 4.6mg/day, 20mg/1mL, 80mg/4mL 140mg/7mL, 160mg/8mL 5mg/10mL, 100mg/20mL /hr, 50㎍/hr ㎍/hr, 25 12㎍/hr, Samyang Biopharmaceuticals Corporation. Eom Taeung Oncology, GMP Manufacturing(APIs, Injections, Patches), DDS Technology 13488, Korea Gyeonggi-do Seongnam-si, 295 Bundang-gu, Pangyo-ro, www.samyangbiopharm.com 25, 20, 15, 10, 7.5, 5, 2.5mg 100mg / 4mL, 500mg / 20 mL 30mg / 5mL, 100mg / 16.7mL 150mg / 25mL, 300mg / 50mL Product Paclitaxel (API) Docetaxel (API) Diclofenac Patch Oncology Injections Active Fentanyl · Company · CEO · Specialty · Head Office Homepage· Paclitaxel Paclitaxel Docetaxel Docetaxel Oxaliplatin Bortezomib Paclitaxel (API), Docetaxel (API), Pemetrexed Pemetrexed Ingredient Rivastigmine Lenalidomide SENS Zoledronic acid Oral_BA Oral_FDT Oral_CSDS Synthetic Paclitaxel (API), Pemetrexed (API) ® ® Paclitaxel Docetaxel nucleic acid delivery) Bortezomib M Pemetrexed PM(Polymeric Micelle) S ® ® PM ® ® ® Technology Description Technology PNP(Polymeric Nano-Particle) (Stability Enhanced Nano Shells for Generic Zolenic Lenalid Pemed (Colonic Specific Drug Delivery System) Products Fentaderm Nanoxel DemenCure Genexol Year 2010 2017 2014 2013 API Oral colitis Patch Injection Category Ulcerative Anticancer Antiemetic Category Main Products Samyang Biopharmaceuticals Corporation is engaged in the development and marketing Corporation is engaged in Samyang Biopharmaceuticals systems and medical devices.of novel drug delivery The business of the 21st century. is focusing on healthcare as its core strategic Samyang Biopharmaceuticals novelclass world of development the for technologies core unique and proprietary developeing to is goal company’s drug delivery systems. GMP Certifications R&D Pipeline

[email protected] [email protected]

General Manager, Business Strategy Manager, General Team • Phone : +82-2-2157-9812 • E-mail : Senior Manager, Overseas Business Team • Phone : +82-2-2157-9861 • E-mail : [email protected] Business development Mr. Seyoon Kim API Sales Mr. Ryan Jae Yoon Kim Overseas Pharmaceuticals Sales Mr. Sung-Seup Shin Overseas Leader, BusinessTeam Team • Phone : +82-2-2157-9857 • E-mail : CONTACT US CONTACT

Corporation. Value Generating Pharma Company Generating Pharma Value Biopharmaceuticals Samyang 40

Pharmaceutical Pharmaceutical 41 sanofi-aventis Korea sanofi-aventis Kyung-Eun (Kay) Bae Diabetes, Cardiovascular Disease, Internal Medicine, Central Nerve System, Infectious arthritis Rheumatoid Disease, and +82-2-2136-9000 +82-2-2136-9099 235, Banpo-daero, Seoch-gu, Seoul www.sanofi.co.kr ® ® ® Founded Sanofi Established Sanofi Korea Established sanofi-aventis Group Established clinical R&D unit under direct control of corporate headquarters Started sanofi-aventis Korea Launched Cenovis, the consumer healthcare brand Started Sanofi Group Integrated Management Committee Received Family-Friendly Company Accreditation by MOGEF Accredited as Innovative pharmaceutical Company by MOHW Re-accredited Family-Friendly Company by MOGEF Acquired Consumer Health Care from Renewed Innovative pharmaceutical company by MOHW ® ® · Company · GM Specialty · · Tel Fax · · Location Homepage· Diabetes Aprovel Essential hypertension, Renal disease type in 2 diabetes with hypertension Eloxatin Colorectal cancer, stomach cancer, pancreatic cancer Taxotere Breast cancer, stomach cancer, non-small cell lung cancer, head and neck cancer, ovarian cancer, esophageal cancer prostate and cancer R&D Pipeline Myelofibrosis, Articular cartilage defects, Muscular atrophy, Diabetes, Rheumatoid arthritis, Dyslipidemia, Atopic dermatitis and Asthma History 1973 1991 2004 2005 2006 2010 2012 2013 2014 2016 2017 2017 Products Plavix Atherosclerosis symptoms Lantus Sanofi: A Health Journey Partner Sanofi: Sanofi dedicated is to supporting people through their health challenges. are We a global biopharmaceutical company focused on human health. prevent We illness with vaccines, provide innovative treatments to fight pain and ease suffering. stand We by the few who suffer from rare diseases and the with millions long- term chronic conditions. With more than 100,000 people in 100 countries, Sanofi transforming is scientific innovation into healthcare solutions around the globe. Sanofi headquartered is Paris, in France and listed in Paris (EURONEX:SAN) and New (NYSE:SNY). York In Korea, Sanofi has three legalentities in the areas of pharmaceuticals and consumer healthcare (Sanofi- aventis Korea), vaccines (Sanofi Pasteur) and specialty care (Genzyme Korea). Sanofi-aventisKorea has been contributing to Korea healthcare industry to move advance through ‘open innovation’. Accredited as Innovative Pharmaceutical Company in 2014, Sanofi-aventis Korea has established and looked forward to seeking out partnerships with promising pharmaceutical companies, bio-techs, clinical research centers as well as academia in Korea to bring innovation where high unmet patient needs exists, while continuously investing in clinical development of new medicines and help Korean partners go global. Empowering Life Empowering Korea sanofi-aventis ® ® ® ® ® Research collaboration Research SangGyunDr. Kim Head of Research • Phone: +82-42-863-9204 • E-mail : [email protected] CONTACT US CONTACT Taxotere Eloxatin Aprovel Lantus Plavix 40 43 NCE NCE Generic Stage IMD/FDC IMD/FDC Launched Launched Launched Pre-clinical Pre-clinical Pre-clinical Pre-clinical Classification Phase 2 (Korea) Phase 1 (Korea) Phase 1 (Europe) Novel Medical Device Phase On Market On Market On Market On Market On Market On Market Indication Anti-malaria Anti-malaria Anti-platelet Heart failure Atherosclerosis Dermal/body filler SHIN POONG PHARM.CO.,LTD SHIN JEI MAN RYU Manufacture and Sales of the pharmaceutical products YOKSAM-RO,161 KANGNAM-GU, SEOUL, 06246, KOREA www.shinpoong.co.kr Acute ischemic stroke Adhesions after surgery Osteoarthritis (one injection) Osteoporosis/Fracture healing · Company · CEO · Specialty Business · Head Office Homepage· Indication Antimalarial Antimalarial Hypertension Osteroarthritis Hyperlipidemia ® Adhesions after surgery TM TM Tab. Gran. ® ® SP-8008 SP-8203 SP-8356 SP-8232 SP-35454 HyalOne Products FreeWink Medicurtain Pyramax Pyramax ® ® Tab. Tab. ® Tab. Gran. ® ® ® Name Hyal Forte Ezerosu Medicurtain Pyramax Pyramax Candeamlo NCE NME Novel Medical Device Category R&D Pipeline Under the management philosophy of ‘for the health of the people’, Shin Poong Pharm. Co., Ltd. specializes Under the management philosophy of ‘for the put into producing every single tablet of life-saving drugs in manufacturing remedy drugs with sincere efforts manufacturing facilities and quality based on our state-of-the-art products to finished from ingredients ranging with and Victory) Venture are committed to realizing the spirit of Shin Poong 3V (Vision, assurance system. We synthesizing technologies obtained through rigorous R&D top-notch competitiveness based on in-house ingredient the one that receives confidence from our customers and that efforts and to further developing the company into beings. contributes to promoting the wellbeing of human Main Products Shin Poong Pharm. Co., Ltd is a R&D oriented multinational pharmaceutical Co., Ltd is a R&D oriented multinational Shin Poong Pharm. company headquartered in Seoul, South Korea, with 7 manufacturing site Main focusing areas global partners in over 59 countries. worldwide with and anti-infective. wound care, musculoskeletal surgical CNS, are CV,

® ® ®

® ®

CandeAmlo Tablets.& Granules. Tablets.& Pyramax Medicurtain Hyal Forte EzeRosu Contact Information Su Mi Oh, Director • Phone : +82-2-2189-3500 • E-mail : [email protected] CONTACT US CONTACT For the health of the people For the health Pharm.Co.,Ltd Shin Poong 42

Pharmaceutical Pharmaceutical 43 Phase I Phase I Status Phase III Phase III Marketed Marketed Marketed Screening Screening Screening Screening Preclinical Registration Registration Registration Approved in US, EU (Licensed out) Information Quadrivalent cell culture influenza vaccine st Korean new chemical entity Korean new herbal drug Korean cell culture influenza vaccine st st st Vaccine Vaccine Vaccine Vaccine Vaccine Vaccine Anti-cancer agent *The 1 Patch formulation with anti-inflammatory Cartilage protective agent *The 1 Orally dissolving film formulation (ODF) forerectile dysfunction (ED) treatment disease exporting worldwide Patch formulation for Alzheimer’s Prevention for influenza virus *The 1 Prevention for influenza virus 1 *The World Bio-better (Bio-better) Description Plasma product BA enhancing tech Botanical / chemical New Chemical Entity Orally dissolving film SK Chemicals Co. Ltd. Mahn-hoon, Park Specially chemicals and life science business 463-400 Gyeonggi-do, Seongnam-si, Korea Bundang-gu, Pangyo-ro, 310, www.skchemicals.com Chemical, combination drug Chemical, patch formulation Chemical, controlled release Recombinant Plasma protein · Company · CEO Specialty · · Location Homepage· - - Epilepsy Product Varicella Varicella Hemophilia Indication Haemophilia Herpes zoster Multiple sclerosis Overactive Bladder Parkinson’s disease Parkinson’s Erectile dysfunction Pneumococcal diseases Seasonal cell culture flu Chronic arterial occlusion Stroke, systemic embolism Hepatitis B immunoglobulin NBP NBP SID143 SID125 SID142 NBP601 NCE407 NBP602 NBP604 NBP607 NBP606 NBP608 SID1601 SID1601 THVD201 Product Sunpla injection (3rd generation platinum complex anti-cancerdrug) Trast patch (Piroxicam) Trast Killilowii, Joins (Clematis mandshurica, Trichosanthes Prunella vulgaris ext) Mvix (Mirodenafil) Rivastigmine patch SKYCellflu SKYCellflu Quadrivalent Main Products SK Chemicals contributes to enhance human health and the quality of life to enhance human health SK Chemicals contributes vaccines and innovativepremium drugs, synthetic by developing new manufacturing technologies. industry in 1999, when it new chapter in the history of the Korean pharmaceutical SK Chemicals opened a world's first third generation platinum complex cancer drug. succeeded in launching SUNPLA, Korea's and the a novel erectile dysfunction agent in Korea. In PDE5 inhibitor, In 2007, the company launched the world's fifth world first orally dissolving film (ODF) formulation containing 2011, it also succeeded in commercializing the the PDE5 inhibitor. manufacturing not only ODF formulation but also transdermal patch the platform technology of In particular, in developing incrementally modified formulation drugs. As a formulation had made SK Chemicals as a leader approved for sale in Europe. SK Chemicals is actively result, dementia patch called SID710 was successfully marketing and exporting the product to major markets. R&D of range wide a possesses now Chemicals SK activities, R&D its to investment ceaseless of virtue the In the Particularly, drug. protein recombinant to products derived plasma and vaccines premium from portfolio vaccine, it succeeded in obtaining the Korea's first marketing next generation technology of cell-culture based vaccine. As a part of continuous commitment to vaccine authorization of cell-culture technology based influenza As a result, the vaccine manufacturing plant in Andong city. R&D, it also completed building a state-of-the-art organizations. licensing agreements with multinational company already entered into a couple of major R&D Pipeline SK Chemicals focuses on developing premium vaccines, plasma derivatives and chemical drugs intherapeutic areas with high unmet medical needs.

Developing Premium Vaccines, New Chemical Entities, Biopharmaceutical Drugs Entities, Biopharmaceutical New Chemical Premium Vaccines, Developing Co. Ltd. SK Chemicals Jeeho HEO General Manager General Rivastigmine patch SKYCellflu Quadrivalent prefilled syringe SKYCellflu prefilled syringe Trast Patch Trast Mvix ODF Joins Tab. Sunpla Inj. Name :  CONTACT US CONTACT • Phone : +82-2-2008-2819 • E-Mail : [email protected] 42 45 HCV/Phase I HIV/Marketed Goal HCV/Marketed HBV/Marketed Diabetes/Marketed Antibiotics/Marketed Antifungal/ Marketed Indication/Stage Phase I in 2018 Phase I in 2018 For clinical trial For clinical trial Tuberculosis/Marketed MRI contract/Marketed Released in 2018 Released in 2021 Released in 2024 Anticoagulant/Marketed A For clinical trial Hyperlipidemia/Marketed Pre-clinical in 2018 Various RNA therapeutics/Clinical Various JP US/EP/JP Customer Domestic/ROW Domestic/JP/ROW Domestic/JP/ROW S.Africa/Germany/CIS Originator (Worldwide) Originator (Worldwide) Originator (Worldwide) Originator (Worldwide) Originator (Worldwide) Originator (Worldwide) HIV Cancer Diabetes Diabetes Anti-viral Anti-viral Project Anticoagulants Anticoagulants MRI contract Media ST Pharm Co., Ltd. Kyungjin Kim Oligo APIs and New Drug Development, CMO(New Drug APIs & Intermediates), Generic APIs 7F MSA Bldg., 891-43, Daechi-dong, Gangnam-gu, Seoul, Korea http://www.stpharm.co.kr HCV drug HCV drug Terizidone Gadobutrol Clopidogrel Atorvastatin Voriconazole Products Diabetes drug Chiral epoxide Chloro-(L)-sugar Antibiotics drug Nucleoside monomers · CEO Specialty · · Location Homepage· · Company

New Drug New Drug Category Generic APIs Category

New Drug APIs Generic APIs Generic APIs ST Pharm extends the product pipelines to generic APIs and intermediates with supportive APIs and intermediates with ST Pharm extends the product pipelines to generic market. enter domestic and global DMFs and high-spec quality control required to timely R&D Pipeline (selected) Main Products 1. Custom Manufacturing 1) New Drug APIs & Intermediates 2) GMP-Oligonucleotides (for RNA therapeutics) 2. Generic APIs & Intermediates Products List (selected) “ST Pharm Provides Reliable and On-time Services Under cGMP Condition” Under cGMP Reliable and On-time Services Pharm Provides “ST top custom manufacturing services (formerly known as Samchully Pharm) is offering Established in 1983, ST Pharm high the client’s in compliance to cGMP to fulfill (API) and their intermediates ingredient for active pharmaceutical and commercialization. of our products in pharmaceutical development expectations for the use Socio Group that has been the leading healthcare company in In 2010, ST Pharm became a member of Dong-A Korea since 1967. under KOSDAQ In 2016, ST Pharm was listed as a public company

CONTACT US CONTACT Jongwon Lee Researcher R&D Supporting Team R&D Center • Phone : +82+31-488-1401 • E-mail : [email protected] ST Pharm Co., Ltd. ST Pharm World Leader in API Custom Manufacture Leader in API World 44

Pharmaceutical Pharmaceutical 45 Pre-clinical Pre-clinical 2011 2010 2009 2016 Year Current Status 2014, 2018 Phase 3 ~ Pre-clinical 2010, 2013, 2014, 2016 2008, 2011, 2014, 2017 1995, 2010, 2011, 2012, Dry eye Indications Bacterial conjunctivitis Ophthalmic/GI indications Facility Taejoon Pharmaceutical Co., Ltd. Lee Young Tae agents Gastrointestinal media, Contrast therapeutics, Ophthalmic 8 Daesagwan-ro 31-gil, Yongsan-gu, Seoul, Korea www.taejoon.co.kr/en/ Ophthalmic solution Sterile ophthalmic solution Sterile ophthalmic solution Sterile ophthalmic solution Sterile ophthalmic solution · Company · Co-CEO Specialty · · Location Homepage· Vendor audit for sterile ophthalmic solution Vendor Vendor audit for sterile ophthalmic solution Vendor Product Name Combination or Improved drugs GMP KGMP EU GMP Anvisa GMP Dry eye product (New Chemical Entity) NAFDAC GMP US FDA Audit Antibiotic product (New Chemical Entity) Vendor Audit (EU) Vendor Vendor Audit (Italy) Vendor Indication: MR imaging in adult and children of all ages for the whole body Indication: MR imaging in adult and children of all contrast enhancement of computerized tomography. urography, angiography, Indication: Myelography, Indication: For the reduction of IOP in patients with open-angle glaucoma, chronic angle-closure glaucoma Indication: For the reduction of IOP in patients with or ocular hypertension Indication: Increase tear production in patients whose tear production is presumed to be suppressed due toIndication: Increase tear production in patients whose sicca. Increased tear production was not seen inocular inflammation associated with keratoconjunctivitis drugs or using punctual plugs. patients currently taking topical anti-inflammatory 7 6 5 4 2 3 1 - -  -  - ‌ No. GMP Certification List Main Products Ophthalmic therapeutics Preservative Free) •XALOST SUD (API: LATANOPROST, •CYPORIN N (API: CYCLOSPORINE, Nano-technology) Contrast Media •Gadobutrol (Pre-filled Syringe) (API: Gadobutrol) •IOBRIX INJ. (API: IOHEXOL) Taejoon Taejoon Pharmaceutical Co., Ltd. is a leading and gastrointestinal agents contrast media, company in ophthalmology, specialty pharmaceutical Pacific Asia Europe, America, of States United the in presence global a with Region Africa.and R&D Pipeline Leading Biotech Company for Better Life Biotech Company Leading Co., Ltd. Pharmaceutical Taejoon Gadobutrol (Pre-filled Syringe) Cyporin N Xalost SUD CONTACT US CONTACT Jun Hee Lee / Business Development • Phone: +82-2-799-0072 • E-mail: [email protected] 44 47 ® ROSMIR completed (Dec. 2017) NDA III II Clinical Investigator’s trial under way trial under Investigator’s I degree burn and chronic skin ulcer. It degree burn and chronic skin ulcer. nd Pre- Clinical Wrinkles degree burn. rd Indications Corneal defects Rotator-cuff tear Rotator-cuff tear Rotator-cuff Cartilage defects Cutaneous wounds Oral mucosal defects TEGO SCIENCE, INC. SCIENCE, TEGO Saewha Jeon Develops and markets products in regenerative medicine, Stem cell and alternative testing93, spaces Magokjungang 8-ro, Gangseo-gu, Seoul 07794, Korea www.tegoscience.com Chemokine Chemokine Category · Company · CEO Specialty · · Location Homepage· is a cultured skin autograft. Its commercialization was Korea's first and world's second. The patient’s and world's second. The patient’s was Korea's first is a cultured skin autograft. Its commercialization is an allogeneic cultured skin sheet indicated for deep 2 is an allogeneic cultured skin sheet indicated for designates a group of human skin models consisting of live human cells. Any or all layers of the of live human cells. designates a group of human skin models consisting ® ® ® is an autologous fibroblast therapy intended for the treatment of nasojugal grooves, or tear trough is an autologous fibroblast therapy intended for ® Dermal fibroblasts (allo) Dermal fibroblasts (auto) Dermal fibroblasts (auto) Mucosal keratinocytes(auto) Mucosal keratinocytes (auto/allo) Kaloderm human skin can be replicated in vitro, making it possible to test the safety and efficacy of cosmetic/therapeutic possible to test the safety and efficacy human skin can be replicated in vitro, making it animal testing. substances without resorting to inhumane and expensive Rosmir own skin cells are cultured and exponentially expanded to produce grafts that are transplanted back on the to produce grafts that are own skin cells are cultured and exponentially expanded wound. It is indicated for large 3 patient’s promotes healing of the wound and minimizes scar formation. Since source cells are from another human, it can formation. Since source cells promotes healing of the wound and minimizes scar types of acute/chronic wound duration. It can be used on all be manufactured ahead and stored frozen for long It is a globally unique product and dermatology markets. and has promising applications in the cosmetic surgery Sales have so far been over potential overseas competitions. that has cost, therapeutic and shelf-life advantages introduce it to overseas markets. limited to South Korea, but work is under way to Neoderm * Arrows indicate current progress with KFDA R&D Pipeline Products Holoderm A World Leader in Cell Therapy & Advanced Regenerative Medicine Advanced Therapy & Leader in Cell World A wound for therapy cell skin regenerative in specializing company biopharmaceutical Seoul-based a is Science Tego allogenic cultured skin grafts widely cell therapy market with autologous and Korea’s healing. It has pioneered technologies in cell culture, skin-graft chief strengths have been leading-edge Tego’s used in burn and ulcer clinics. into wider regenerative medicine areas involving musculo- manufacturing and cryopreservation. It is now evolving Science has been with plans for overseas expansion. Tego skeletal, ophtalmological and dematological targets, listed in KOSDAQ since 2014. deformities. It was approved for marketing in December 2017 and sales will commence during the first half of 2018. deformities. It was approved for marketing in December

[email protected] [email protected] ® ® ®

® Neoderm Rosmir Kaloderm Holoderm • Fax: +82-2-2107-3173 • E-mail : • Fax: +82-2-2107-3173 • E-mail : Seung-wun Baek, Manager Business Development Team • Phone: +82-2-818-2932 CONTACT US CONTACT Jeon, Jaewook Chief Strategy Officer • Phone: +82-2-818-2900 TEGO SCIENCE, INC. TEGO SCIENCE, At the leading edge of cell therapy edge of cell At the leading 46

Pharmaceutical Pharmaceutical 47 After Phase III clinical Phase II (Planned) Phase II (Approved) Phase II (Underway) Phase III (Underway) Phase III (Underway) Phase III (Underway) Development Stage USA USA USA China Korea Korea Country DNA DNA DNA Protein Catheter DNA+Virus DNA+Virus Technology DNA + Injection ViroMed Yongsoo Kim 1) DNA/protein-based biopharmaceuticals biopharmaceuticals DNA/protein-based 1) Phytotherapeutics2) (botanical drugs/nutraceuticals) 5th Bldg 203, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea www.viromed21.com ViroMed conducting is a phase III clinical trial for diabetic peripheral ViroMed successfully completed a phase I/II trial for amyotrophic lateral lateral amyotrophic for trial I/II phase a completed successfully ViroMed Specialty Business Breast Cancer · Company · CEO · · Head Office Homepage· Target Disease Target Thrombocytopenia Ischemic Heart Disease Chronic Diabetic Foot Ulcer Amyotrophic Lateral Sclerosis Diabetic Peripheral Neuropathy VM206 VM501 Product VM202-ALS VM202-PAD VM202-PAD VM202-DPN VM202-CAD successful phase I trial for ischemic heart disease (VM202-CAD), a phase II study underway is in Korea for subjects who have had percutaneous coronary intervention (PCI) for acute myocardial infarction. VM206 – Therapeutic VM206 a therapeutic is cancer vaccine delivered through intramuscular injection and induces an immune response against the tumor-associated antigen Her2/neu, found in several types of cancers such as breast cancer. A phase I clinical study for breast cancer has been successfully completed in Korea, showing that the administration of VM206 would effectively induce both humoral (antibody)and cellular (CTL) immune responses against tumor. The product beingis safety and effectively developed for patients who have received surgery and/or chemotherapy. A phase II trial planned is for Korea. VM501 – Recombinant Protein for Chemotherapy-Induced Thrombocytopenia (CIT)The only drug approved for CIT by the US protein FDA a recombinant is called Neumega. interleukin Its (IL-11) use 11 has been highly limited because of serious side effects associated with the drug. VM501 a genetically is engineered designed to produceinterleukin a high level (IL-11) of efficacy, 11 but with improved safety. After successful phase I and II studies, a phase III clinical study currently is ongoing in China. VM202 – New and Innovative Drug for Cardiovascular and Neurological Diseases VM202 a DNA-based is medicine designed to express two isoforms of hepatocyte growth factor (HGF) gene. HGF has been extensively researched and known is to induce the formation of new collateral blood vessels and the growth and regeneration of damaged peripheral nerve cells. Currently, VM202 under is clinical trials for 4 indications in cardiovascular and neurological disease categories. In these studies, VM202 delivered is through intramuscular injection around the affected regions. ① neuropathy (VM202-DPN) in the US. ② Representative (Clinical trial) Product – Biologics sclerosis (VM202-ALS), also known as Lou Gehrig’s disease then its phase II IND was approved by the US FDA. The program has received fast track designation and orphan drug designation from US FDA. ③ trialof chronic non-healingischemic foot ulcers diabetesin patients (VM202-PAD) underway is thein US. ④ ViroMed Co., Ltd. (“ViroMed”), a leading biologics company focusing on developing novel and innovative drugs,innovative and novel developing on focusing company biologics leading a (“ViroMed”), Ltd. Co., ViroMed tradedpublicly a is Atlanta. ViroMed office in a US and Korea 1996, headquartered in Seoul, in established was has assembled a diverse yet ViroMed KOSDAQ stock exchange (084990) from 2006. company listed on the therapeutics targeting cardiovascular and linked pipeline of new and innovative technologically and conceptually runs several clinical and China. ViroMed and immune disorders in the US, Korea, neurological diseases, cancers, chronic diabetic neuropathy, (diabetic peripheral III clinical trials phase active 2 This includes trials internationally. lateral sclerosis) in phase II clinical trial in the US. Anfoot ulcer) and an approved rare disease (amyotrophic in Korea. In China, a phase III clinical trial is underway foradditional phase II (coronary artery disease) is ongoing cow to also runs a botanical therapeutics program as a cash chemotherapy-induced thrombocytopenia. ViroMed balance the long-term biologics programs. Leading Biotechnology Company Targeting Cardiovascular Disease, Cardiovascular Targeting Biotechnology Company Leading Disorder. Immune-related Cancer and Neuropathy, Co., Ltd. ViroMed Seungshin Yu, Ph.D. Director Strategic Business Development • E-mail : [email protected] Contact Information 46 49

Phase 2 Phase 3 Phase 3 Phase 3 Phase 2 Phase 3 Phase 3 Phase 1 Phase 1/2 Phase 1/2 Preclinical Preclinical Lead discovery Lead discovery Lead discovery Lead discovery Lead discovery Lead discovery Lead discovery Lead discovery Lead discovery Lead discovery Lead discovery Lead discovery Lead discovery Lead discovery Lead discovery Current stage Indication Yuhan CorporationYuhan Lee hee, Jung Pharmaceutical Seoul Dongjak-gu, Noryangjinro 74 http://www.yuhan.co.kr/Eng/index.asp NCE NCE NCE IMD IMD IMD NCE IMD IMD IMD NCE IMD NCE NCE NCE NCE NCE NCE siRNA siRNA Type Herbal Biologics Biologics Biologics Biologics Biologics Biologics · Company · CEO Specialty · · Location Homepage· Supply of nutrition of Supply Treatment for hypertension and hyperlipidemia newborns of syndrome distress respiratory for Treatment Antibiotics functions Antiacidic Anti-inflammatory agent heartburn of indigestion & Alleviation Keloid NASH NASH NASH NSCLC Obesity Asthma Otitis media Otitis Solid cancerSolid cancerSolid cancerSolid cancerSolid cancerSolid cancerSolid Solid cancerSolid Solid cancerSolid Solid cancerSolid Solid cancerSolid Periodontitis Hypertension Indications Grave's orbitopathy Grave's Diabetic neuropathy Periodontitis, arthritis Chronic constipation, IBS Hyperlipidemia diabetes / Hyperlipidemia hypertension / Hyperlipidemia hypertension / Product name YH-BIO YH-BIO YH-BIO YH-BIO YH-BIO YH1177 YH-NCE YH-NCE YH-NCE YH-NCE YH-NCE YH-NCE YH-NCE YH-NCE YH-NCE YH-NCE YHD1119 YH14755 YHP1701 YH12852 YH22162 YH26153 YH25724 YHP1604 YH24931 YH23537 YH25448 3-Chamber TNA (Total Nutrient Admixture) Tablet Duowell Newfactan Tablet Yucla Almagate Suspension Antiphalmine S Willogel Double Action Suspension Projects Gastrointestinal disorders Metabolic Cardiovascular & disorders Immunology & Inflammation disorders Cancer R&D Pipeline We welcome you to join us in our journey to create a healthier and more prosperous society. you to join us in our journey to create a healthier and more prosperous society. welcome We Products Our large-scale Shihwa Synthetic Plant and Ochang General Formulation Plant employ the latest cutting edge technology withOur large-scale Shihwa Synthetic Plant and Ochang General these plants allow us to deliver active pharmaceutical ingredients manufactured full FDA, EMEA and PMDA approval. Together, to the highest standards to our partners across the globe. medicinal chemistry through to process innovation and clinicalWith full spectrum drug-development capabilities from consumer products to improve is relentlessly committed to delivering precision medicines and quality trials, Yuhan first acid-pump antagonist of have yielded Revanex, the world’s health and quality of life. Our focused R&D efforts hepatitis a number of new drug entities for antibiotics, cancer, its class designed to treat gastric ulcers, as well as filled with new pharmaceutical is committed to taking the lead toward a future C, arthritis, and osteoporosis. Yuhan cardiovascular and metabolic disorders, and inflammatory diseases. discoveries, with ongoing research in oncology, As a leading global producer and distributor of pharmaceuticals, APIs/ and distributor producer of As a leading global toimprove is mission intermediates and consumer Yuhan’s goods, products innovative high quality, offering by and well-being health efforts to progress. supportand social services with ongoing in parallel

Head QuartersHead 74 Noryangjinro Dongjak-gu, Seoul, 06927, Korea • Phone : +82-2-828-0181 • Fax : +82-2-828-0300 CONTACT US CONTACT

Best Partner Best Yuhan Best Partner Yuhan Corporation Yuhan 48

Pharmaceutical Pharmaceutical 49

h e t Reg/ Pricing Futur Grow

III 2017 (Clinical study in USA) Merged with ‘KT&G Life Science’ ‘$70M Export Prize’ awarded by KITA 2016 II

Certified as “Innovative drug company” in Korea

2015

I 2013 Development Status ‘$50M Export Prize’ awarded by KITA

2011 New Cephalosporin plant in Namyang factory Pre-Clinic Yungjin Pharm. Co.,Ltd. Jae Joon Lee Cephalosporins, API Formulation & Korea Seoul, Songpa-gu, Olympic-ro35da-gil, 13, Office : Head www.yungjin.co.kr 2010

‘$20M Export Prize’ awarded by KITA 2006

Research

· Company · CEO Specialty · · Location Homepage· New Jeonju factory or API production 2000

1989 Factory for finished products in Namyang Indication 1984 MRSA Vaccine MRSA Spinal Stenosis / SR Depression / New salt IPF / New strength Depression / New salt COPD / (Asthma) Arthritis Rheumatoid / (OA) Mitochondiral Disease Diabetes TNBC AML, The world’s first Bacampicillin synthesis 1974

Area First API plant; Introduction of penicillin to domestic market Immunology CV CNS Respiratory CNS Respiratory Immunology Metabolic Disorder Metabolic Disorder Oncology Therapeutic

Botanical Drug Botanical New Chemical Entity Biological Drug Combo, SR, etc. lishment ab st 1952 Importing medicine from JP & US E IMDs Name YPL-001 YPN-005 YPF-1827 KL-1333D Project YAD-2128 YLS-1501 YDP-2225 KL-1333M YSA-2021 YRA-1909 New Drug R&D Pipeline History Yungjin Pharm. Co., Ltd has been playing a major role as a forerunner in the Korean pharmaceutical industry forerunner in the Korean Co., Ltd has been playing a major role as a Pharm. Yungjin from diseases with relieve the suffering of mankind mission statement, "To since 1952. With our inspiring successful contribution our and safe pharmaceutical products", we have shown our innovative, effective 25 awards including total of globally as well. As a result, we have received not only within Korea, but and Industry Award Development, the Prime Minister Award, for Superior Product the President Award commitment to the development of demonstrate our sustainability, many others. These accomplishments In addition, through overseas and domestic segments. innovative products and business excellence in both business globally. our experience and expertise, we are leading CMO/CDMO The medicine for your life The medicine Yungjin Pharm. Co.,Ltd. Yungjin Cefpodoxime proxetil tab. / gran. Meropenem inj. Propacetamol inj. Limaprost alfadex tab. Limaprost alfadex tab. Cefcapene pivoxil tab. / gran Imipenem cilastatin inj. Jeffrey Park International Division Business • Phone : +82-2-2041-8244 • E-mail : [email protected] CONTACT US CONTACT 48

Supplement

1. Products Expected to Export 2. Technology Transfer 3. Certifications from Health Authorities Supplement 53 ------Listed Note marked on WHO EUAL/CE CE marked CE marked CE marked CE marked EU Global Global Global Global Global Global Global Global Global Global Global Global Global Global Global Global Global Global MENA US, EU, country Expected MENA, CIS MENA, CIS MENA, CIS, Middle East Non- Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine probiotics Molecular Molecular Molecular Molecular Molecular Molecular Molecular Molecular RNAi drug Category siRNA drug siRNA drug siRNA drug Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Diagnostic Kit Diagnostic Kit Diagnostic Kit Diagnostic Kit Diagnostic Kit Diagnostic Kit Diagnostic Kit Diagnostic Kit HIV-1 Scars Alopecia Narcotics Narcotics Heartburn Antibiotics Antibiotics NEW Drug MERS-CoV Influenza A anti-obesity Indication PROBIOTICS Gastric ulcer Antineoplastics Antineoplastics Hepatitis B virus Hepatitis C virus Gastric Hyperacidity Well-being products Well-being Humanpapillomavirus Humanpapillomavirus Lipid-Lowering agents Essential Hypertension New Influenza A (H1N1), Hypertension/Dyslipidemia resistant tuberculosis (MDR-TB) Molecular Diagnostic New Influenza A(H1N1),Influenza A Zika, Dengue and Chikungunya viruses (chronic obstructive pulmonary disease) Keloid Treatment and Removal of Keloid Keloid Treatment Mycobacterium tuberculosis, Multidrug- IPF (Idiopathic Pulmonary Fibro sis) COPD Non-small cell lung cancer of EGFR mutation siRNA siRNA siRNA Phospate Lafutidine Imipenem, Cilnidipine Oxaliplatin Fimasartan Amlodipine Doxorubicin PCR reagent PCR reagent PCR reagent PCR reagent PCR reagent PCR reagent PCR reagent PCR reagent Tamiflumate Rosuvastatin Meropenem 1g siRNA , miRNA Fimasartan with Fimasartan with Cilastatin sodium Remifentanyl HCl Morphine Sulfate Colloidal Aluminum Lactobacillus gasseri Atorvastatin Calcium Active Ingredient Fimasartan with HCTZ

- - ® ® ® -IPF HPV HCV HBV TM TM New HIV-1 HIV-1 - Lung ® ® ® ® ® ® ® ® ® TM ® ® ® TM Kit Tab. Plus 500mg BNR17 Besto Kanarb Keloids PCR Kit PCR Kit PCR Kit Oxalitin Gelfos Todula Tuvero Kanarb Dukarb Morphine Alopecia ADmycin Sinraci Inj. Sulfate Inj. Remiba Inj. Vitamin Inj. Vitamin AccuPower AccuPower AccuPower Time PCR Kit Time SMAiRNA SMAiRNA Mepem Inj. 1g Mepem Inj. 1g cancer target BC Atorvastatin Genotyping Kit TB&MDR Real- Multiplex Real- SMAiRNA Time RT-PCR Kit RT-PCR Time Time RT-PCR Kit RT-PCR Time A Real-Time RT- A Real-Time Quantitative RT- Quantitative RT- MERS-CoV Real- Quantitative PCR Product name Inf A (H1N1) &Inf AccuPower AccuPower AccuPower AccuPower SMAiRNA AccuPower ZIKV(DENV, CHIKV) CHIKV) ZIKV(DENV, LTD. BIONEER BIONEER Pharm­ co.,Ltd. Boryung BCWORLD aceutical CORPORATION CORPORATION PHARM. CO., Company 1. Products Expected to Export Expected to 1. Products 52

Supplement Supplement 53 ® ® Peri Note Lipid Generic Generic of Smof of Smof Kabiven Global Global country Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Expected bag) bag) CNS Non- Product Therapy Antiviral Oncology Oncology Stem cell Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine G.I Agents anesthetic Anticancer Antibiotics Anticancer Antibiotics Antibiotics Antibiotics Antibiotics Antibiotics IV Solution Biologicals Biologicals IV Solution (3-chamber (1-chamber Category Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Bronchodilator Antispasmodic Small molecule Cancer Cancer Anemia Infection Infection Infection Infection Infection Anorexia Anesthesia Anti-cancer Anti-cancer Anti-cancer Indication Neutropenia Osteoarthritis Anti-diabetics Anti-diabetics Gastric cancer Gehrig’s disease) Gehrig’s Food Supplement Anti-hypertensives Parenteral Nutrition dysentary syndrome Immunosuppressant Chronic renal failure Hepatitis B infection Alzheimer's dementia tonsillitis, pharyngitis etc. disease or Parkinson's disease Total Parenteral Nutrition (TPN) Parenteral Nutrition Total Symptomatic treatment of severe relapse period of chronic gastritis Respiratory distress caused by airway dementia associated with Alzheimer's amyotrophic lateral sclerosis(ALS, Lou obstruction of bronchial asthma, acute media, mastoiditis, paranasal sinusitis, and spasmodic colic, intestinal colic and Bronchiectasis, bacterial pneumonia, otitis Gastric and duodenal ulcer, acute gastritis, Gastric and duodenal ulcer, Symptomatic treatment of mild to moderate Renal and urinary colic hepatic, gall bladder bronchitis, chronic bronchitis, or emphysema Glucose Imatinib Propofol charcoal Linezolid Entecavir Docetaxel Irinotecan Metformin Tacrolimus 37.5, 75mg Teicoplanin Polmacoxib Amlodipine Soybean oil Pemetrexed Vancomycin Triglycerides Gemcitabine Moxifloxacin Ciprofloxacin Lobeglitazone Erythropoietin Candesartan + Medium-Chain oral adsorptive lysinate 500mg marrow derived Lobeglitazone + Olive oil, Fish oil Autologous bone Krill Oil Omega-3 Lipid, Amino acid, Roxatidine acetate Megestrol Acetate Paclitaxel 10mg/ml Methylol cephalexin Phloroglucinol 80mg Active Ingredient Rivastigmine 9, 18mg Tulobuterol 0.5, 1, 2mg Tulobuterol mesenchymal stem cell

® Duvie Acelex Gemtan solution Megex-I Leukivec Omega-3 TacroBell Belotaxel Cantabell OmapOne Pemta Inj. BR Krill Oil Renamezin Tapocin Inj. Tapocin Epokine Inj. Duvimet XR Citopcin Inj. Calmtop Inj. Gastric Cap. Freefol MCT Vancorin Inj. Vancorin Enteone Tab. Leukokine Inj. Liporaxel Oral Peripheral Inj. Neuronata-R FLOSPAN Tab. FLOSPAN Moveloxin Inj. Resnalin Patch Rivamensa Patch Product name Cinezolid Tab&Inj. Cepharmethyl Cap. OmapOne Lipid Inj. CJ Inc Inc. Corp. Chong Pharm­ pharm­ co.,Ltd. Crystal- Boryung Daewon EUTICAL CO., LTD. aceutical aceutical Corestem DAEHWA Kun Dang Genomics, PHARMAC Company HealthCare corporation 52

Supplement Supplement 55 PAHO Note through WHO & PQ from Procured WW WW USA, WHO Brazil ASIA) ASIA) ASIA, INDIA) INDIA) EGYPT, EGYPT, MENA) MENA, MENA, CHINA) JAPAN, JAPAN, LATAM) AFRICA, AFRICA, (RUSSIA, country WW (EU, WW (EU, WW (EU, worldwide worldwide worldwide worldwide worldwide worldwide Worldwide Worldwide Expected USA, ROW) MALAYSIA) Russia, CIS) CHINA, CIS) INDONESIA, WW (SYRIA, (AUSTRALIA, WW (NORTH WW (NORTH WW (JAPAN, WW (JAPAN, WW (LATAM, WW (LATAM, WW (LATAM, WW (LATAM, ETC ETC Generics Generics Generics Generics Generics Generics Generics Generics Vaccines biologics biologics biologics biologics biologics biologics Product t Biologics Antibiotic Generics & Generics & Generics & Generics & Generics & Generics & Generics & Generics & Category Value-added Value-added Value-added Value-added Value-added Value-added Value-added Value-added Value-added Value-added Value-added Value-added Value-added Value-added Recombinant New chemical medical device puberty Indication Tuberculosis spinal fusion Acute wound Gallstone etc Hemophilia A Antiulcer program CT contrast media Pulmonary Disease Erectile Dysfunction Erectile Dysfunction Dental sinus lift graft Growth hormone deficiency Growth hormone deficiency diseases, Acute/Chronic diarrhea medical device - adhesion barrier Gastric & duodenal ulcer, gastritis Gastric & duodenal ulcer, Anemia in end stage renal disease Anemia in end stage renal glabellar lines, upper limp spasticity For the Prophylaxis against Influenza esophageal-gastric and large intestinal Liver & bile disease including cholestasis, For the prevention and control of bleeding Relif of painful symptoms associated with Acute Exacerbation of Chronic Obstructive Diabetic foot ulcer, oral mucositis, wounds ulcer, Diabetic foot episodes and preoperative management in Prostate cancer, Endometriosis, Precocious Prostate cancer, Concomitant hypertension and dyslipidemia EGF EPO APA hGH EGF Type B Type BMP-2 BMP-2 chitosan Sildenafil Sildenafil Iopromide Sucralfate Leuprolide Somatropin Cycloserine Zabofloxacin Rosuvastatin Olmesartan + Type A (H1N1) Type A (H3N2) Type VIII, recombinant poloxamer, gelatin, poloxamer, Purified Inactivated Purified Inactivated Purified Inactivated D-aspartate Hydrate Ursodeoxycholic acid Active Ingredient Dioctahedral smectite (AcidPumpAntagonist) Botulinum toxin type A Influenza Virus Antigen Influenza Virus Antigen Influenza Virus Antigen Influenza Virus Ranitidine + Bismuth + Blood coagulation factor Albis URSA Eposis Olostar Nabota Nurigra DW206 Novosis Luphere Dehecta Neovest Zabolante Mediclore GCFLU inj. Easyef Spray Novosis – OS Nurigra Chew Closerine Cap. Growtropin Inj. Easyef Ointment Product name Green Gene F inj. Caretropin 22.5 IU Pharm Pharm­ Co. LTD aceutical. Dong Wha Daewoong Dong-A ST GC Pharma Company 54

Supplement Supplement 55 WHO Note US FDA PQ from CE Mark Designation Orphan Drug granted from - China China China South China, Taiwan, Taiwan, America country Australia, East Asia, India, U.S., Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Expected Canada, EU, Japan, South- OTC Food Food Food Food & Food & Plasma Plasma Plasma Plasma Plasma Product Product Vaccines Vaccines Beverage Beverage Endocrine Endocrine Derivatives Derivatives Derivatives Derivatives Derivatives Category Ophthalmic Ophthalmic supplement supplement supplement Recombinant Recombinant Anticoagulant Allergy & ENT Growth Immunity Indication Osteoporosis eye syndrome Anticoagulant Intestinal health Clostridium tetani exposure to HBsAg Hangover remedies Hangover remedies 5) Kawasaki Syndrome Endogenic disease, dry Pituitary hormone agent Increase tear production Perennial allergic rhinitis 4)Guillain-Barre Syndrome enzyme replacement therapy 1)-/Hypogammaglobulinemia patients with liver transplant For treatment of hemophilia A For prophylaxis against Varicella severe bacterial or viral infections severe bacterial or viral infections For patients with Hunter Syndrome For patients with Hunter Syndrome myelosuppressive anti-cancer drugs For the Prophylaxis against Influenza For the Prophylaxis against 1) For prophylaxis of hepatitis B after 2)Combined therapy with antibiotics in 2)Combined therapy with antibiotics 3)Idiopathic Thrombocytopenic Purpura 3)Idiopathic Thrombocytopenic For prophylaxis of tetanus and reduction (Mucopolysaccharidosis II, MPS II) as an (Mucopolysaccharidosis II, Arthritis, muscle pain, anti-inflammation immunization against infection caused by of tetanus symptoms by providing passive a patient treated with chemotherapy using 2) For prophylaxis of hepatitis B in neonates For prevention of recurrence of hepatitis B in For decreasing the duration of neutropenia in Human Curcumin Curcumin Factor VIII Ketoprofen Vasopressin Idursulfase-ß adminstration Human G-CSF Type A (H1N1) Type A (H3N2) Type Zinc gluconate Azelastine HCl Cholecalciferol Type B-Victoria Type for intravenous Human Tetanus Human Tetanus Heparin Sodium Immunoglobulin Immunoglobulin Human Hepatitis Type B-Yamagata Type B Immunoglobulin Immunoglobulin-G Cyclosporin 0.5mg lactic acid bacillus Calcium carbonate Human Hepatitis B Purified Inactivated Purified Inactivated Purified Inactivated Purified Inactivated Purified Inactivated Human Coalugation Sodium Hyaluronate Sodium Risedronate, Active Ingredient Mometasone furoate, Varicella Vaccine(Live) Varicella Influenza Virus Antigen Influenza Virus Influenza Virus Antigen Antigen Influenza Virus Antigen Influenza Virus Antigen Influenza Virus Pegylated Recombinant Inj. Spray Hutos GCFLU GCC inj. Hunterase Hepabig.inj Sero-Tet inj. Sero-Tet (Single dose) Neulapeg inj. Green VIII inj. Nadossukssuk I.V.Hepabig inj. I.V.Hepabig READY Q Drink Nasaflex Nasal READY Q Chew Hutos Probiotics Quadrivalent inj. KETOTOP Plaster Product name Risenex Plus Tab. Risenex Plus Tab. Varicella Vaccine- Varicella T-Sporin Eye Drops T-Sporin Hutos Joateunteun I.V.-Globulin SN inj. I.V.-Globulin Hyaluron Eye Drops Heparin Sodium Inj. Hanlim Vasopressin PHARM. HANLIM CO., LTD. GC Pharma Company Handok Inc. 54

Supplement Supplement 57 ------Note EU EU Any Any Asia Asia USA Asia Latin Asia Asia Global Global Global Global Global Global Global Global Global Global Arabia Europe Vaccine America, country Asia, US, Northeast Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Expected Middle Eas Peru, Saudi Southwest South-East Middle East Saudi Arabia Except Korea Asia, Europe, South America CV OA Drug Drug Drug Drug Premix Turkey, Turkey, system System System Urology Urology Urology Vaccine Vaccine medicine medicine Medicine Musculo- Medicine Cambodia Urogenital Antibiotics Antibiotics Category Respiratory Respiratory Prescription Prescription Prescription prescription prescription I.V. Solution I.V. I.V. Solution I.V. I.V. Solution I.V. I.V. Solution I.V. Solution I.V. Anibacterial OTC Product Orphan Drug Orphan Drug Orphan Drug Raw Material Anticoagulant Skeletal system Central Nervous Central Nervous BPH Drug ED, BPH ED, BPH Epilepsy thrombosis Esophagitis Indication Dyslipidemia Osteoarthritis Fabry Disease Anti-thrombotic Asthma,Rhinitis Improves Health Antihypertensive Gaucher Disease Influenza Vaccine Influenza Vaccine line of CML(chronic myeloid Nocturnal enuresis Parkinson's disease Anti-obesity Agents Alzheimer's disease nd inflammatory disease Supply of all Nutrition Improves performance Lipid based IV solution Amino Acid IV Solution Amino Acid IV Solution Amino Acid IV Solution Carbapenem Antibiotics Carbapenem Antibiotics Lercanidipine HCL 10mg postmenopausal women Nerve block and infiltration leukemia)-CP(chronic phase) Prevention of osteoporosis in Quinolone Anibacterial Agent cardiogenic shock, septic shock. and 2 st Cough : acute and chronic bronchitis Gastric Ulcer, Duodenal Ulcer, Erosive Duodenal Ulcer, Gastric Ulcer, Increase of tear production in patients Increase of tear production with suppressed tear formation due to with suppressed tear formation 1 For the treatment of acute hypotension, For the treatment of acute hypotension, keratoconjunctivitis sicca- related oscular keratoconjunctivitis sicca- related mL, Orlistat Heparin Tadalafil Radotinib Ilaprazole Abciximab +Ezetimibe in dentistry Amlodipine electrolytes Electrolytes Dutasteride Meropenem Pramipexole Levofloxacin Galantamine Cyclosporine Imiglucerase Rosuvastatin virus antigen virus antigen 0.2mg/0.4mL Levitiracetam Levocetirizine Valsartan and Valsartan Use in topical, Montelukast + Korea Ginseng infiltration and 15 amino acids Hyaluronic acid Norepinephrine Agalsidase beta 8 amino acids, 3 levodropropizine Trivalent purified Trivalent electrolytes & etc. 15 amino acids & 4 Bitartrate 8mg/4mL Refined soybean oil ibandronate sodium Lidocaine HCI 10mg Refined soybean oil, Articaine HCI 40mg/ Imipenem, Cilastatin inactivated Influenza inactivated Influenza Quadrivalent purified Active Ingredient Glucose, Amino Acid, desmopressin acetate Tamsulosin + Tadalafil Tamsulosin Taurine, Multi Vitamin Taurine, conduction anesthesia ® ® ® Gugu Duted Premix Lipision Heparin Rosuzet Fabagal Freamine Clotinab Abcertin 1:100,000 Prepenem Gugutams Pospenem Noltec tab. Supect cap. Epinephrine Hyalrheuma Monterizine Hepatamine Nephramine Drovan (Tab) Levofloxacin Uremin (Tab) ZERO-X Cap. HCI 4% with Norepirin inj. Levitiracetam HIFORGE Tab. Mirap (ER Tab) Combiflex Lipid Epinephrine inj. Huons Articaine Clacier Eye drop Tarmirin (SR Tab) Tarmirin Product name WONBI-D LIQUID Lidocaine HCI 1% ILYang Flu Vaccine Flu Vaccine ILYang ILYang Flu Vaccine Flu Vaccine ILYang Bitartrate 0.018mg GINSENG ENERGY Levotuss (Tab, SYR) Levotuss (Tab, Pre-filled Syringe inj Pre-filled Syringe inj. JW Pharm Korea Co.,Ltd Hanmi Pharm. Co.,Ltd Kolmar Pharm­ IL-YANG IL-YANG Hyundai HUONS PHARM- Co., Ltd. CO., LTD. CO., LTD. aceutical ISU Abxis ACEUTICAL Company 56

Supplement Supplement 57 ------Note Release Release Release Release Release Controlled Controlled Controlled Controlled Controlled Fixed Dose Fixed Dose Fixed Dose Formulation Formulation Formulation Formulation Formulation Formulation Combination Combination Combination New Dosage EU EU, EU, Asia Asia, Brazil, Global Global Global Global Global Global Global Global Global Russia LATAM MENA, MENA, Russia, MENA, Mexico, country Vietnam/ Vietnam/ ROW, etc ROW, Mongolia Mongolia Myanmar Cambodia Southeast Philippines Worldwide Worldwide Expected US, EU, etc , Southeast asia, Latin america Latin america Mexico, Brazil Eastern Europe Southeast Asia product product product medicine medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Biological Biological Biological Category Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription uct (Prescrip- tion medicine) Medical device Medical device Medical device Biological prod- Wrinkles Antibiotics Antibiotics Antibiotics Antibiotics Respiratory Respiratory Infertility Indication Hypertension Hypertension Joint arthritis Psoriasis vulgaris Cough suppressant Anti-viral Medicine Antithrombotic drugs Wrinkle correction Gastrointestinal symptoms Pain caused by rheumatism Cardiovascular system drugs Cardiovascular system drugs Growth hormone deficiency Ischemic symptoms, Thrombosis Upper respiratory tract infections cerebral palsy, Glabellar wrinkles cerebral palsy, Anemia in chronic renal disease Acute coronary syndrome (antiplatelet) Antifungal, acute/chronic tracheitis etc., Antifungal, acute/chronic tracheitis Blepharospasm, Focal spasticity in pediatric ext. 5.01g 0.5mg 300mg Omega-3+ Omega-3+ Amoxicilin Amoxicilin Calcipotriol Oseltamivir Atorvastatin lante 285mg dipropionate Rosuvastatin Erythropoetin 1,250mg+Pot. monohydrate, Aspirin 100mg sodium 250mg Losartan 50mg Hyaluronic acid Hyaluronic acid Hyaluronic acid Betamethasone Losartan 100mg Mosapride 15mg Cilostazol 200mg Sarpogrelate HCl recombinant FSH Ampicillin sodium human Somatropin 500mg+ Sulbactam Aceclofenac 200mg Clavulante 312.5mg Ipratropium bromide 2,000mg+Pot. Clavu- Amlodipine 5mg and Amlodipine 5mg and Azithromycin hydrate Azithromycin Active Ingredient Pelargonium sidoides Clopidogrel 75mg and monohydrate 0.521mg Botulinum toxin type A Levodropropizine 90mg Budesonide micronized Tab. ® CR Tab. CR Tab. CR Tab. CR Tab. CR Tab. Duo Cap. Tab5/50 ® ® Tab5/100 ® ® ® ® ® ® EPO sion hGH rFSH Yvoire solution ointment Neuramis Neuronox 2000/5 mg Calmio gel, 2000/10 mg Kalomin Amocra syrup Oseltami Cap. Clanza Unigril Gastiin Losasc Azimax dry syrup Cilostan Levotics Product name Losasc tatin mini capsule tatin mini capsule Pulmican Suspen- Hyruan plus/SIHA Ampibax Injection Clavixin Amocra Duo syrup Aventro Inhalation Aventro Omega-3/Atorvas- Omega-3/Rosuvas- LG Inc. Ltd. Korea Korea Kuhnil United Co.,Ltd Kolmar Pharm­ Co., Ltd. Medytox aceutical Chemical, Pharm. Inc. Company 56

Supplement Supplement 59 ------etc. free free to EU Note Already Generic to India, to Egypt No patent Thailand, Exporting Exporting exporting Same PK, Tween-80 Tween-80 China etc. Lower API Lower API & same PK Cremophor & same PK tablet form infringement formulation formulation China China South- Russia, EU, US, America America America America, country Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Expected CSI, Africa, China, USA China, USA east, Latine east, Latine east, Latine Asia, Latine Middle east Asia, Middle Asia, Middle Asia, Middle America, etc. Active Active Active Active medicine medicine medicine medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine Ingredients Ingredients Ingredients Ingredients Category Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription (Blood product) (Blood product) (Blood product) Medical device Medical device Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical gastritis Dementia Anti-cancer Anti-cancer Anti-cancer Anti-cancer Anti-emetic Severe pain Antithrombotic Antithrombotic Indication Anti-malaria Anti-malaria Anti-dhesive Hypertension Hyperlipidemia Antihyperlipidemia Alzheimer’s disease Alzheimer’s COX-2 selective NSAID transplant recipients Agammaglobulinemia Treatment of Osteoporosis Treatment through physical restoration HMG-CoA reductase inhibitor HMG-CoA reductase inhibitor Intra-articular injection indicated for Intra-articular injection indicated Temporary correction of facial wrinkles Temporary Wound healing and tissue regeneration healing and tissue Wound Treatment of gastroduodenal ulcers and Treatment reduction of knee joint mechanical friction reduction of knee joint mechanical Nutrition supply to cornea and conjunctiva and cornea to supply Nutrition Hypo-albuminemia, Hemorrhagic shock Prophylaxis of hepatitis B recurrence in liver APIs APIs APIs APIs & HES Sodium Sodium Fentanyl Ezetimibe Paclitaxel Paclitaxel Docetaxel Docetaxel Oxaliplatin Artesunate Artesunate Bortezomib Rebamipide Candesartan Rivastigmine Rivastigmine Palonosetron Lenalidomide Amlodipine & Human normal Pyronaridine & Pyronaridine & Cholecalciferol Rosuvastatin & Zoledronic acid immunoglobulin immunoglobulin G Human hepatitis B Sodium hyaluronate Clopidogrel bisulfate Atorvastatin Calcium Active Ingredient Alendronate sodium + Human serum albumin Sodium Polynucleotide Sodium Polynucleotide Polydeoxyribonucleotide Polydeoxyribonucleotide

In- ® ® ® ® n® Tablets Granules ® IV ® Orals Patch Patch Tablet Tablet jection Tablets Tablets Calcium Calcium Rejura injection Ezerosu Oncology Oncology Celecoxib Conjuran Injectables Injectables Liv-Gamma Clopidogrel SK Albumin Atorvastatin Rejuvenex® Candeamlo Hepabulin IV Fentaderm® Rosuvastatin Nanoxel® M DemenCure® NEUSTATIN-A NEUSTATIN-A Genexol® PM PLATLESS Tablet PLATLESS Medicurtain bisulfate (form 1) Product name Re-an® eye drop AIDBONE PLUS D Pyramax BAMEDINE Tablet Rivastigmine patch Pyramax SK Samjin Samjin Pharm. Co.,Ltd Pharm- Co. Ltd. Co., Ltd. Co., Ltd. Pharma- Products aceutical Research Samyang aceuticals Chemicals Biopharm- Company Shin Poong Corporation 58

Supplement Supplement 59 - - - - - PQ Asian Note testing to India to some methods for WHO countries Exporting Exporting to animal Alternative Preparation Asia, Asia, Middle Middle America America America America America America America America EU, Asia EU, Asia country East, Latin east, Latin East, Latin east, Latin Expected US, EU etc. US, EU etc. US, EU etc. US, EU etc. US, EU etc. east, Latine Asia, Latine Asia, Latine Asia, Latine World Wide World World Wide World World Wide World World Wide World East, Africa, US, EU, Asia US, EU, Asia US, EU, Asia US, EU, Asia US, EU, Asia US, EU, Asia Asia, Middle Asia, Middle Asia, Middle Asia, Middle, CIS and so on API API API API API (ODF) Product Product Product Vaccine Vaccine medicine medicine medicine medicine medicine medicine medicine medicine medicine medicine medicine medicine medicine Research Medicine) Medicine) Medicine) Category Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription Prescription OTC product Cell Therapy (Prescription Cell Therapy (Prescription Cell Therapy (Prescription Tester Kit for Tester ETC Medicine ETC Medicine ETC Medicine ETC Medicine (Blood product) (Blood product) others Dry eye Asthma Antibiotics Indication examination of newborns Angiography Conjunctivitis Osteoarthritis anti HIV/AIDS Anti-glaucoma Anti-glaucoma Anti-glaucoma hyperlipidemia Anti-coagulant anti Tuberculosis influenza disease influenza disease Supply of nutrition Metabolic disease Erectile dysfunction Erectile dysfunction degree burn over 30% of TBSA nd Improvement of Nasojugal Grooves - Deep 2nd degree burn(2005.03) - Diabetic Foot Ulcer(2010.06) Treatment for htypertension and Treatment degree burn over 10% of TBSA Human blood coagulation factor Ⅷ Human blood coagulation factor rd Prophylaxis and treatment of tetanus Prophylaxis and Osteoarthritis, Tenosynovitis, Myalgia & Osteoarthritis, Tenosynovitis, For cosmetics testing and drug discovery - Deep 2 - 3 Active immunization for the prevention of Active immunization for the prevention of Bowel cleansing for x-ray and endoscopic Gastric & duodenal ulcer, erosive gastritis Gastric & duodenal ulcer, Treatment for respiratory distress syndrome Treatment Iohexol antigen antigen Tadalafil & others Piroxicam Stavudine Terizidone acid+Lipid Potassium Allogeneic Anhydrous lol maleate Autologous Telmisartan Telmisartan Mirodenafil Latanoprost Latanoprost Human Skin Montelukast Cyclosporine Rosuvastatin Human blood Keratinocytes Keratinocytes Human tetanus Human tetanus Glucose+Amino immunoglobulin Olopatadine HCl Sodium Alginate Reconstituted 3D Bovine Lung Surfa Polyethylen Glycol Purified inactivated Purified inactivated Atovastatin Calcium coagulation factorⅧ Clopidogrel Bisulfate Active Ingredient Clematis mandshurica influenza virus surface influenza virus surface - Latanoprost plus Timo Autologous Fibroblasts Amoxicillin Clavulanate ® ® ® ® API API API API API Free Trast Mvix Joins Iobrix Xalost ETBI Inj. Rosmir Alpadine Coolprep Lamina G Cyporin N Neoderm TNA (Total TNA (Total SKYCellflu SKYCellflu Kaloderm 3-Chamber Holoderm Newfactan Xalost Plus Yucla Tablet Yucla Quadrivalent Tetabulin IV Tetabulin Tadalafil ODF Tadalafil Duowell Tablet Product name NutrientAdmixture) Xalost Preservative SK INC., TEGO Yuhan Yuhan Co. Ltd. Co., Ltd Taejoon Taejoon ceutical Co., Ltd. Pharma- ST Pharm SCIENCE, Chemicals Company Corporation 58

Supplement Supplement 61 Note country Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Expected East, Africa, Asia, Middle, CIS and so on CV CV CNS CNS Antibiotics Antibiotics Antibiotics Antibiotics Antibiotics Antibiotics Category ETC Medicine OTC Medicine OTC Medicine OTC Medicine Infection Infection Infection Infection Infection Infectioin Indication Hyperuricemia Spinal stenosis Antiacidic functions Anti-inflammatory agent Anti-inflammatory polyps, Acute rhinosinusitis Anti-inflammatory, Analgesic Anti-inflammatory, Alleviation of heartburn & indigest Anti-inflammatoryAntipyretic, Analgesic Nasal Symptoms of allergic rhinitis. Nasal Nasal Symptoms of allergic Linezolid Almagate Limaprost L-menthol Febuxostat Loxoprofen HCl+Na2CO3 Propacetamol Cefotiam HCl/ Sodium alginate Sodium alginate Cefditoren Pivoxil Methyl Salicylate Methyl Salicylate Cefcapene Pivoxil Calcium carbonate Ceftizoxime Sodium Sodium bicarbonate Cefmetazole Sodium Active Ingredient Momethasone Furoate Lotion Willogel Granule) Granule) (API, Inj.) (API, inj.) Suspension Ceftizoxime Opast (Tab.) Cefmetazole DoubleAction Linezolin (tab.) Spray Solution (API, Tab., Fine (API, Tab., (API, Tab., Fine (API, Tab., Antiphlamine S Antiphlamine Nazacare Nasal Febuxostat (API) Loxoprofen (API) Product name Cefditoren Pivoxil Cefcapene Pivoxil Denogan (API, inj.) Cefotiam (API, inj.) AlmagateSuspension Yuhan Yuhan Pharm. Yungjin Yungjin Co.,Ltd. Company Corporation 60

Supplement Supplement 61 ------NCE IMD IMD IMD IMD IMD Note Vaccine Biosimilar Biosimilar use) liquid RTU(ready-to- Japan Global Global MENA US / EU US / EU US / EU US / EU East Asia country Worlwide Worlwide Worlwide Worlwide Worlwide Worlwide Worlwide Worlwide Worlwide Targeted Targeted Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide ROW & China ROW & China ROW & China LATAM, South- LATAM, ------

N/A N/A N/A N/A N/A N/A N/A N/A N/A (USA) Phase 1 Phase 1 Phase IIa Australia) Launching Launching completed Overseas Phase 1/2a (Completed) (Netherland) - - - Phase I Korea Process Phase 1 Phase 3 Phase 1 Phase 3 Phase III Phase III Phase III Development StatusDevelopment Launched Launched Launched Preclinical Preclinical Preclinical Preclinical Launching Launching Preclinical Preclinical Phase Ib/II Pre-clinical Pre-clinical Phase 1/2a Phase 1/2a Non-clinical Non-clinical Non-clinical Non-clinical development Process development Process development Process development Process GERD (MSA) Cancer Cancer Anemia Anemia Diabetes Oncology Anticancer Leukopenia AMD, DME Indication Dyslipidemia Hypertension Hypertension Hypertension Colon Cancer Hypertension Schizophrenia Degeneration Renal enemia Osteoarthritis hyperlipidemia systemic lupus AML, CLL, DLBCL & Hyperlipidemia & Hyperlipidemia Multiple myeloma Parkinson’s Disease Parkinson’s erythematosus (SLE) Rheumatoid Arthritis Age-Related Macular Autoimmune Disease (OA/cartilage defect) ABSSSI, Osteomyelitis and other serious Staph multiple system atrophy Pancreatic cancer & MDS Hand Foot Mouth disease infections including MRSA Hyperlipidemia & Diabetes Biologic Biologic CKD-701 Oncology CJ-12420 CJ-40001 CJ-30060 CJ-30061 CJ-30056 CJ-30059 candidate candidate CG400549 CG026806 CG200745 RTU (pemetrexed) Category CKD-11101 technology)) ® (voglibose+metformin) small moleculesmall small moleculesmall ® (ARB: Fimasartan) CJ-40010 (Vaccine) CA20AT04(BM-MSC) CS10BR05(BM-MSC) New Chemical Entity CS30MS02(cartilage) (atorvastatin+metformin) Beta biosimilar candidate (candesartan+amlodipine) Pemta CKD-504 (Small Molecule) CKD-506 (Small Molecule) CKD-519 (Small Molecule) CKD-516 (Small Molecule) CKD-581 (Small-Molecule) manufacturing technology) manufacturing technology) (darbepoietin α biosimilar) Hyaluronic acid (cell bank & Botulinum toxin (cell bank & VogMet CKD-760 (Adalimumab) biosimilar (ranibizumab biosimilar candidate) CJ-40012 (Ranibizumab biosimilar) CKD-12101 () biosimilar Methoxy Polyethylene Glycol-Epoetin (amlodipine + valsartan + atorvastatin) (amlodipine + valsartan + rosuvastatin) HPV vaccine (cell bank & manufacturing (Darbepoetin- alfa biosimilar candidate) CJ Inc. Inc. Corp. Pharm­ co.,Ltd. Crystal­ Boryung PHARM. CO., LTD. aceutical aceutical Corestem Genomics, BCWORLD Chong Kun Company HealthCare corporation Dang pharm­ 2. Technology Transfer 2. Technology 60

Supplement Supplement 63 - - Note Asia China US/EU US/EU MENA US/EU US/EU USA/EU USA/EU USA, EU country worldwide worldwide worldwide US/China/ Targeted Targeted Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Japan, East World wide World wide Worldwide Worldwide - - - - -

(EU) (EU) (US) (US) Ph 2 1b/2a Phase Phase 2 Phase 2 Phase 2 Phase 1 planned, Phase 2 launched launched launched Ph I com- Ph I com- Ph I com- Ph III on- going (JP) Ph II com- completed pleted (EU) pleted (JP), pleted (JP), US pre-IND Overseas and Phase I pleted (US), Global Ph III Preparing PK Ph I on-going Ph III planned Ph III planned IND approved - O Ph 2 Phase I Korea Phase I Phase II Phase 2 Phase II Phase 2 Phase 2 Phase III Development StatusDevelopment Phase 2 launched launched Approval launched Launched Marketed preclinical completed Phase 1b/2 Phase 3 IND Phase 1b/2a Phase 3 ended disease Anemia Anemia pertussis Lumbargo solid tumor Neoplasia HPV Cancer Indication Neutropenia Colon cancer AGHD/PGHD Breast cancer Gastric cancer pharyngitis etc. Type 2 diabetes Type Type 2 Diabetes Type Hunter syndrome deficiency (PGHD) Immuno-Oncology deficiency (AGHD) sinusitis, tonsillitis, Overactive Bladder Surgery area marker Diabetic Neuropathy Mixed hyperlipidemia mastoiditis, paranasal Varicella Vaccine(Live) Varicella Adult growth hormone Diabetic foot ulcer, oral Tetanus, diphtheria and Tetanus, pneumonia, otitis media, media, otitis pneumonia, Bronchiectasis, bacterial mucositis, acute wounds acute mucositis, Cervical Intraepithelial Anemia in end stage renal Pediatric growth hormone Growth deficiency hormone Osteoarthritis, Rheumatoid, Osteoarthritis, Rheumatoid, biosimilar) ® biosimilar) ® IMD IMD Vaccine Vaccine DA-3880 biologics biologics Biologics Biologics Biologics biologics Analgesic DMB-3111 Antibiotics Anticancer Category Biologics (ADC) Biologics (EGFR) HyTropin(GX-H9) HyGlutide(GX-G6) HyPoietin(GX-E2) HyGrastim(GX-G3) Papitrol-188(GX-188) HyLeukin-7(IL-7-hyFc) DA-9801 (Botanical drug) DA-1241 (GPR119 agonist) Papitrol-188(Combination) DA-8010 (M3 receptor antagonist) (Trastzumab, Herceptin (Trastzumab, (Darbepoetin alfa, Aranesp ­ Inc. Ltd. Pharm Co. LTD Daewon PHARM. HANLIM EUTICAL CO., LTD. CO., LTD. DAEHWA Genexine, aceutical. aceutical. Dong-A ST PHARMAC Company GC Pharma Daewoong Daewoong Pharm. Co., Handok Inc. 62

Supplement Supplement 63 Sanofi Sanofi Note Athenex Athenex Athenex antibody Company Company bispecific ex. Korea, ex. Korea, to Janssen WW rights WW rights Eli Lilly and Licensed to Licensed to Licensed to to Spectrum to Spectrum to Eli Lilly and Licensed from WW rights ex. WW rights ex. WW rights ex. WW rights ex. WW rights ex. China licensed China licensed Korea licensed Innovent to co- Japan licensed develop a novel Pharmaceuticals Pharmaceuticals Partnership with Pharmaceuticals Korea, China and Korea licensed to Korea licensed to Korea licensed to immuno-oncology EU Asia USA, EU USA, EU East Asia country Targeted Targeted Japan, EU, Japan, East Japan, USA, Phase I Phase I Phase I Phase II Phase II Phase II Phase II Phase II Phase III Phase III Phase III Pre-clinical Overseas EU Phase I NDA Korea Phase I Phase I Phase I Phase I Phase II Phase III Phase III Development StatusDevelopment Preclinical Pre-clinical Pre-clinical Pre-clinical Pre-clinical Pre-clinical Pre-clinical Pre-clinical GHD AMD Diabetes Diabetes Leukemia Indication Neutropenia Solid tumors Solid tumors Solid tumors Solid tumors Breast cancer erythematosus Systemic lupus Acute bronchitis Obesity & NASH Diabetes & Obesity Acute Myeloblastic Diabetes & Obesity Breast, Lung cancer Rheumatoid arthritis Rheumatoid arthritis Autoimmune disease Short bowel syndrome Small Cell Lung Cancer Mucopolysaccharidosis Allergic rhinitis, pruritus Allergic rhinitis, Hepatocellular Carcinoma Cogenitial Hyperinsulinism GCG) therapy) HM30181A) HM30181A) HM12460A/ GCSF analog) RAF inhibitor) dual inhibitor) LSD1 inhibitor Insulin analog) PENTAMBODY IMD long-acting hGH) Herb acting GLP-2 analog Oraxol™(Paclitaxel + Stem cell long-acting GLP/GCG) LAPSGCSF; long-acting HM12470(LAPSInsulin/ HM14220(LAPSInsulin/ Category Oratecan™(Irinotecan + HM71224(BTK inhibitor) HM43239(FLT3 inhibitor) HM43239(FLT3 HM71224 (BTK inhibitor) HM15211(LAPSGLP/GIP/ LAPSGLP-1 Combination) Rolontis™(eflapegrastim; long-acting GLP-1 analog) HM95573(2nd-generation HM15136(LAPSGlucagon; efpeglenatide(LAPSGLP-1; HM81442(FGFR4 inhibitor) HM15450(LAPSASB; long- GCG; long-acting GLP/GIP/ HM12525A(LAPSGLP/GCG; HM12525A(LAPSGLP/GCG; KX2-391(Src kinase/tubulin acting enzyme replacement Small molecule Small molecule efpegsomatropin(LAPShGH; HM15912(LAPSGLP-2; long- LAPSInsulin115; long-acting LAPSInsulin115; long-acting Poziotinib(Pan-HER inhibitor) long-acting glucagon analog) New New (NCEs) Entities Technology Biologics Chemical Hanmi Pharm. PHARM. HANLIM CO., LTD. Company 62

Supplement Supplement 65 ------IMD Note P2Y12 Immune inhibitor inhibitor leukemia checkpoint XO inhibitor Acute myeloid Antibody biosimilar - Any Global Global Global Global Global Europe country Asia, US, Targeted Targeted Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Middle EastMiddle Asia, Europe, ------○ N/A N/A N/A N/A N/A N/A Asian Clinical Clinical US Ph 2 America a part of Preclinical and South Preclinical Preclinical stan MMA completed in progress Overseas 3 completed 3 Launched in Middle East and Kazakh- Mexico, Iran population Ph population ○ ○ ○ ○ ○ PC PC Phase I Korea Phase II Phase 1 Phase 1 Phase 1 Phase II Development StatusDevelopment Phase Ⅰ Launched Launched Launched Launched Launched Preclinical Preclinical Launched Launched Preclinical Laucnched Laucnched Laucnched Laucnched Laucnched Laucnched Pre-clinical NDA approved line of nd Gout phase) Cancer Cancer Epilepsy Analgesic Antitussive Antitussive Indication and 2 GI modulator Fabry Disease st Antithrombotic Antithrombotic Antithrombotic Hemoglobinuria Anti-viral agent Gaucher Disease 1 Anti-hypertensive Dry eye syndrome Dry eye syndrome Multiple Myeloma Dry eye syndrome Dry eye syndrome Atherothrombosis Sjogren syndrome Sjogren Atopic Dermatitis Cancer (Solid Tumor) Rheumatoid arthritis Rheumatoid Gout / Hyperuricemia CML(chronic myeloid leukemia)-CP(chronic Paroxysmal Nocturnal Glabellar wrinkles, etc. Androgenic Alopecia Protective agent of the Gastric Ulcer, Duodenal Duodenal Gastric Ulcer, HepatoCellular Carcinoma Acute Myeloid Leukemia / Ulcer, ErosiveUlcer, Esophagitis gastric mucous membrane ® ® GI NCE NCE NCE NCE CNS SA001 ISU104 ISU305 SJP002 SJP1601 Fabagal SJP1604 Biologics Abcertin Category Small moleculeSmall Small moleculeSmall Cell Therapeutic Prescription drug Prescription Medicine Prescription Medicine Prescription Medicine Fixed Dose Combination Fixed Dose Combination New Dosage Formulation Prescription drug(Biologics) Controlled Release Formulation Controlled Release Formulation Controlled Release Formulation Controlled Release Formulation Controlled Release Formulation Biologics (Botulinum toxin product) LG JW Inc. Ltd. Korea Pharm United Samjin Co.,Ltd Pharm- HUONS IL-YANG PHARM. Co., Ltd. Hyundai Medytox Corporation CO., LTD. aceutical aceutical ISU Abxis Chemical, Company Pharm. Inc. Pharmaceutical 64

Supplement Supplement 65 ODF Fund) Safe Patch Patch Patch Note Better patient release release Oral BA polymer Biologics Solubility Solubility Marketed (Korea Drug Sustained Sustained and Welfare) and Welfare) and Welfare) and Welfare) enhancing enhancing Development enhancing, based DDS compliance KOREA KDDF KOREA MOHW KOREA MOHW KOREA MOHW KOREA MOHW Gene delivery (Ministry of Health (Ministry of Health (Ministry of Health (Ministry of Health supported Project supported Project supported Project supported Project supported Project Japan US, EU US, EU US, EU US, EU US, EU US, EU US, EU US, EU USA, EU, country Targeted Targeted Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide ------N/A Ph 2 Screening Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Clinical(P1) Overseas - - Ph 1 Ph 1 Ph 2 Lead Phase I Korea Development StatusDevelopment Approval Marketed Discovery launching Discovery Screening Screening Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Marketed Clinical(P2) Clinical(P1) Screening Screening (completed) (completed) Formulation optimization Formulation Pain CNS wound disease disease Diabetes Oncology Oncology Oncology Dementia Anti-stroke Hemophilia Anti-cancer Anti-cancer Anti-cancer Severe pain Indication Anti-platelet Parkinson’s D. Parkinson’s Heart failure Fibrotic disease /Osteoporosis Fracture healing Osteoarthrosis prostate cancers Neuropathic pain Atherosclerosis Multiple Sclerosis Dermal/body filler Erectile dysfunction Endometriosis, uterine Active immunization for Active immunization for Burn, Diabetic Foot Ulcer Anticancer (rh. Factor VII) myoma, BPH and breast / the prevention of influenza the prevention of influenza Stroke, systemic embolism and various acute& chronic TM TM tech. tech. SID143 SID125 SID141 NBP604 SP-8203 SP-8356 SP-8008 SP-8232 SID1604 SID1606 SP-35454 TDS tech. TDS tech. SKYCellflu HyalONE Category FreeWink SiRNA DDS ALK5 inhibitor GPR40 agonist polymer-based polymer-based polymer-based parenteral DDS parenteral DDS Immunotherapy Tumor-targeting GnRH antagonist long-acting DDS tech. ROR-gamma Antagonist SKYCellflu Quadrivalent Leuprolide Microsphere

SK INC TEGO Pharm. Co.,Ltd Co. Ltd. Samyang aceuticals Biopharm- SCIENCE, Chemicals Corporation Company Shin Poong 64

Supplement Supplement 67 Note Latin Latin Latin China) China) Korea) Korea) country (excluding Korea and (excluding (excluding (excluding worldwide worldwide Targeted Targeted Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide US, EU, Asia, US,EU, Asia, US,EU, Asia, ------Phase2 (Active) (Active) (Active) (Active) Phase II Phase II Phase III Phase III Phase III (approved) Overseas - - - - - Korea Phase1 Development StatusDevelopment Phase 1/2 Phase 1/2 Preclinical preclinical Phase3 ended NASH Sclerosis Oncology Neuropathy Indication BPH with ED GI prokinetics GI COPD/Asthma Spinal Stenosis Neuropathic pain Thrombocytopenia Diabetic Peripheral Amyotrophic Lateral Chemotherapy-induced Coronary Artery Disease Chronic Diabetic Foot Ulcer Chronic Diabetic CV CNS Urology Category Respiratory Plasmid DNA Plasmid DNA Plasmid DNA Plasmid DNA Recombinant Protein New chemical entity New chemical entity Recombinant protein Recombinant Yuhan Pharm. Yungjin Co.,Ltd. Co., Ltd. ViroMed ViroMed Company Corporation 66

Supplement Supplement 67 Note Supply company APIs to a Company Japanese scheduled products to a Japanese Supply bulk- PMDA PMDA PMDA PMDA PMDA PMDA PMDA PMDA PMDA PMDA PMDA J GMP ANVISA EU GMP EU GMP EU GMP WHO PQ WHO PQ WHO PQ Thai GMP Thai GMP Inspection Inspection Inspection Inspection Inspection Inspection Inspection Inspection Inspection Japan GMP Japan GMP Japan GMP Japan GMP Japan GMP certification certification certification certification certification certification International Philippines GMP Philippines GMP Infection Infection Infection Infection Infection Infection Infection Infection Infection Oncology Respiratory Antibiotiecs Antibiotiecs Antibiotiecs Antibiotiecs Indication Tuberculosis Antihistamine Schizophrenia Cardiovascular Cardiovascular Cardiovascular Urology System Immunosuppressant Growth hormone deficiency For the Prophylaxis against Influenza For the Prophylaxis against Influenza Inj. Inj. Inj. Inj. Inj. Inj. Inj. API API API API API API API API Vial Vial Tab. Syrup Tablet Tablet Capsule Capsule. Injection Injection Vial, AQ, Pen Vial, dosage form Type B Type Linezolid Linezolid Alacepril A (H3N2) A (H3N2) A (H1N1) A (H1N1) B-Victoria Tacrolimus Fimasartan Tamsulosin Somatropin Cycloserine Doxorubicin Pitavastatin Aripiprazole B-Yamagata Montelukast Moxifloxacin Moxifloxacin Cefotiam Hcl clavulanate Fexofenadine Cefopodoxime Cefopodoxime Cefozopran Hcl Cefazolin sodium Cefmenoxime Hcl Ambroxol HCl (API) Purified Inactivated Purified Inactivated Purified Inactivated Purified Inactivated Purified Inactivated Purified Inactivated Purified Inactivated Sesquihydrate (API) Active Ingredient Pantoprazole Sodium Influenza Virus Antigen Influenza Virus Amoxicillin/Potassium Bacampicilin hydrochloride Ceftriaxone Sodium hydrate Influenza Virus Antigen Type Antigen Type Influenza Virus Influenza Virus Antigen Type Antigen Type Influenza Virus Influenza Virus Antigen Type Antigen Type Influenza Virus Antigen Type Influenza Virus Influenza Virus Antigen Type Antigen Type Influenza Virus Antigen Type Influenza Virus ® ® ® tab. ® dry syrup ® GCFLU GCFLU Pengood Alacepril Multi inj. Closerine First-Sin Kmoxilin GCFLU inj. Best-Call Tacrolimus Fimasartan Tamsulosin Tamsulosin Ceftriaxone Doxorubicin Pitavastatin Aripiprazole Rasenazolin Banan Montelukast Cinezolid Inj. Quadrivalent Pan-Sprorin Fexofenadine Moveloxin Inj. Moveloxin Inj. Cinezolid Inj. GFLU multi inj. Growtropin Inj. Quadrivalent inj. Product name Banan CJ Corp. Pharm Chong Pharm­ pharm­ co.,Ltd. Boryung aceutical aceutical Kun Dang Dong Wha Dong-A ST GC Pharma HealthCare Company corporation 3. Certifications from Health Authorities from Health 3. Certifications 66

Supplement Supplement 69 2009 2012 2015 2012 2012 2012 Note cancelled Launching FDA Syria PIC/S (ANVIS) (ANVIS) EU GMP Authority Ivory Coast GMP (BGV) Kazakhstan Yemen FDA Yemen Oman MOH Jordan MOH Saudi Arabia Ethiopia FDA Uganda NDA Taiwan FDA - Taiwan Tanzania FDA Tanzania Colombia FDA Colombia FDA Peru Authority Ukraine- PIC/S certification (Germany BGV) Brazil Authority Brazil Authority International Epilepsy Indication Hypertension Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Type II diabetes Type Antithrombotic agent Edema., Hypertensionos Gastroesopha geal reflux disease Corticosteroid-responsive dermatoses form form form form form form form form form form from form form form form form form form form Solid Tablet Tablet Capsule Semi-solid bath drops dosage form Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage Solid dosage dosage form formulation Eye Clobazam Losartan K Furosemide tetrahydrate Glibenclamide Desoxymethasone Active Ingredient Amlodipine camsylate Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Glimepiride Metformin Esomeprazole strontium Clopidogrel napadisilate 10mg tablet 2mg + 2mg + 0.25% 500mg 500mg 2/500mg 2/500mg 2/500mg 1/250mg 2/500mg 2/500mg 2/500mg 2/500mg 2/500mg 2/500mg 2/500mg 2/500mg 2/500mg 2/500mg 2/500mg 5/100mg Lasix tab. Prolonged- Prolonged- Daonil tab. Amosartan Frisium tab. AMARYL M Pidogle Tab. 20mg, 40mg Amaryl M IR Amaryl M IR Amaryl M IR Amaryl M IR Amaryl M IR Amaryl M IR Amaryl M IR Amaryl M IR METFORMIN METFORMIN Tab. 5/50mg, Tab. Amaryl M SR Amaryl M SR GLIMEPIRIDE Amaryl M SR Amaryl M SR Amaryl M SR Amaryl M SR Amaryl M SR release tablet release tablet 500mg coated Esperson oint. AMARYL MET coated tablets + METFORMIN Amaryl Met XR Glamaryl combi Esomezole Cap. IR GLIMEPIRIDE 2mg/500mg film Product name Glimepiride 2 mg Hanmi Pharm. Company Handok Inc. Handok Inc. 68

Supplement Supplement 69 - GMP GMP 2012 2013 2013 2017 2017 2015 Note Certification Certification Peru GMP Japan Russia Poland Council) GCC(Gulf US - FDA US - FDA Colombia, Certificate Non-sterile Quasi-Drug Kazakhstan KSA - SFDA of Health of Kazakhstan Turkey, Iran, Turkey, PMDA GMP PMDA GMP PMDA GMP PMDA GMP PMDA GMP PMDA GMP Cooperation EU - Ministry ANVISA GMP ANVISA GMP MFDS (Korean Japan - PMDA Japan - PMDA Japan - PMDA certification Turkey, Mexico Turkey, Iran, Colombia, the Republic of COFEPRIS GMP COFEPRIS GMP International Philippines FDA FDA) PIC/S GMP Jordan, Pakistan lungs Diuretics Antibiotics Antibiotics Antibiotics Antibiotics Indication anti-diabetic Hypertension Hypertension Hypertension Anti-thrombotic Fungal Infection Fungal Infection Gaucher Disease Local Anesthesia Dental Anesthesia Treatment of heart failure Treatment Diluent for injectable drug glucose supplement during Treatment of Osteoarthritis Treatment intravascular access devices Vitamin, Mineral & Nutrition Vitamin, tubing system and in dwelling Hypokalemia, cardiac collapse, hypoglycemia, Cerebral edema, symptoms of seasonal allergies supplement of water, Diagnosis supplement of water, Flushing compatible intravenous Shock, Cardiac disease, Non-oral Gastroesopha geal reflux disease Treating high blood pressure in the Treating asthma symptoms and to relieve the API API API API Solid Solid Solid Bottle Tablet Tablet Tablet Tablets Tablets Tablets Syringe Capsule Prefilled Injection Injection Injection Injection Ampoule Ampoule Ampoule Ampoule Cartridge BFS 20mL BFS 20mL bath drops bath drops Dispersion dosage form formulation Eye formulation Eye Glucose Bosentan Anagliptin Abciximab Losartan K Losartan K Losartan K Azocemide Itraconazole Itraconazole tetrahydrate Imiglucerase Lidocaine HCl Sodium Chloride Sodium Chloride Cilastatin sodium Cilastatin sodium Sodium Hyaluronate Taurine 2000, others Taurine Montelukast sodium Active Ingredient Lidocaine, Adrenaline Amlodipine camsylate Amlodipine camsylate Amlodipine camsylate Amlodipine camsylate Meropenem trihydrate Meropenem trihydrate Esomeprazole strontium Norepinephrine Bitartrate Imipenem monohydrate and Imipenem monohydrate and ® ® for Inj. Inj. 1% Mixture Mixture 5/100mg 5/100mg 5/100mg Inj. 0.9% Clotinab Abcertin IYEN2000 Imipenem Anagliptin Epilido Inj. Amosartan Amosartan Amosartan Azocemide Hyaclon Inj. Meropenem 20mg, 40mg Tab. 5/50mg, Tab. Tab. 5/50mg, 5/50mg, Tab. Tab. 5/50mg, Tab. Norepirin Inj. 20% Glucose Toracona tab. Toracona Prepenem Inj. Lidocaine HCl Pospenem Inj. Bosentan Tab. Itrazonazole SD Esomezole Cap. Isotonic Sodium Sodium Chloride Product name Montelukast tab. Chloride Solution JW Hanmi Pharm. IL-YANG HUONS CO., LTDl PHARM- ISU Abxis Corporation CO., LTD. ACEUTICAL ACEUTICAL Company Pharmaceutical 68

Supplement Supplement 71 - - - - - 2013 2012 2010 2010 2014 2017 2013 Note GMP GMP GMP GMP GMP GMP GMP China China PMDA PMDA PMDA PMDA PMDA PMDA PMDA PMDA EU GMP EU GMP EU GMP EU GMP FDA GMP & EU GMP WHO GMP WHO GMP China, USA certification certification certification certification PMDA GMP certification certification certification certification certification certification certification certification Certification Certification EU(Germany) Germany(EU) EU(Germany) EU(Germany) Germany(EU), Japan(PMDA) Japan(PMDA) Japan(PMDA) certification Brazil(ANVISA) Preparing cGMP CE certification CE certification Australia (TGA) International NSAID NSAIDs Medicine Medicine Anti-ulcer Antibiotics Anti-cancer Anti-cancer Anti-cancer Anti-cancer Anti-cancer Anti-cancer Anti-biotic Anti-biotic Indication Anti-malaria Anti-malaria Anti-platelet Joint arthritis Anti-adhesion Medical device Antithrombotics Hepatits B vaccine Alzheimer’s disease Alzheimer’s Anti-hypertensive Anti-hypertensive Anti-hypertensive DTP-HepB-Hib vaccine Glabellar wrinkles, etc. Growth hormone deficiency Growth hormone Active immunization for the prevention of influenza disease API API API API API PFS Vial Vial API API API API API API Patch Tablet Tablet Tablet Plaster Injection Injection Injection Injection Injection Injection Injection Injection Nutrition Granules supply to and tissue Temporary Temporary cornea and conjunctiva (lyophilized) correction of regeneration Blood product facial wrinkles dosage form Wound healing Wound Sodium Sodium antigen Oncology Oncology Oncology Cilostazol Paclitaxel Paclitaxel Docetaxel Docetaxel Valsartan Diclofenac Injectables Injectables Injectables Irbesartan Omeprazole Pemetrexed Rivastigmine Telmisartan Gemcifloxacin Hyaluronic acid diethylammonium Hepatits B vaccine human Somatropin hydroxyethyl starch Purified inactivated Synthetic Paclitaxel Sodium hyaluronate, Clopidogrel bisulfate Sulbactam sodium Active Ingredient Loxoprofen sodium Fosfomycin sodium DTP-HepB-Hib vaccine influenza virus surface Sodium Polynucleotide Botulinum toxin type A Polydeoxyribonucleotide Polydeoxyribonucleotide Pyronaridine, artesunate Pyronaridine, artesunate

® ® ® Tab. Gran. ® ® ------eye drop hGH ® Patch Active OMED Factive Plasma Euvax B product) injection Rejuran Biologics Oncology Oncology Oncology Oncology Ingredient SKYCellflu Injectables Injectables derivatives Injectables Injectables Rejuvenex Hyruan plus Euforvac-Hib Rivastigmine Medicurtain Paclitaxel(API) Pyramax Docetaxel(API) Pharmaceutical Pyramax (Botulinum toxin Re-an Product name

LG SK Inc. Ltd. Pharm. Co.,Ltd Co. Ltd. Co., Ltd. Pharma- Samyang Products Medytox aceuticals Biopharm- Research Chemical, Chemicals Corporation Shin Poong Company 70

Supplement Supplement 71 - - - - Note API API API KGMP KGMP KGMP PMDA PMDA PMDA EDQM PMDA PMDA PMDA PMDA PMDA PMDA PMDA PMDA PMDA PMDA PMDA PMDA USFDA EU GMP EU GMP CE Marking certification certification PMDA GMP- USFDA, TGA, USFDA, TGA, USFDA, TGA, USFDA, TGA, US FDA GMP- TGA GMP-APITGA USFDA, EDQM certification ANVISA GMP- International TBSA Dry eye Antiviral Antiviral Antiviral Antiviral Antiviral Infection Infection Infection Infection Infection Infection Infection Infection Antibiotic Antibiotic Antibiotic Antiplatelet Antiplatelet Indication degree burn(2005.03) anti HIV/AIDS anti HIV/AIDS anti HIV/AIDS anti HIV/AIDS anti Anti-glaucoma Anti-glaucoma nd degree burn over 30% of nd Diabetic Foot Ulcer(2010.06) degree burn over 10% of TBSA Deep 2 rd Deep 2 3 Improvement of Nasojugal Grooves ------Inj. API API API API API API Sheet Sheet Capsule Solution Solution Solution Injection API, Tablet API, Tablet Intradermal Fine Granule API, Injection API, Dry syrup dosage form PMH API 1 API 2 API 3 API 4 Cefdinir maleate Ribavirin Cilostazol Voglibose Piperacillin Zidovudine Zidovudine Zidovudine Zidovudine Latanoprost Levofloxacin Autologous Sodium CMC Cefotiam HCl Keratinocytes Cefditoren Pivoxil Ceftriaxone Sodium Cefmetazole Sodium Active Ingredient Cefcapene Pivoxil HCl Cefaclor Monohydrate Latanoprost plus Timolol Latanoprost plus Timolol Caftazidime Pnetahydrate Autologous Fibroblasts Allogeneic Keratinocytes ® ® ® - - - - API 1 API 2 API 3 API 4 Xalost Cefdinir Rosmir Cefaclor MC Free Ribavirin Cefotiam Cilostazol Voglibose Cefditoren Cefcapene Kaloderm Holoderm Xalost Plus Piperacillin Ceftriaxone Caftazidime Levofloxacin Cefmetazole Product name INC., TEGO Yuhan Pharm. Yungjin Yungjin Co., Ltd Co.,Ltd. Taejoon Taejoon ceutical Pharma- Co., Ltd. SCIENCE, ST Pharm Company Corporation 70

Supplement PB 72 memo